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ABSTRACT 
Essential hypertension is usually characterized by an elevated systemic vascular 
resistance although in the early stages and in younger individuals there may be a raised 
cardiac output with normal or reduced vascular resistance. Most groups of anti-
hypertensive drugs will lower vascular resistance whereas some, particularly the beta-
blockers, are thought to increase vascular resistance which may be potentially deleterious. 
These haemodynamic effects are rarely assessed because of the difficulty in measuring 
cardiac output. With the availability of new equipment to estimate cardiac output and 
cardia index (CI) repeatedly using non-invasive techniques, it is now possible to exaimne 
these haemodynamic effects with minimum patient discomfort. 
TWs thesis describes studies using the technique of transthoracic electrical 
bioimpedance (TEB) with an automated device the BOMED NCCOM3-R7. This allows 
computerized data acquisition of cardiac index and related variables and subsequent 
calculation of systemic vascular resistance index (SVRI) from simultaneous recordings of 
blood pressure using an automatic sphygmomanometer. The system was initially tested 
for reproducibility in a group of twelve healthy volunteers in supine, standing and sitting 
positions and during isometric exercise on six separate occasions. The coefficient of 
variation (CV) for CI ranged from 5.5 -7.5 % in the various conditions. The mean C.V. 
I 
for stroke index (SI) varied from 6.0 - 8.7 % and for SVRI from 7.0 • 9.7 %. 
Hypertensive patients who were not on therapy were studied with the technique 
before starting therapy and after two and four weeks of treatment with the usual starting 
doses of the selected drugs from the main groups of anti-hypertensive agents. The drugs 
and dosage used were atenolol 50 mg o.d., pindolol 5 mg b.d., doxazosin 1 mg o.d., 
enalapril 5 mg o.d, nifedipine retard 20 mg b.d., methyldopa 250 mg b.d. and 
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cyclopenthiazide with potassium SR 0.25 mg o.d.. All the drug dosages reduced blood 
pressure at two and four weeks except for doxazosin 1 mg which also had little effect on 
any of the other parameters. Surprisingly, atenolol did not alter CI but did reduce SVRI 
significantly (10%) in all the different postures. Pindolol also reduced SVRI (18%) and 
increased CI (12%) with a significant negative correlation between these two parameters 
in the supine position. Thus the lowering of blood pressure by these beta-adrenoceptor 
antagonists either with intrinsic sympathomimetic activity (ISA) or betai-selectivity 
without ISA appeared to be associated with vasodilatation. Enalapril reduced blood 
pressure and this was associated with a significant reduction in SVRI (12%) in the supine 
position but not in other positions. No significant haemodynamic change apart from the 
reduction in blood pressure was detected in the nifedipine retard treated group of patients. 
Methyldopa significantly reduced both the blood pressure (6-10%) and the heart rate (5-* 
6%) in all positions but not CI and there was no change in SVRI. Although 
cyclopenthiazide is thought to lower blood pressure by decreasing extravascular volume, 
no significant changes were observed in heart rate or cardiac output after two and four 
weeks of treatment. 
We also examined the acute haemodynamic effects of atenolol and pindolol two 
hours after the initial dose in a subgroup of patients. We found that atenolol lowered heart 
rate significantly more than pindolol in all positions as well as during isometric exercise 
despite the small number of patients in our study. Although blood pressure was lowered 
at two hours post dose by both beta-adrenoceptor antagonists, the SVRI did not 
significantly fall in any of the different postures or during the isometric exercise. Overall, 
we considered that TEB was a useful method to evaluate the haemodynamic responses to 
anti-hypertensive drug therapy. 
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CHAPTER 1 INTRODUCTION 
1.1 POSTULATED PATHOPHYSIOLOGY OF ESSENTIAL HYPERTENSION 
Hypertension has been regarded generally as a consequence of disorders of the 
body's blood pressure regulating system. Blood pressure is affected by the lumen of 
arteries which are considered as resistance vessels and by the cardiac output (CO). 
Furthermore, CO is the volume of blood that the heart pumps in one minute and may 
be affected by the following factors: changes in blood volume and electrolyte 
composition, the action of the autonomic nervous system, other circulating hormones 
and the inotropic effects on the heart (Korner, 1982). 
Blood pressure in normotensive and hypertensive individuals is a continuum 
and the definition of normal, borderline and high blood pressure is arbitrary (Swales, 
1979). Swales (1979) suggested to define hypertension as the range of blood pressure 
which produces untoward clinical sequelae as defined by large epidemiological surveys 
and similar statistics. The definitions of hypertension put forward by several reputable 
organizations are as follows: the Fourth Joint National Committee defined 
hypertension as when the average of two or more diastolic blood pressures on two or 
more clinical visits is 90mmHg or greater (Houston, 1989), the National Institutes of 
Health in 1993 recommended that hypertension is a blood pressure reading equivalent 
or greater than 160/95 mmHg with measurement on one occasion or reported currently 
taking antihypertensive medication (National High Blood Pressure Education Program, 
1993) and the World Health Organization criteria (the fifth Korotkoff phase) defined 
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hypertension as 160/95 mmHg or above and borderline hypertension with blood 
pressure in the range of 140-159 / 90-94 mmHg whereas readings below 140/90 
mmHg were considered normal (Swales, 1979). The classification of blood pressure 
for adults age 18 years and above from the National Institute of Health (1993) is 
shown in table 1.1. 
Table 1.1 Classification of blood pressure for adults age 18 years and older 
『•、-'、| ^ ^释I職•曙:】 
Normal <130 <85 
High normal 130-139 85-89 
Hypertension: 
Stage 1 (Mild) 140-159 90-99 
Stage 2 (Moderate) 160-179 100-109 
Stage 3 (Severe) 180-209 110-119 
Stage 4 (Very severe) >210 >120 
It is claimed that the haemodynamic abnormalities of patients with established 
essential hypertension are an increased systemic vascular resistance (SVR) which 
includes peripheral vascular resistance and renal vascular resistance, causing increased 
blood pressure (Komer, 1982)(Houston, 1989). The outcome of increased arterial 
pressure is the hypertrophic structural changes in the arteries and arterioles and then 
reduced CO. Potential end organ damage may result not only from high blood pressure 
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but also from reduced blood flow and low oxygen perfusion to tissues (Weil & Waite, 
1982). Theories of the aetiology postulate that it is related to changes in CO and tissue 
perfusion and the evidence for this is as follows: 
a) The autoregulation theory of hypertension was proposed by Borst J.G.G. and 
Borst de Geus A. (1963) to explain the transition from high cardiac output in the early 
stage to high total peripheral vascular resistance in the later stage of hypertension. 
High CO gives rise to elevated blood pressure which results in excessive perfusion of 
peripheral tissues and brings about a perfusion of the peripheral circulation at an 
excessive level. This phenomenon triggers a myogenic response with increasing tension 
in the arteries and arterioles. Under such circumstance, a compensatory increase in 
SVR returns CO to normal levels and sustains high blood pressure in the later stages of 
hypertension (Komer, 1982). 
b) Julius (1988) postulated a new concept to explain the above phenomenon 
further. The central nervous system seeks to preserve high blood pressure in the early 
stages of hypertension by increasing CO. Structural arteriolar hypertrophy may then 
result under the stimulus of chronic high blood pressure. As a result of the increased 
responsiveness of the hypertrophied arterioles, elevated vascular resistance occurs and 
the equivalent blood pressure control could be sustained whilst allowing the CO return 
to a normal level (Julius, 1988). 
c) According to Sramek (1993), the cause of essential hypertension is 
vasoconstriction and the patient is in a hypodynamic state. This state is caused by a 
suprenormal level of systemic vascular resistance (which is increased afterload). The 
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patient with normal preload and contractility becomes a hypodynamic hypertensive 
with so called essential hypertension (Sramek, 1993). 
There are several obstacles which hinder the identification of the 
pathophysiological mechanisms of essential hypertension. Firstly, it takes a long time, 
usually years, for high normal blood pressure or borderline hypertension to develop 
into established hypertension. Secondly, it is difficult to distinguish factors which may 
cause hypertension though factors which sustain high normal blood pressure may be 
identified. Thirdly, some disorders which we may detect in hypertension, for instance, 
decrease in renin secretion as induced by elevated renal artery pressure, may be the 
outcome rather than a cause of the hypertension. Lastly, it is inappropriate to draw 
direct conclusions on human hypertension from hypertensive animal models (Swales, 
1979). • 
The exact cardiovascular disorders of hypertension are not fully understood 
and there is a large variability between individuals (Thompson & Joekes，1981). All in 
all, the primary haemodynamic goal in treating hypertension is to diminish systemic 
vascular resistance while at the same time to preserve cardiac output, renal blood flow 
and perfusion to other vital organs at rest and during exercise (Houston, 1989). 
The clinical significance of hypertension is that for each increment in systolic 
and diastolic blood pressure, the risks of cardiovascular damage, renal failure, 
congestive heart failure, myocardial infarction, angina pectoris and coronary heart 
disease increase correspondingly (Houston, 1989). It is well recognized that the 
mortality rate of cardiovascular disease including coronary heart disease, stroke, renal 
disease and all other causes increases proportionally with higher diastolic blood 
pressure as well as systolic blood pressure. From the findings of the Australian 
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Therapeutic Trial in mild hypertension, it is known that active drug treatment for 
mildly elevated blood pressure reduces mortality for both ischaemic heart disease and 
cerebrovascular accidents in comparison to placebo. That study was conducted in a 
group of patients aged 30 - 69 years with diastolic blood pressure (DBP) between 95 
and 110 mmHg and systolic blood pressure (SBP) less than 200 mmHg. The results of 
the study support the epidemiological data of the causal relationship of blood pressure 
and cardiovascular disease or put it in other words, hypertension is a risk factor for 
cardiovascular disease (Lovell, 1982). Fortunately, there has been a decline in 
cardiovascular mortality over the past two decades which was mainly because of the 
recognition of the close relationship between high blood pressure and cardiovascular 
risk factors by both physicians and the general public (National High Blood Pressure 
Education Program, 1993). 
The numerous clinical sequelae of hypertension occur in various body systems. 
They are vascular (arteries and arterioles) hypertrophy, atheroma, dissecting aneurysm 
of the aorta, increased renal vascular resistance with a reduced renal blood flow, 
pressure natriuresis and diuresis, abnormalities in renin secretion, left ventricular 
hypertrophy and failure, congestive heart failure, myocardial infarction and 
cerebrovascular accidents (Swales, 1979). 
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1.2 MEASUREMENT OF CARDIAC OUTPUT (CO) BY TRANSTHORACIC 
ELECTRICAL BIOIMPEDANCE (TEB) AND OTHER METHODOLOGIES 
Measurement of cardiac output (CO) can be either invasive or noninvasive 
depending on pathophysiological conditions of the patients involved or the purpose 
and scope of the study. The former includes Pick's method, dye dilution, 
thermodilution or radionuclide dilution and the latter electrical impedance cardiography 
or transthoracic electrical bioimpedance (TEB), dual-beam Doppler echoaortography, 
mechanosphygmography or M mode echocardiography. All the invasive and 
noninvasive methods mentioned above estimate CO and stroke volume (SV) indirectly 
(Breithaupt, Erb, Neumann, Wolf & Belz，1990). CO and SV are among the most 
useful indicators of the function of the heart. More precisely, CO is an important 
parameter to determine the systolic fiinction of the left ventricle (Breithaupt et cd,， 
1990) which is fundamental to physicians both in the acute emergency situation and in 
the clinical environment. Noninvasive CO estimation is generally more appealing than 
invasive measurement since the latter is limited to acute monitoring of patient 
conditions and it carries certain patient risks (Moore, Sansores, Guimond & Abboud， 
1992). In the Sixties, noninvasive TEB was developed as an alternative method to 
measure CO in situations not suitable for invasive technique. With improvement in 
electrode application, modification of the formula to calculate CO and availability of 
software to display real time on-line CO measurement and other haemodynamic 
parameters, more and more studies have been conducted to compare the validity of CO 
estimation between TEB and other methodologies. 
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The validity of the noninvasive measurement of CO has been demonstrated by 
many studies which were conducted to correlate noninvasively obtained CO data with 
those determined by the better recognized invasive technique(s) (Hetherington, Teo, 
Haennel, Greenwood, Rossall & Kappagoda，1985) (Looyenga, Liebson, Bone, Balk 
& Messer，1989) (Wong, Tremper, Stemmer, O'Connor, Wilbur, Zaccari, Reeves, 
WeidofF & TrujUlo, 1990). In a study comparing CO by thermodilution, TEB and 
supra-sternal Doppler ultrasound in 68 patients with acute clinical conditions, 
simultaneous CO determination by thermodilution and TEB were available in 56 
pateints (Wong et al, 1990). The authors observed a correlation coefficient (r) of 0.61 
and a mean difference of the two methods (bias) of-0.67 士 1.72 (SD) 1/min. They also 
concluded that the agreement of the two methods was best in patients who were 
mechanically ventilated, who had not had cardiac or aortic surgery (Wong et at.， 
1990). 
On the other hand, studies have also been performed to compare measurement 
of stroke volume by electrical impedance cardiography with other different noninvasive 
techniques (Aust, Belz, Belz & Koch, 1982) (Edmunds, Godfrey & Tooley, 1982) 
(Breithaupt et al., 1990) (Moore et al, 1992). Edmunds A T. et. al. (1982) carried out 
a study to compare CO measurement by the transthoracic impedance cardiography and 
the indirect Pick CO2 rebreathing method. The study involved nine adults and fourteen 
children and they were all healthy volunteers. The machine used for impedance 
measurements of CO was an early model of TEB, the Minnesota Impedance 
Cardiograph, which was used with strip electrodes and Kubicek's formula for 
calculating SV. As there was a sound correlation, r = 0.94，between the results of the 
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two techniques (after a correction factor related to packed cell volume was applied) 
and changes of lung volume as a result of breath holding or expiratory resistance did 
not affect the impedance measurement of CO, the authors recommended the use of 
TEB, and found it suitable even for patients with respiratory illnesses including asthma 
or bronchiolitis (Edmunds et al., 1982). 
Breithaupt K. et. al (1990) compared four noninvasive techniques, electrical 
impedance cardiography, dual-beam Doppler echoaortography, mechano-
sphygmography and M mode echocardiography of the left ventricle to measure stroke 
volume in nine healthy volunteers (24-40 years). They found that the electrical 
impedance cardiography had the correlation closest to the principal component using 
principal component analysis with r = 0.89. The correlation coefficients, r, for the dual-
beam Doppler echoaortography, mechanosphygmography and M mode 
echocardiography of the left ventricle were r = 0.87’ r = 0.84 and r = 0.66 respectively. 
They concluded that the first three noninvasive techniques were all of good validity in 
estimation of SV (Breithaupt et al, 1990). Although the electrical impedance 
cardiography in this study used Kubicek's formula which is different from the Sramek-
Bernstein's formula used in the transthoracic electrical bioimpedance (TEB) in the 
present project, the Sramek-Bernstein's formula was actually modified from Kubicek's 
formula to overcome some of the drawbacks and thus was believed to be an 
improvement. 
Noninvasive measurements of CO and SV have always been criticised as being 
less accurate and less reliable than those obtained by invasive techniques. However, it 
is noted by many reputable researchers that even the invasive techniques have flaws in 
their design principles and cannot give true values of SV. Hence, it has been commonly 
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agreed that a standard method for measurement of CO does not really exist (Appel, 
Kram, Mackabee, Fleming & Shoemaker, 1986) (Bernstein, 1987) (Salandin, Zussa, 
Risica, Michielon, Paccagnella, Cipolotti & Simini, 1988) (Breithaupt et al, 1990) 
(Jewkes, Sear, VerhoefF, Sanders & Foex, 1991) (Thomas, 1992). The present study 
was designed to evaluate CO estimation by TEB in healthy volunteers in different 
positions and during isometric exercise and in a group of Chinese hypertensive patients 
both before and after treatment with different groups of antihypertensive agents. The 
study design, results and discussion, together with a detailed literature review of the 
validity and reproducibility of TEB are delineated in chapters 2, 3, 4，5 and 6. 
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1.3 MEASUREMENT OF BLOOD PRESSURE 
Readings of blood pressure are affected by many factors. The two main types 
of contributing factor are patient factors and measurement factors. The former includes 
variation within the patient, seasonal and diurnal variation, physical activity, degree of 
obesity, smoking habit, caffeine and/or alcohol intake, talking while measuring blood 
pressure, stress and other illnesses, recent meals, environmental temperature, different 
postures, effects of other medications and many others. The latter includes incorrect 
sphygmomanometer cuff size or incorrect application of the cuff，auscultatory gap 
missed, not using phase V KorotkofF sounds for taking diastolic blood pressure and the 
measurement not being recorded in both arms at the initial visit, to name but a few 
(Houston, 1989). 
It is of prime importance to affirm that the blood pressure readings obtained are 
representative of the individual's usual levels. The guidelines of the National High 
Blood Pressure Education Program (1993) suggest the following techniques which 
help in determining the individual's usual readings: arrange for the patient to sit 
comfortably with their arms resting at heart level; they should not smoke or take 
caffeine within 30 minutes of the measurement; blood pressure should be measured 
after 5 minutes of rest in the supine or sitting positions; ensure correct cuff size is used 
and both systolic and diastolic blood pressure are recorded with the disappearance of 
KorotkofF sounds phase V taken as the diastolic blood pressue. Lastly, two or more 
blood pressure readings should be taken and averaged.If the initial two readings differ 
by more than 5 mmHg, additional measurements should be taken (National High Blood 
Pressure Education Program, 1993). 
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When recording blood pressure readings, the mean of several readings in 
different positions is more reliable and accurate in diagnosing the severity of 
hypertension. On the other hand, office blood pressure readings are usually higher than 
measurements taken at home. Moreover, it is not unusual to find that patients with 
mild hypertension, as defined by office measurements and not taking any anti-
hypertensive drugs, have normal daytime ambulatory blood pressure readings 
(Houston, 1989). Contemporary studies have shown that ambulatory blood pressure 
monitoring at home and/or work is more useful in diagnosing the severity of 
hypertension and the effectiveness of treatment. It has been demonstrated that target 
organ damage relates more closely to the out-of-office blood pressure measurements 
(National High Blood Pressure Education Program, 1993). 
the report of the National High Blood Pressure Education Program (1993) 
recommends that it is inappropriate to diagnose hypertension based on only one single 
blood pressure measurement. Two or more clinic visits over a period of weeks are 
required to confirm the diagnosis provided the average reading of diastolic blood 
pressure is 90 mmHg or above and/or systolic blood pressure is 140 mmHg or above. 
An exception would be if systolic blood pressure was 210 mmHg or above and/or 
diastolic blood pressure was 120 mmHg or above at the first visit when it would 
generally be necessary to start treatment immediately (National High Blood Pressure 
Education Program, 1993). 
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“ 1,4 USE OF ANTIHYPERTENSIVE A GENTS IN ESSENTIAL HYPERTENSION 
The pharmacologic treatment of mild hypertension (DBP: 90-100 mmHg) has 
not reduced the morbidity and mortality from the manifestation of coronary heart 
disease, namely, angina and/or myocardial infarction as much as might be predicted 
from epidemiological studies. Whereas hypertensive arteriolar disease (cerebro-
vascular accidents, congestive heart failure and renal insufficiency) is more effectively 
prevented by blood pressure control, atherosclerotic complications (coronary heart 
disease, myocardial infarction, angina, peripheral and generalized atherosclerosis) 
resulting from occlusive arterial disease are not so well controlled by lowering blood 
pressure (Houston, 1989). 
Moreover, we should be aware of the economic drawbacks of hypertension on 
society and adopt the most appropriate preventive measures accordingly. The total 
cost of the pharmacologic therapy of hypertension is alarming and long-term. It 
encompasses the acquisition cost of the drug; coprescription of additional drugs to 
diminish the side effects of the first drug; untoward effects on quality of life, for 
instance, physical performance and potential disability; unwanted metabolic changes, 
for instance, dyslipidaemia; cost of clinical visits; subsequent laboratory and technical 
monitoring of blood tests and electrocardiogram for potential hypertensive organ 
damage and coronary heart disease risks; and continuous health care costs which 
include possible hospitalization, long-term outpatient visits, rehabilitation and early 
retirement (Houston, 1989). 
It has been mentioned that patients with mild hypertension have a higher 
cardiac output and heart rate but normal total peripheral resistance at rest in the early 
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State (Korner, 1982)(Houston, 1989). However, Lund-Johansen (1983) demonstrated 
[ 
that in a ten year follow-up study, CO and S V gradually decreased with an increase in 
TPR both at rest and during exercise, particularly in patients aged 17 to 39 years. He 
also commented that physicians seldom consider the mechanisms of actions of anti-
hypertensive drugs in reducing blood pressure and their potential for reversing the 
gradual changes that have occurred in the high-pressure compartment of the 
circulatory system. Although the early signs of haemodynamic disorders associated 
v^th hypertension are not easy to detect, estimation of CO and SVR may provide very 
useful information for choosing an appropriate anti-hypertensive agent(s) and in 
determining the origin of hypertension(Lund-Johansen, 1983). 
Likewise, the majority of clinical trials of anti-hypertensive drugs focus 
mainly on the drug's effect on blood pressure. The clinical efficacy of the drugs 
studied is usually only determined by the blood pressure reduction and the 
tolerability by the frequency and level of adverse effects. In reality, hypertension 
itself is the clinical manifestation of a series of underlying haemodynamic disorders 
which lead to high blood pressure. Accordingly, the primary goal of treating 
hypertension should be to lower blood pressure by reducing total peripheral vascular 
resistance, and to maintain cardiac output, renal blood flow and oxygen perfusion to 
other organs both at rest and during exercise. Thus, an easy-to-operate, real time 
• • 
on-line and non-invasive means to provide information relating to the patients' 
haemodynamic state is potentially valuable in the assessment and management of 
hypertension. 
• • I 
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^ Furthermore, various antihypertensive drugs have been used in the treatment of 
hypertension for a long period of time. They are believed to have differing 
antihypertensive mechanisms, which include the reduction of cardiac output by 
blocking the postjunctional Pi-receptors as with atenolol or decreasing the plasma 
volume as with thiazide diuretics. However, the efficacy of these antihypertensive 
drugs and their effect on the haemodynamic state are not yet fully known. More 
studies need to be done to verify their exact haemodynamic effects. A review of the 
pharmacologic and haemodynamic effects of the antihypertensive drugs studied is 
given in Chapter 4. 
In summary, the purpose of the present study was to evaluate and compare the 
responses of blood pressure, cardiac output and total peripheral vascular resistance to 
the standard initial doses of drugs from the major groups of antihypertensive agents, a 
betai-adrenoceptor antagonist, a calcium channel blocker, an angiotensin-converting 
enzyme inhibitor (ACEI), a thiazide diuretic, a centrally-acting alpha] agonist and an 
alphai-adrenoceptor antagonist in Chinese patients with essential hypertension using a 
non-invasive impedance cardiography technique - the transthoracic electrical 
bioimpedance (TEB). 
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CHAPTER 2. THE METHOD OF TRAmmomcic ELECTBICAL 
BIOIMPEDANCE 
11 INTRODUCTION 
Transthoracic electrical bioimpedance (TEB) provides a noninvasive method 
of estimating aortic blood flow by measuring resistance to an alternating electric 
current (AC) of thoracic body tissues. The equipment used in this study was the 
commercial instrument BOMED NCCOM3-R7 from BOMED Medical Manufacturing, 
Irvine C.A. A sinusoidal AC current of 2.5 mA and 70kHz is applied between current 
injecting electrode pairs on the lateral aspects of the neck and on the mid-axillary line 
at the level of xiphisternum of the lower chest. Since the AC current is of low 
magnitude and high frequency，it is safe and not perceptible to the subject. The voltage 
is then detected by two inner sensing electrode pairs placed 5 cm from the 
corresponding current injecting electrodes and parallel to the current path (Figure 2.1). 
An impedance (Z) signal is produced using Ohms law and processed to give the first 
derivative dZ/dt signal with the automated instrument. Basal impedance (Z。)，peak rate 
of change of impedance (dZ/dt(max)) and the ventricular ejection time (VET, B-X 
interval) are calculated using algorithms incorporated in a microprocessor (see Figure 
2.2). In addition, stroke volume (SV) and cardiac output (CO) are calculated using the 
Sramek-Bernstein formula (Thomas, Molyneux, Kelly & Smith, 1990) (Sramek, 
1993). 
. . . • . ••• • ‘ 
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Figure 2.1 Electrode positions for measuring thoracic impedance changes. 
Pairs of electrodes are placed 5 cm apart at the level of the neck and 
xiphisterniim. I represents current injecting electrode and R represents sensing 
electrode for recording transthoracic electrical bioimpedance signal. 
» 
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Figure 2.2 Derivation of systolic time intervals from the ECG and first 
derivative impedance cardiogram (dZ/dt). B represents aortic valve opening, Z 
represents peak aortic flow, and X represents aortic valve closure. PEP = pre-
ejection period and VET = ventricular ejection time. 
« 
• , I 
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The principle of TEB is that the thorax acts as a volume conductor. An AC 
current between the current injecting electrodes seeks a conductive pathway. As blood 
is a good conductor of electricity and air is non-conductive, the current passes through 
the aorta, the superior vena cava and the inferior vena cava but not the lungs (which 
contain a large amount of air in the alveoli). The changes in impedance resulting from 
physiological changes within the chest are processed and recorded. It also quantifies 
impedance changes in any shape of tissue segment (Sramek, 1993). 
2 2 DEVELOPMENT OF THEORY 
Nyboer first demonstrated that changes in transthoracic electrical impedance 
(dZ/dt) could be used as an alternative means for measuring CO non-invasively in 
1959. Since then, Kubicek developed an equation which was generally adopted for 
measurement of ventricular stroke volume or cardiac output. Ventricular ejection time 
and maximum rate of impedance change during systole (dZ/dt in ohms/sec) were 
obtained directly from the analogue chart using a tetrapolar band electrode system. 
Although results from this showed a good correlation with those from invasive 
methods, the value of AZ/sec is not very sensitive to changes in transtransthoracic 
impedance induced by the cardiac cycle whilst the subject is breathing spontaneously 
(Appel, Kram, Mackabee, Fleming & Shoemaker, 1986). Thus, recordings were 
usually taken with the subjects holding their breath. 
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� SV= P t , ^ TLVE (dzm Kubicek's equation 
Z � 
where: Pb = specific resistivity of blood (ohm.cm) 
L = distance between the sensing electrodes (cm) 
TLVE = ventricular ejection time (sec) 
(dZ/dt) max = maximum rate of systolic upstroke impedance change 
(ohm/sec) 
Zo = base impedance (ohms) 
Kubicek assumed the shape of the thorax of an adult was a cylinder with its 
base circumference equivalent to the circumference of thorax at the level of the xiphoid 
process. The specific resistivity of blood (pb) which alters with hematocrit was also 
included in his formula. However, no single universal pb-Hct relationship could be 
defined and Quail A.W., Traugott F.M., Porges W.L. and White S.W. (1981) showed 
that the value pb was relatively constant about a mean of 135 Qxm when the 
hematocrit was around 40 % and they named it as mean transthoracic resistivity (pt). 
If the impedance (Z) of a uniform conductor is directly related to its specific resistivity 
(p) and length (L) and is inversely related to its area (A), that is, 
7 L 
then by substituting Z = Z�and p = p。： 
Zo A 
P。：T 
into the Kubicek equation to eliminate pt, the following modified Kubicek equation 
resulted: 
R 




� SV = TT r ' L (volume of a cylinder). . 
In fact, the justification for elimination of pt is not only a mathematical substitution but 
also that the changes in arterial impedance resulting from alterations in blood resistivity 
are fundamentally small (less than 5.5% of the total) (Bernstein, 1986b). 
Later, Sramek estimated that the circumference (C) of the thorax at the xiphoid 
level was approximately three times the distance or length (L) between the neck and 
the lower thorax where sensing electrodes were applied. Putting C = 3L and C = Inx 
(circumference of a circle) into the modified Kubicek equation gives: 
乙 3 (c/ZMtLx 
SV = — — . . Sramek s equation 
14 〜石 Zo 
However, this equation overestimated the SV two fold (200%). Sramek considered 
that the tissue participating in the impedance resembled a truncated cone (see Figure 
2.3) with a volume which was one-third of the volume of the encompassing cylinder 
used in Kubicek's derivation. Sramek also found that the measured length (L) is 
equivalent to approximately 17% of the body height ( H in cm) in the normal adult 
population. Also, if CO is positively related to body weight and the latter is directly 
related to body height, then CO should be directly proportional to body height. The 
Sramek equation for SV was therefore presented as follows: 
… ( 0 . 1 I H ? T dZ /c/f [匪I 
where (0.17H)V4.2 is equivalent to the volume of electrically participating 
transthoracic tissure (VEPT). Nevertheless, the above Sramek equation is still not ideal 
because for every 2 to 3 cm alteration in the length (L: adult ranges: 25-32 cm) entered 
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‘ as the height (H), a 20% to 30% error in SV calculation will be produced because L is 
in the third power in the Sramek equation (Bernstein, 1986b). 
Regarding the overestimation of CO by TEB in low flow states (Jewkes, Sear, 
VerhoefF, Sanders & Foex, 1991), the NCCOM-3 computer (BoMed Medical 
Manufacturing Ltd., Irvine, CA) has an algorithm incorporated to compensate for 
(dZ/dt)max values in the lower CO ranges. The value of (dZ/dt)max is dependent on the 
length (L) of thorax between the sensing electrodes as well as the level of Z�and it has 
a linear relationship with the peak ascending aortic blood flow and velocity (Bernstein, 
1986b). 
This basic equation for stroke volume does not take into account alterations of 
body habitus, that is, height versus weight or weight versus body surface area. The 
assumption that L is 17 % of height is only correct for individuals with ideal body 
weight. A term 5 (delta) which is a weight correction indicating the adjusted ratio of 
the patient's measured weight (kg) to his/her ideal body weight (kg) (de Divitis, Fazio, 
Petitto & al, 1981) has been added into the Sramek equation. Thus, the transthoracic 
length (L) is actually estimated from the patient's height with a correction for body 
weight (Bernstein, 1986b). 
C 、 ， 加 7"】3) T dZ 1 dt、崎、 
SV = S ' T.^p ' — Sramek-Bemstein s equation 
V 4.2 J '处 Z � 
This Sramek-Bernstein equation has been incorporated into BOMED 
NCCOM3-R7 which calculates and displays stroke volume from the values of base 
impedance (Z。)，the ventricular ejection time and the maximum magnitude of the 
impedance change dZ/dt(max) and using the heart rate then gives an estimate of cardiac 
output .The monitor can also use standard ECG disposable electrodes which are more 
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Figure 2.3 Schematic representation of an adult thorax showing Kubicek，s 
thoracic encompassing cylinder of length, L (dashed lines). Sramek's smaller 
volume conductor, the frustum (truncated cone), of equal base circumference 
and L are noted to extend from the common base to the root of the neck (solid 
lines). 
* 
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convenient and will not hinder free respiration as the previously used band-electrodes, 
which encircled the chest, tended to do.These disposable ECG electrodes are joined by 
connecting wires and the frequency applied is over 70 kHz which reduces the skin-to-
electrode interface impedance (Sramek, 1982). 
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2.3 MEASUREMENTS OF HAEMODYNAMIC PARAMETERS 
The apparatus BOMED NCCOM3-R7 detects impedance change, then calculates the 
following parameters (Sramek & DeBow, 1988). For the normal ranges of BOMED 
haemodynamic parameters, see Table 2.1. 
1. Cardiac output/index (CO/CI) - represents the volume of blood that the 
heart pumps in one minute. It is measured in litres/minute (1/min). Normal resting 
cardiac output of a 50 kg woman is 5.0 L/min and that of a 85 kg man is 8.5 L/min. 
When the cardiac output is divided by body surface area (BSA), it provides the cardiac 
index (CI) which allows comparison between individuals. CO can also be indexed by 
dividing by body weight. 
2. Stroke volume/index (SV/SI) - represents the volume of blood the heart 
pumps with each contraction. Its value depends on age and body size of the subject. 
Also, it is influenced by heart rate, preload, contractility, and afterload. It has to be 
divided by BSA to facilitate interindividual comparisons. 
3. Heart rate (HR) - it acts as a compensatory variable between SV and CO, for 
a heart with a normal conduction system, a lower HR, usually implies a better left 
ventricular function. 
CO = SVxHR 
4. Peak flow (PF) - it means the fastest rate of left ventricular volumetric delivery 
of blood during the ejection phase (ml/sec). It provides some information on left 
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ventricular function. Peak flow index (PFI) is derived by dividing PF by BSA in order 
to compare this values among persons of different ages and sex. 
5. Systolic time ratio (STR) - it indicates left ventricular performance status and 
is used by the BOMED NCCOM3-R7 to calculate EF. 
STR = PEP/VET 
Systolic time intervals (STI) were originally measured from tracings of ECG 
phonocardiogram and arterial pressure trace. It can also be measured from dZ / dt 
trace and ECG. 
6. Ejection fraction (EF) - it represents the emptying capability of the left 
ventricle. It is derived from the percentage of the total volume of blood in the left 
ventricle before the start of the systole phase (the end-diastolic volume (EDV)) which 
is ejected as SV in systole. 
EF = SV/EDV 
Relationship of EF with the systolic time intervals (STI): 
a) Total electromechanical systole (QS2) is the time lapse between the 
beginning of systole (Q of ECG QRS complex) to the closing of the aortic 
valve (S2) and it is inversely related to HR. 
b) Ventricular ejection time (VET) is the time period of mechanical systole of 
the heart. It is related to SV. 
c) Pre-ejection period (PEP) is the time of isovolumic systole. 
(Q - S2) = PEP + VET 
STR = PEP/VET 
EF = 0.48- 0.64 PEP / VET 
I 
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7. £nd-diastolic volume/index (EDV/EDI) - it denotes the volume of blood in 
the left ventricle just before the start of systole. It should also be divided by BSA to 
obtain values for meaningful comparison between individuals. 
8. Index of contractility (IC) - it expresses the measurement of the ejection 
phase of the ventricular contraction. It is therapeutically useful in that it can check the 
volaemic state of patients, whether they are hypo-, normo- or hypervolemic and the 
response of the heart to inotropic therapy by determining alteration of ventricular 
contractility. 
9. Thoracic fluid index (TFI) - it represents the total electrical impedance of the 
thorax between the base of the neck and the level of the diaphragm. The conductive 
blood and tissue fluids, less conductive thoracic tissues and non-conductive air in the 
lungs account for the total conductivity of the thorax. As it is influenced by 
transthoracic fluid changes, TFI decreases in cases of pulmonary oedema. Moreover, 
taken together with IC, it can help to distinguish the origin of oedema (cardiogenic or 
non-cardiogenic oedema). For instance, in cardiogenic oedema as a result of pump 
failure, the increased transthoracic fluids will be associated with a decrease in IC. 
10. Acceleration index (ACI) - it indicates the inotropic (contractile) status of the 
left ventricle of the heart. The BOMED NCCOM3-R7 calculates the dz /dt signal and 
the maximum rate of change of impedance (dZ/dt (max)) is taken as the . ACI. Its value 
depends on fluid volume, preload and afterload of the individual. 
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11, Ventricular ejection time (VET) - it computes the time of mechanical systole 
of the ventricles from the dz / dt signal of the BOMED. It is HR and pump state 
dependent. It can be used to calculate the PEP, 
PEP = VET X STR 
12. Ejection ratio (ER) - it is the ratio of VET divided by heart rate period 
(HRP). As it indicates changes in preload, it is also called preload index (PI). ER 
increases with the same percentage as the preload increases. 
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Table 2.1 Normal ranges ofBoMED haemodynamic parameters (NCC0M3-
R7 Operator's manual pp.39 - 43). 
Cardiac index 2.8 - 4.21/min/m^ 2.8 - 4.21/min/m^ 
Stroke index 30 - 65 ml/m^ 30 - 65 ml/m^ 
End-diastolic index 45 - 100 ml/m^ 45 - 100 ml/m^ 
iiii; i i iS; : riii^ec^l2 170- 370 irnl/secW 
Ij&iiiii iSiciioii "eS+V^Yd ,^ 5d-65®/o=gc)od 56-S%F=good 
Heart rate 75 beat/min 65 beat/min 
Transthoracic fluid index 27 - 48 Ohm (supine) 20 - 33 Ohm (supine) 
i i i i i ifiJiiiii^iciiiiii^ sec ! (supine) 6.045-6.075 sec'* (supine) 
•••i;je-Siiiirriiiliii?i^c!i“iriiSeiy…••… ij'd 了iT•私 liiSi^ M二•访 j^ibif 
Systolic time ratio 5-30%=high, 30-50%=good 5-30%=high, 30-50%=good 
Acceleration index 0.9 -1.6 sec"^  (supine) 0.9 - 1.6 sec'^  (supine) 
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Table 2.2 The advantages of transthoracic electrical bioimpedance compared 
to other methods of estimation of cardiac output. 
1. Non-invasive versus invasive technique (the dilution of an indicator, dye, thermo-
dilution. 
2. Subject is free to move, thus allows monitoring during active exercise. 
3. Results are reproducible. 
4. Ease of application. 
5. Operator independent versus doppler ultrasound. 
6. Minimal patient risk. 
7. The cost is low versus cardiac catheterization. 
8. Little active co-operation from the subjects required. 
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2.4 LITERATURE REVIEW- VALIDITY OF THE TECHNIQUE 
The use of the transtransthoracic electrical bioimpedance technique (TEB) was 
introduced more than twenty years ago. Nevertheless, the validity of the technique is 
still a matter of debate. Various studies have been conducted to examine the 
reproducibility of TEB over time as well as comparison of the technique with other so 
called standard methods of CO measurement. While there are studies supporting the 
validity of TEB, others report poor correlation between results from it and established 
reference methods. In the following section, a review of the reproducibility of TEB in 
healthy volunteers and the comparison of the technique with other methods of CO 
measurement in different patient groups is delineated. 
Jewkes C.，Sear J.W., VerhoefF F., Sanders D.J., Foex P. evaluated the 
performance and reproducibility of T E B using the BOMED N C C 0 M 3 in 1991. They 
examined different aspects of the validity of TEB in volunteers and patients. Firstly, 
for the variability of TEB over short time periods and on several occasions, they found 
good coefficients of variation for stroke volume at rest over a 30 minute period as well 
as on four occasions. Secondly, when CO and SV measurements by TEB were 
compared with thermodilution in intensive care patients, correlation coefficients (r) for 
CO and SV were 0.72 and 0.83 respectively which were considered as fair (Jewkes et 
“/., 1991). 
However, a study determining the effect of mechanical ventilation on CO 
measurement by TEB using Kubicek's equation and by thermodilution in eight acutely 
ill patients showed that lower CO values were obtained from TEB than that from 
thermodilution and there was poor correlation between the results from the two 
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methods. The authors concluded that TEB was unreliable in mechanically ventilated 
patients (Preiser, Daper, Parquier, Contempre & Vincent，1989). In spite of the 
correlation of SV measurements using the Kubicek method with other reference 
methods in healthy subjects found in another study, the Kubicek method was criticised 
by Thomas (1992) for ignoring contributing factors such as right ventricular ejection, 
pulmonary blood flow, changes in venous volume and changes in blood resistivity in 
the systolic reduction in impedance. Moreover, the basal impedance in the Sramek-
Bernstein formula is in the first power while that in the Kubicek formula is in the 
second power. The advantages of the former are that the effects of change in fluid 
volume of the lungs on SV are diminished and the calculation of the volume of 
electrically participating tissue is more reliable (Thomas, 1992). 
Appel P.L., Kram H.B., Mackabee J., Fleming A.W., Shoemaker W.C. (1986) 
emphasized that a satisfactory tracing of the dZ/dt waveform was crucial for a valid 
SV calculation as well as the importance of a correct input of transthoracic length (L). 
This is because L is in the third power in the numerator of the Sramek-Bernstein 
formula, hence, each one cm error in L may give rise to a 10% error in the calculated 
SV. Moreover, these authors strongly recommended the use of TEB in titration of 
drug and fluid therapies and its application in the accident and emergency department, 
during surgery and during the postoperative ICU period because it offers recordings 
continuously and thus provides warning for the need of more intensive treatment 
(Appel etal., 1986). 
Althought Bernstein (1986) demonstrated an acceptable correlation of CO 
measurement between TEB and thermodilution (TD), he acknowledged the limitations 
of TEB in overestimating CO in patients with aortic valvular insufficiency and 
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ventricular septal defects whereas it produced underestimation of CO in patients with 
hyperdynamic sepsis (Bernstein, 1986a). Similarly, there was another study which 
revealed that TEB overestimated at low values of CO and underestimated at high 
values of CO (Jewkes et ai, 1991). The authors explained that alterations in volume of 
blood in the thorax at situations of low and high CO produced changes in the 
impedance value. It is because these impedance changes were detected by a current 
between the transthoracic sensing electrodes which seeks a conductive pathway via the 
aorta, the superior vena cava and the inferior vena cava. For TEB is essentially a 
technique of estimating blood flow by measuring changes in the electrical conductivity 
of body tissues between the transthoracic sensing electrodes. Moreover, it was 
suggested that the reason that TEB produced low CO values in septic and hypertensive 
patients could be the result of continuous rather than pulsatile blood flow in these 
patients (Appel et al, 1986). 
Castor G., Klocke R.K., Stoll M., Helms J., Niedermark I. (1994) further 
explained that TEB overestimated SV in spontaneously breathing patients because the 
ejection velocity during systole was supposed to be constant in both the Kubicek as 
well as the Sramek formula which was not the case in reality. Another reason that was 
postulated was that changes in shape and duration of the ejection wave occur as 
haemodynamic conditions alter. TEB also overestimated CO in low flow and 
underestimated during sepsis in this study. However, the authors believed that 
differences in transthoracic fluid volumes did not affect basic impedance (Zo) and this 
point of view was also supported by the study conducted by Edmunds A T., Godfrey 
S. and TooleyM. (1983). 
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Thompson (1981) argued that it is not the absolute value for CO but the 
changes in CO which are of greater importance to physicians or clinical 
pharmacologists. This is because changes in CO give an indication of the 
haemodynamic effects of drugs and hence an assessment of their therapeutic efficacy. 
In addition, this author pointed out that subjects are free to move during impedance 
monitoring which allow measurements to be made in different postures and even 
during exercise which is not possible with some of the other methods of CO 
measurement (Thompson & Joekes，1981). 
A study investigating the effects of different electrode types and electrode 
placement found that the use of certain different electrode types resulted in no 
differences in SV and CO (Jewkes et al., 1991). Whilst changes in electrode placement 
in the horizontal and diagonal planes did not result in significant changes in CO or SV, 
the same alterations in the longitudinal plane produced a graded change. The authors 
also argued that the wide variation in correlation coefficients for TEB against 
thermodilution (TD) was due to the different populations studied, the different 
reference techniques used for comparison and the correlation coefficient only indicated 
association but not agreement between the methods compared. In addition, it was a 
common viewpoint of many authors that all methods of CO measurement had their 
own inherent inaccuracies, and that no one method could be used as a gold standard 
(Appel et al, 1986) ，(Salandin, Zussa, Risica, Michielon, Paccagnella, Cipolotti & 
Simini, 1988)，(Jewkes et al.，1991)，(Thomas, 1992). Moreover, whilst TD is often 
regarded as the gold standard method, we cannot ignore the small but significant 
cardiovascular risk and mortality from this invasive technique which is also not 
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appropriate for most normal volunteer studies (Castor, Klocke, Stoll, Helms & 
Niedermark, 1994). 
Castor et. al. (1994) summarized that the main sources of error of TEB were 
electrode placement and that transthoracic length (L) is calculated as a percentage of 
subject's height in the Sramek-Bernstein formula which produces an error of about 
10%. Also, he mentioned that limitations of TEB were aortic regurgitation, 
tachyarrhythmias, open heart surgery and extreme obesity whereas advantages of TEB 
were the use of normal ECG electrodes which were comfortable for the subject and the 
technique could be performed after a short period of training of the operator. 
Moreover, there was a study which found that the agreement of changes in SV 
from baseline after interventions with pharmacological agents was better than that of 
the baseline values (Thomas, Cooper, Ekwuru, Fletcher, Gilbody, Husseyin, Ishaque, 
Jagathesan, Reddy & Smith, 1992). This proved that impedance cardiography could 
detect the changes in blood flow induced by drugs. In the same study, the authors 
verified that there was a good correlation between CO from TEB and oxygen 
consumption during submaximal exercise. Also, the mean difference or bias between 
TEB and dye dilution measurements of SV was not significant. The capability of TEB 
to follow changes in SV induced by other drugs were further confirmed in other 
studies (Boldt et al, 1988: Goldstein et al, 1986). 
Recently, Castor et. al. (1994) reported good agreement between CO 
measurements by TD and TEB under different clinical conditions including intermittent 
positive pressure ventilation, during apnoea and during spontaneous ventilation 
whereas in the same study, agreement between CO measurements by TD and another 
non-invasive technique, Doppler ultrasound (DU) was poor under all the clinical 
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conditions studied. They also argued that the discrepancies between CO measurements 
by TEB or DU compared with TD occurred because TEB and DU measured CO of 
left heart, whilst the TD catheter was actually inserted in the right heart through the 
right internal jugular vein and the latter actually measured right ventricular stroke 
volume which changed according to inspiration and expiration. In this regard, TD was 
considered to be less precise because of its non-continuous flow characteristic. 
Although there was one study (Donovan, Dobb, Woods & Hockings, 1986) 
which reported the lack of precision which was determined by the standard deviation 
of the bias (Bland & Altman, 1986) when TEB was compared with TD in critically ill 
patients, the TEB used in that study was an old instrument using Kubicek's empirical 
formular for CO measurement. In contrast, there was another study comparing CO 
measurements by TEB and TD in severely ill surgical patients (Appel et al., 1986). 
» 
They used the BoMed NCC0M3 equipment which utilizes the Sramek-Bemstein 
equation, and the transthoracic length (L) of the patients studied was calculated from 
17% of the patient's height and adjusted for weight with reference to Bernstein's 
correction chart. They found a good correlation between the two methods with a 
coefficient correlation (r) equals to 0.83. 
In addition, another study comparing CO measurement by TEB and TD in 
critical care patients (Clancy, Norman, Reynolds, Covington & Maxwell, 1991), which 
also included analysis of hospital cost for cardiac assessment by these two methods, 
revealed that not only a sound correlation of CO estimation by TEB with TD (r=0.91) 
was established, but also cost analysis revealed that the use of TEB was on average US 
$600 less than TD. Besides, acceptable agreement of SV estimation by TEB and TD 
was also found in intensive care patients (Northridge, Findlay, Wilson, Henderson & 
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Dargie, 1990), (Thomas, 1992). Furthermore, promising results from a large study in a 
paediatric intensive care unit showed that TEB could detect changes in CO of 土 5®/�(p 
< 0.005) with a power of 0.95. It affirmed the ability of TEB to determine 
cardiovascular changes resulting from either pharmacologic or procedural stressors 
(Mickell,Lucking，Chateri& Young, 1990). Furthermore，agreement between TEB 
and dye dilution in CO determination was validated in children and better correlation 
was obtained when the volume of electrically participating tissue was estimated 
directly from measurement of transthoracic length and circumference (O'Connel, 
Tibballs & Coulthard，1991). It was also found that the agreement of SV measured by 
TEB and dye dilution was satisfactory at rest and during graded upright bicycle 
exercise. However, in another study TEB largely underestimated SV during exercise as 
compared to the values measured by dye dilution (Thomas, 1992). 
- • 
Another study was conducted to measure CO simultaneously by the TEB and 
the indirect CO2 rebreathing method in eleven healthy male at rest and during different 
grades of exercise (Moore, Sansores, Guimond & Abboud, 1992), the authors also 
determined data on oxygen consumption at three levels of exercise which were then 
used to compare with the CO estimation. An acceptable agreement was found between 
the two techniques at 60 and 120 W exercise on a cycle ergometer. However, 
agreement between them at rest and at 180 W exercise was not as good as that at 60 
and 120 W exercise because the small arteriovenous CO2 difference at rest was 
difficult to be detected by the CO2 rebreathing method whereas the TEB method was 
liable to error at severe degree of exercise (180 W). Also, significant correlations were 
found between CO by both techniques and between CO and oxygen consumption. The 
.L 
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authors considered that the results justified the use of TEB in measuring CO during 
mild or moderate levels of exercise in healthy subjects (Moore et al, 1992). 
In a study of multiple comparisons of CO measurements by TEB, TD and Pick 
methods using the last two methods as reference techniques in two separate 
comparisons, the authors concluded that it was inappropriate to compare values 
measured by TEB against other standard methods which had errors in themselves 
(Salandin et al.’ 1988). The coefficients of variation for each of the three methods 
were similar indicating that TEB produced clinically acceptable CO measurements. 
Notwithstanding, the within-subject coefficients of variation revealed that the 
reproducibility of cardiovascular variables generated by TEB was better than that 
obtained by TD. As the within-subject coefficients of variation on different occasions 
detect cardiovascular changes within a person, the comparable coefficients of variation 
in CO measurement obtained by TEB and other reference methods imply it is 
applicable in pharmacodynamic monitoring (Thomas, 1992). Denniston J.C., Maher 
J.T., Reeves J.T., Cruz J.C., Cymerman A. and Grover R.F. (1976) also concluded that 
TEB is widely accepted for measuring intra-individual haemodynamic changes. 
Additionally, the use of TEB in pregnancy was also established in a study 
comparing CO in peripartum patients by TEB and TD. It showed strong agreement 
between the two techniques (within 土 20o/o) (Masaki, Greenspoon & Ouzounian, 
1989). Moreover, the place of TEB for CO estimation in patients with pacemakers has 
been reviewed (Ovsyshcher & Furman，1993). The authors claimed that a good 
correlation with an r value of 0.7 to 0.9 has been found in most studies comparing the 
TEB technique with other reference methods and that the high reproducibility of TEB 
is comparable or even better than other widely used techniques in pacemaker patients. 
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In addition, TEB permits the detection of trends of small changes in CO on a 
continuous basis. 
On the contrary, only a fair correlation and significant bias were found when 
CO was measured by thermodilution and TEB in postaortocoronary bypass patients. 
The unfavorable results were probably due to distorted anatomy and physiology of the 
patients studied, together with the presence of mechanical ventilation, chest tubes and 
other supportory devices. These may hinder the correct positioning of electrodes on 
the neck as well as lower chest and thus give faulty results (Sageman & Amundson’ 
1993). Similarly, poor correlation between TEB and thermodilution in measuring CO 
was demonstrated in a group of patients with severe sepsis and having artificial 
ventilation of the lungs (Young & McQuillan, 1993). 
In summary, the reproducibility of TEB over time is well documented and 
validated in the literature and most of the studies comparing TEB with other standard 
methods of CO estimation showed promising results. Moreover, TEB can detect small 
changes of CO produced by postural changes, during exercise and stressor procedures 
or induced by pharmacological agents which permits its use in the clinical 
pharmacology setting. With its non-invasive, easy to perform and continuous 
monitoring properties, the use of TEB in intensive care settings as well as out-patient 
clinics for cardiac assessment is further verified before more invasive monitoring is 
required. However, extensive use of TEB in place of other methods of haemodynamic 
monitoring warrants more comprehensive and meticulous studies in different clinical 
situations. 
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CHAPTER 3 A STUDYON REPRODUCIBILITY OF THORACIC 
ELECTRICAL BIOIMPEDANCE IN HEAL THYSUBJECTS 
3.1 OBJECTIVES 
The purpose of this study was to determine the reproducibility of the 
haemodynamic parameters generated by the transthoracic electrical bioimpedance 
(TEB) technique over time and to help validate its application in the clinical setting. 
3.2 METHODOLOGY 
3.2.1 Subjects 
Twelve Chinese healthy volunteers (six female and six male) were recruited for 
evaluating the variability and reproducibility of the thoracic electrical bioimpedance 
technique. Their physical characteristics are summarized in Table 3.1. Body mass index 
(BMI) was calculated by the dividing body weight with the square of body height. 
Their blood pressure were measured by an automatic sphygmomanometer (Dinamap 
8100, Critikon) which was used throughout the study. They all had unremarkable 
medical historys with their blood pressure readings in the normal range. They all gave 
their written informed consent and the study was approved by the ethical committee of 
the Chinese University of Hong Kong. 
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Table 3.1 Physical characteristics of healthy subjects (n = 12). 
Physical Characteristics Mean (SEM) . . _ . : 
Age (years) 37.8 (23 - 57) ^ 
Body weight (kg) 55.3 (3.2) 
Height (cm) 159.5 (1.7) 
Body surface area (m^) 1.55 (0.1) 
Body mass index 21.6 (0.9) 
Systolic blood pressure (mmHg) 105.3 (2.6) 
Diastolic blood pressure (mmHg) 64.8 (2.5) 
Mean arterial pressure (mmHg) 78.2 (2.1) 
Heart rate (beats/min) 63.9 (2.6) 
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3.12 Study design 
Subjects were instructed to fast overnight and attend the Clinical Pharmacology 
Studies Unit (CPSU) in the Department of Clinical Pharmacology, Chinese University 
of Hong Kong, Prince of Wales Hospital, Shatin, Hong Kong as scheduled. On the 
morning of the scheduled day, they was asked to lie down comfortably in the supine 
position for ten minutes before the non-invasive haemodynamic monitoring 
measurement was commenced. The procedure was performed by me throughout the 
whole study and lasted for around half an hour and the same procedure was repeated 
five times at intervals of six to twelve days. 
3.13 Non-invasive haemodynamic monitoring 
Self-adhesive pregelled Ag/AgCl adult E C G electrodes (CONMED Corporation, 
USA) were applied to the neck and lower chest as shown in Figure 2.1 in chapter 2 
and the cables were connected between the subject and the BOMED N C C 0 M - R 7 
impedance cardiograph. The different haemodynamic parameters were recorded on a 
personal computer connected to the thoracic electrical bioimpedance ( T E B ) - BOMED 
NCCOM3-R7 by an RS-232 connector. The BOMED impedance cardiograph analyses 
the changes in the impedance signal during each cardiac cycle and indicates 
continuously in real time the following digitally displayed variables which can be 
indexed by body surface area (BSA): cardiac index (CI), stroke index (SI), end-
diastolic index (EDI), peak flow index (PFI), ejection friaction (EF), heart rate (HR), 
thoracic fluid index (TFI), index of contractility (IC), ejection ratio (ER), systolic time 
ratio (SIR) and acceleration index (ACI) in slow mode (SM) and in fast mode (FM) 
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CI, SI, EDI, PFI, EF and HR only. Slow mode represents averaged values of the 
haemodynamic parameters after every 16 beats detected and analysed by the TEB 
while FM represents calculation and display of relevant parameters for each heart beat 
which can be analysed. 
Personal parameters pertaining to each subject including a specific subject 
code, body weight and body height were entered into the machine to calculate BSA 
which was then used to estimate the stroke volume index using the Sramek-Bemstein 
formula as stated in section 2.2. Thoracic length (L) was calculated by 17% of height 
adjusted for weight according to Bernstein's correction nomogram incorporated in the 
machine (Bernstein, 1986). After input of the subject's particulars, the haemodynamic 
variables estimated by the TEB were saved on the hard disk of the computer along 
with the' real time of acquisition. The recorded data were then transfered onto floppy 
disks for further analysis by other spreadsheet and statistical software (see section 
3.2.6). Haemodynamic measurements were measured at each monitoring session using 
the following protocol: 
Minutes Supine - Standing 
0 Start 10 minutes supine rest 
10 Record in SM for 4 minutes 
14 Change to FM one minute prior to standing position 
15 Subject stands, FM maintains for 2 minutes 
17 Subject stands, change to SM for 3 minutes 
Sitting - Handgrip 
20 Start 5 minutes in sitting position 
25 Record in SM for 2 minutes 
27 Start handgrip in SM for 2 minutes 
29 End 
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3.2.4 Blood Pressure Measurement 
Blood pressure was measured with an automatic sphygmomanometer 
(Dinamap 8100，Critikon). A cuff was applied on the right upper arm of the subject 
and blood pressure readings were taken at one-minute intervals throughout the study. 
Mean arterial pressure (MAP) is calculated automatically by the Dinamap. Total 
peripheral resistance index (dyne.sec,cm-5.m-2) was calculated as the quotient between 
• • 2 
mean arterial pressure (mmHg) times 80 and the cardiac index (1/min/m ). 
3.2.5 Isometric Exercise 
The isometric exercise in the form of a handgrip was included in the last section 
of the haemodynamic monitoring protocol. It was performed using a modified hand 
dynamometer because the commercial grip dynamometer could be released by the 
subject once the target value was achieved. The self-made hand dynamometer was 
devised in our department (Anderson, 1993). It consists of a rubber bulb affixed to a 
portable sphygmomanometer in place of the cuff The approximate substituted values 
in Kg on the dynamometer compared to mmHg on the sphygmomanometer was 
estimated in a group of 15 female volunteers. This was done because the modified 
dynamometer could not measure high enough for maximum handgrip in a strong male. 
Their maximum grip was first measured by the grip dynamometer (in kg) and then by 
the modified hand dynamometer (in mmHg) and the same procedure was repeated 
three times. Subsequently, the mean of the three readings for each device was 
calculated and the following estimation was made for each of the volunteers: 
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Mean value in mmHg ^ . / . . 
—=Conversion factor 
Mean value in Kg 
Then all the conversion factors obtained were averaged. From these results, it was 
found that there was approximately 13.6 mmHg to 1 Kg. Thereafter, a conversion 
factor of 13 mmHg was selected since it was more appropriate to slightly 
underestimate the handgrip rather than over-estimate it because most of the subjects 
found it di伍cult to maintain 30% of their maximum handgrip for the required time. In 
short, maximal voluntary contraction (MVC) was first estimated from a maximum 
hand grip of the subject's left hand by a grip dynamometer (0-100 kg W; Takei Kiki 
Kogyo, Japan) and the reading in Kg was then multiplied by 13 to convert the value 
into mmHg. Then the subject was instructed to maintain 30% of the calculated 
handgrip value in mmHg for continuous period of two minutes using the left hand. 
Data in the second minute of isometric handgrip exercise were used for the 
calculations. 
3,16 Data analysis 
Recordings generated by the BoMed NCCOM3-R7 were saved in a 
programme developed in Lab Windows software and written in by an experienced 
programmer in the Computer Services Unit of the Chinese University of Hong Kong 
and incorporated in a PC compatible computer. Only data in slow mode (SM) were 
used for subsequent mathematical and statistical processing. Around three to four lines 
of data in SM can be obtained in each minute and they were saved in an IBM DOS 
compatible ASCII file initially. The stored data of different parameters in rows were 
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then imported into a spreadsheet software (QUATTRO PRO for Windows, version 
5.0，Borland International, 1993) for further analysis. A spreadsheet with headings of 
eleven impedance-derived parameters was made prior to data input. Imported data 
were then divided into sections according to the specific time intervals of different 
positions and isometric exercise of the non-invasive haemodynamic monitoring 
protocol. The last three columns of the spreadsheet were indications of time in hours, 
minutes and seconds respectively. For data recorded during isometric e x e r c i s e , � 
subdivision into smaller sections in one minute intervals was made because only data of 
the second minute was utilized for calculation in order to present the effect of peak 
handgrip. Raw data in each section were labelled and averaged using the statistical 
function of the spreadsheet software (@ functions - @AVG) for each subject (see 
Figure 3.1). These averaged haemodynamic parameters over four minutes in the supine 
position after lying for ten minutes, three minutes in the erect position commenced 
after standing for two minutes, two minutes after sitting for five minutes and over the 
last minute of the two-minute handgrip exercise were saved for further calculation 
later. 
Likewise, a blank summary form called 'blinical pharmacology cardiovascular 
assessment" form with all the labels and formulas was created in a spreadsheet file (See 
Figure 3.2). Mathematical calculations including body mass index (BMI) and 
calculated systemic vascular resistance index (SVRI) were entered as formulas in 
specific cells. Since SVRI is a function of MAP and CI, it is related to the latter two 
parameters as SVRI = MAP * 80 /CI. Thus, whenever data were entered into these 
cells, corresponding values were calculated spontaneously. Then, this form was saved 
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under a different filename according to the assigned code of the subject and it was so 
designed for easy referencing of each subject's record later. Moreover, for the purpose 
of this thesis, only data on cardiac index (CI), stroke index (SI) and heart rate (HR), 
together with blood pressure readings and SVRI were transferred and examined for 
statistical significance in another new master spreadsheet. This master spreadsheet as it 
was called included all the calculated mean values of the parameters for all subjects in 
the six monitoring sessions (see Figure 3.3). Means and standard errors (SEM) of 
these values were then calculated (SEM was obtained by putting in the formula such as 
@STDS(A1"J10) / @SQRT(10)) which divides the standard deviation by the square 
root of the number of values. Furthermore, t values of changes in comparison to 
baseline in every positions and during isometric exercise were computed by the 
quotient of mean and standard error for primary statistical significance. 
3.2.7 Statistical analysis 
The haemodynamic data saved in floppy disks were imported into a spreadsheet 
software (QUATTRO PRO for Windows, version 5.0, Borland International, 1993) for 
mathematical calculations of mean and standard deviation (S.D.). Coefficient of 
variation (C.V.) was derived from the following formula: 
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Figure 3.2 An illustration of a summary spreadsheet called "Clinical Pharmacology 
Cardiovascular Assessment" for each healthy subject of the integrated hypertension 
study. 
STARTING DA STOP DATE 
1 Not on medication 
2 
^ f c CI SI HK SBP DBP MBF . SVRI 
l/min/m^ ml/m^ b/min mmHg mmHg mmHg dyne.sec/civr/m^ 
SUPINE 3.30 60.23 55.15 97.25 54.75 72.75 1763.64 
STANDING 3.03 42.42 71.67 99.00 58.00 76.33 2013.19 
SITTING 3.03 45.88 66.00 98.00 58.50 76.00 2009.92 
HANDGRIP 2.94 40.60 72.00 112.00 71.00 82.00 2231.29 
mm 5 
SUPINE 4.28 70.00 61.00 98.00 51.75 71.75 1341.57 
STANDING 3.27 44.17 73.92 100.33 58.33 75.33 1844.90 
SITTING 3.33 50.75 65.63 104.00 57.50 73.50 1768.42 
HANDGRIP 3.15 46.25 68.75 108.00 70.00 86.00 2184.13 
圓 。。• 
SUPINE 4.13 69.08 59.62 99.25 56.75 70.00 1355.68 
STANDING 3.19 49.30 64.90 101.67 54.67 74.67 1872.52 
SITTING 3.13 46.63 66.88 105.00 57.50 71.00 1817.60 
h a n d g r i p 2.95 42.75 69.00 113.00 51.00 83.00 2250.85 
SUPINE 4.49 72.64 61.71 99.25 55.25 69.25 1235.03 
STANDING 3.49 47.15 74.00 98.33 50.33 73.33 1679.88 
SITTING 3.76 53.63 70.13 89.50 50.50 66.50 1413.95 
HANDGRIP 3.50 49.00 71.50 102.00 52.00 80.00 1828.57 
SUPINE 3.81 64.36 59.36 98.25 53.25 69.75 1465.67 
STANDING 3.19 47.73 66.82 99.67 54.67 71.67 1796.77 
SITTING 3.21 50.88 63.38 98.00 46.00 66.50 1656.03 
HANDGRIP 3.13 46.00 67.75 102.00 60.00 80.00 2048.00 
圓 
SUPINE 3.63 61.79 58.50 99.00 58.00 73.00 1609.45 
STANDING 2.83 43.09 65.73 102.33 59.00 80.00 2263.67 
‘ SITTING 3.06 47.57 63.71 100,00 50.50 73.50 1923.36 
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3.3 RESULTS 
3.3.1 Systolic blood pressure 
• Reproducibility in the supine position on six different occasions 
The within-subject mean of SBP over the six occasions varied from 93.8-120.0 
mmHg with the group mean 105.3 mmHg. The within-subject variability as shown by 
the mean of the individual coefficients of variation was 2.6 土 1.7 % ranging from 0.8-6.2 
%. The between-subject variability of SBP ranged from 6.6 to 8.7 % and the group 
mean C.V. was 7.7土0.8 %. For the percentage change of supine SBP in the six TEB 
monitoring sessions in comparison to the mean value of the six visits of the twelve 
healthy subjects, see figure 3.4. 
• Reproducibility in the standing position on six different occasions 
The group mean of within-subject between-occasions average SBP was 108.6 
mmHg with the range 97.2-120.6 mmHg. The within-subject variability of SBP ranged 
from 1.5-5.3 % and the group mean C.V. was 3.1 土 1.4 %. The between-subject 
variability as indicated by the mean of the group coefficients of variation was 7.5土0.5 
% with the range from 6.6 to 8.0 %. 
1 
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Figure 3. 4 Graph showing the percentage change of supine systolic (above) 
and diastolic (below) blood pressure in the six TEB monitoring sessions in 
comparison to the mean value of the six visits of the twelve healthy subjects. 
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• Reproducibility in the sitting position on six different occasions 
The within-subject between-occasions mean of SBP ranged from 97.7-119.4 
mmHg and the group mean was 107.9 mmHg. The mean of the individual coefficients 
of variation was 4.3土 1.8 % ranging from 1.9-7.8 %. The between-subject variability of 
SBP as indicated by the mean of the group coefficients of variation was 7.4土 1.3 % 
with the range 5.8 to 8.8 %. 
• Reproducibility during handgrip on six different occasions 
The within-subject between-occasion mean of SBP ranged from 107.2-146.7 
mmHg with the group mean 123.0 mmHg. The within-subject variability varied from 
1.7-9.3 % and the mean individual coefficients of variation was 4.4±2.0 %. The 
between-subject variability of SBP ranged from 8.1-13.3 % and the group mean C.V. 
was 10.0±2.0 %. 
3.3.2 Diastolic blood pressure 
• Reproducibility in the supine position on six different occasions 
The within-subject mean of DBP over the six occasions varied from 54.9-77.8 
mmHg with the group mean 64.7 mmHg. The within-subject variability as shown by 
the mean of the individual coefficients of variation was 4.0土 1.4 % ranging from 1.8-6.6 
%. The between-subject variability of DBP ranged from 10.7-12.8 % and the group 
mean C.V. was 11.8土0.8 %. For the percentage change of supine DBP in the six TEB 
monitoring sessions in comparison to the mean value of the six visits of the twelve 
healthy subjects, see figure 3.4. 
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• Reproducibility in the standing position on six different occasions 
The group mean of within-subject between-occasions average DBP was 68.6 
mmHg with the range 54.5-80.4 mmHg. The within-subject variability of DBP ranged 
from 2.2-6.9 % and the group mean C.V. was 4.6土 1.5 %. The between-subject 
variability as indicated by the mean of the group coefficients of variation was 12.7±2.1 
% with the range from 10.4-16.3 %. 
• Reproducibility in the sitting position on six different occasions 
The within-subject between-occasions mean of DBP ranged from 53.4-78.4 
mmHg and the group mean was 68.6 mmHg. The mean of the individual coefficients of 
variation was 5.2±1.8 % ranging from 3.5-9.6 %. The between-subject variability of 
DBP as indicated by the mean of the group coefficients of variation was 13.6±2.5 % 
with the range 10.0-16.0 %. 
• Reproducibility during handgrip on six different occasions 
The within-subject between-occasion mean of DBP ranged from 59.3-97.5 
mmHg with the group mean 78.1 mmHg. The within-subject variability varied from 
2.3-17.4 % and the mean individual coefficients of variation was 7.8土5.1 %. The 
between-subject variability of DBP ranged from 13.5-20.7 % and the group mean C.V. 
was 17.5±2.8 %. 
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3.3.3 Mean arterial pressure 
• Reproducibility in the supine position on six different occasions 
The within-subject mean of MAP over the six occasions varied from 70.2-92.8 
mmHg with the group mean 80.0 mmHg. The within-subject variability as shown by 
the mean of the individual coefficients of variation was 4.2+2.6 % ranging from 2.3-
12.1 o/o. The between-subject variability of MAP ranged from 8.3-10.6 % and the 
group mean C.V. was 9.6土0.8 %. 
• Reproducibility in the standing position on six different occasions 
The group mean of within-subject between-occasions average MAP was 85.3 
mmHg with the range 75.2-93.6 mmHg. The within-subject variability of MAP ranged 
from 1.9-4.9 % and the group mean C.V. was 3.8土0.9 %. The between-subject 
variability as indicated by the mean of the group coefficients of variation was 8.3士0.8 
o/o with the range from 7.5-9.5 %. 
• Reproducibility in the sitting position on six different occasions 
The within-subject between-occasions mean of MAP ranged from 71.2-94.0 
mmHg and the group mean was 84.5 mmHg. The mean of the individual coefficients of 
variation was 4.8土2.0 % ranging from 2.1-7.8 %. The between-subject variability of 
m a p as indicated by the mean of the group coefficients of variation was 9.6土 1.3 % 
with the range 8.1-11.9%. 
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• Reproducibility during handgrip on six different occasions 
The within-subject between-occasion mean of MAP ranged from 82.3-108.3 
mmHg with the group mean 96.9 mmHg. The within-subject variability varied from 
2.7-14.3 % and the mean individual coefficients of variation was 5.7±2.9 %. The 
between-subject variability of MAP ranged from 8.3-13.7 % and the group mean C.V. 
was 11.0±2.3 %. Table 3.2 and table 3.3 summarized the variability of haemodynamic 
and blood pressure parameters in healthy subjects. 
3.3.4 Heart rate 
• Reproducibility in the supine position on six different occasions 
The within-subject mean of HR over the six occasions varied from 53.7-79.8 
beats/min with the group mean 67.4 beats/min. The within-subject variability as shown 
by the mean of the individual coefficients of variation was 5.4士1.9 % ranging from 2.4-
9.2 %. The between-subject variability of HR ranged from 12.7 to 16.2 % and the 
group mean C.V. was 14.1 士 1.3 %. For the percentage change of supine HR in the six 
TEB monitoring sessions in comparison to the mean value of the six visits of the 
twelve healthy subjects, see figure 3.5. 
• Reproducibility in the standing position on six different occasions 
The group mean of within-subject between-occasions average HR was 76.8 
beats/min with the range 60.8-90.4 beats/min. The within-subject variability of HR 
ranged from 3.0-8.1 % and the group mean C.V. was 5.7土1,5 %. The between-subject 
I 




I H ^ ^ ^ ^ 
M 
S -20 一 a 
t -30 -
•40 J 1 1 1 1 1 I 
VI V2 V3 V4 V5 V6 
O female healthy subjects • male healthy subjects 
Figure 3. 5 Graph showing the percentage change of supine heart rate in the 
six TEB monitoring sessions in comparison to the mean value of the six visits of 
the twelve healthy subj ects. 
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variability as indicated by the mean of the group coefficients of variation was 13.2 土 1.2 
% with the range from 11.3 to 14.5 %. 
• Reproducibility in the sitting position on six different occasions 
The within-subject between-occasions mean of HR ranged from 57.2-84.7 
beats/min and the group mean was 71.5 beats/min. The mean of the individual 
coefficients of variation was 5.5±2.7 % ranging from 2.3-11.8 %. The between-subject 
variability of HR as indicated by the mean of the group coefficients of variation was 
13.7士 1.5 % with the range 11.8-15.6 %. 
• Reproducibility during handgrip on six different occasions 
The within-subject between-occasion mean of HR ranged from 60.4-88.6 
beats/min with the group mean 76.7 beats/min. The within-subject variability varied 
from 2.0-8.0 % and the mean individual coefficients of variation was 4.6土1.4 %. The 
between-subject variability of HR ranged from 11.7-14.6 % and the group mean C.V. 
was 13.5 土 1.2%. 
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3.3.5 Thoracic fluid index 
• Reproducibility in the supine position on six different occasions 
The within-subject mean of thoracic fluid index (TFI) over the six occasions 
varied from 22.64 - 29.09 with the group mean 26.58. The within-subject variability as 
shown by the mean of the individual coefficients of variation was 5.4 土 1.5 o/o ranging 
from 2.2 - 7.2 %. The between-subject variability of TFI ranged from 7.5 to 12.0 % 
and the group mean C.V. was 9.1 士 1.8 %. For the percentage change of supine TFI in 
the six TEB monitoring sessions in comparison to the mean value of the six visits of 
the twelve healthy subjects, see figure 3.6. 
• Reproducibility in the standing position on six different occasions 
The group mean of within-subject average TFI over the six visits was 29.2 with 
the range 26.2 - 30.1. The within-subject variability of TFI ranged from 2.0 - 9.2 % 
and the group mean C.V. was 5.3 土 2.0 %. The between-subject variability as indicated 
by the mean of the group coefficients of variation was 9.2 土 0.9 % with the range from 
8.3 to 10.6 o/o. 
• Reproducibility in the sitting position on six different occasions 
The within-subject between-occasions mean of TFI ranged from 25.3 - 31.0 
and the group mean was 28.1. The mean of the individual coefficients of variation was 
5.7 土 1.9 % ranging from 2.3 - 8.8 %. The between - subject variability of TFI as 
indicated by the mean of the group coefficients of variation was8.6 士 1 .1� /�with the 
range 7.5-10.1%. 
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Figure 3. 6 Graph showing the percentage change of supine throacic fluid 
index in the six TEB monitoring sessions in comparison to the mean value of the 
six visits of the 
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• Reproducibility during handgrip on six different occasions 
The within-subject mean ofTFI over the six occasions ranged from 25.1 - 30.9 
vnth the group mean 28.0. The within-subject variability varied from 2.6 - 8.5 % and 
the mean individual coefficients of variation was 5.7 土 1.7 %. The between-subject 
variability ofTFI ranged from 7.6 -10.6 % and the group mean C.V. was 9.1 士 1.1 %. 
3.3.6 Stroke index 
• Reproducibility in the supine position on six different occasions 
The within-subject mean of SI over the six occasions varied from 29.7-68.8 
ml/m^ with the group mean 51.9 mMvc?. The within-subject variability as shown by the 
mean of the individual coefficients of variation was 8.0+2.4 % ranging from 4.1-12.3 
%. The between-subject variability of stroke index ranged from 23.3 to 28.5 % and the 
group mean C.V. was 26.4±1.9 %. For the percentage change of supine SI in the six 
TEB monitoring sessions in comparison to the mean value of the six visits of the 
twelve healthy subjects, see figure 3.7. 
• Reproducibility in the standing position on six different occasions 
The group mean of within-subject average SI over the six visits was 33.3 ml/m^ 
with the range 24.2-48.4 ml/m .^ The within-subject variability of stroke index ranged 
from 2.7-8.3 % and the group mean C.V. was 6.0±1.9 %. The between-subject 
variability as indicated by the mean of the group coefficients of variation was 23.5 土 1.2 
% with the range from 21.9 to 25.4 %. 
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Figure 3. 7 Graph showing the percentage change of supine stroke index in the 
six TEB monitoring sessions in comparison to the mean value of the six visits of 
the twelve healthy subjects. 
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• Reproducibility in the sitting position on six different occasions 
The within-subject mean of SI over the six occasions ranged from 25.6-51.6 
ml/m^ and the group mean was 36.1 ml/m .^ The mean of the individual coefficients of 
variation was 8.7+2.4 % ranging from 6.1-13.3 %： The between-subject variability of 
SI as indicated by the mean of the group coefficients of variation was 25.2±3.5 % with 
the range 19.1-28.8%. 
• Reproducibility during handgrip on six different occasions 
The within-subject mean of SI over the six occasions ranged from 24.6-51.0 
ml/m^ with the group mean 34.0 ml/m^. The within-subject variability varied from 4.1-
14.2 o/o and the mean individual coefficients of variation was 7.5+3.1 %. The between-
subject variability of SI ranged from 17.8-26.6 % and the group mean C.V. was 
24.0土3.2 %. 
3.3.7 Cardiac index 
• Reproducibility in the supine position on six different occasions 
The within-subject mean of CI over the six occasions varied from 2.23-4.27 
l/min with the mean value for the group being 3.42 l/min. The within-subject variability 
as shown by the mean of the individual coefficients of variation was 6.2±2.4 % with 
C.V. values for each subject ranging from 3.5-11.2 %. The between-subject variability 
of cardiac index ranged from 19.6 to 22.4 % and the group mean C.V. was 21.0土 1.0 
o/o. For the percentage change of supine CI in the six TEB monitoring sessions in 
comparison to the mean value of the six visits of the twelve healthy subjects, see figure 
3.8. 
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Figure 3. 8 Graph showing the percentage change of supine cardiac index in 
the six TEB monitoring sessions in comparison to the mean value of the six visits 
of the twelve healthy subjects. 
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• Reproducibility in the standing position on six different occasions 
The group mean of within-subject average CI over the six visits was 2.49 1/min 
with the range 1.95-3.17 1/min. The within-subject variability of cardiac index ranged 
from 3.3-7.9 % and the group mean C.V. was 5.5土 1.6 %. The between-subject 
variability as indicated by the mean of the group coefficients of variation was 14.6土 1.2 
% with the range from 13.1 to 16.1 %. 
• Reproducibility in the sitting position on six different occasions 
The within-subject between-occasions mean of CI ranged from 1.92-3.25 1/min 
and the group mean was 2.52 1/min. The mean of the individual coefficients of 
variation was 7.5±2.1 % ranging from 4.3-12.1 %. The between-subject variability of 
cardiac index as indicated by the mean of the group coefficients of variation was 
17.8土1.6 % with the range 15.8-20.0 %. 
• Reproducibility during handgrip on six different occasions 
The within-subject mean of CI over the six occasions ranged from 2.06-3.08 
1/min with the group mean 2.55 1/min. The within-subject variability varied from 2.7-
12.2 % and the mean of the individual coefficients of variation was 7.5+3.5 %. The 
between-subject variability of cardiac index ranged from 12.6-17.7 % and the group 
mean C.V. was 15.7土 1.9%. 
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3.3.8 Systemic vascular resistance index 
• Reproducibility in the supine position on six different occasions 
The within-subject mean of SVRI over the six occasions varied from 1461.8-
3157.3 dyne.sec/cmVm^ with the group mean 1993.9 dyne.sec/cmW. The within-
subject variability as shown by the mean of the individual coefficients of variation was 
8.1 土3.2 % ranging from 4.0-13.8 %. The between-subject variability of systemic 
vascular resistance index ranged from 27.9 to 35.7 % and the group mean C.V. was 
32.5±2.9 %. For the percentage change of supine SVRI in the six TEB monitoring 
sessions in comparison to the mean value of the six visits of the twelve healthy 
subjects, see figure 3.9. 
• Reproducibility in the standing position on six different occasions 
The group mean of within-subject average systemic vascular resistance index 
over the six visits was 2803.6 dyne.sec/cmVm^ with the range 1911.8-3453.2 
dyne.sec/cmVm^ The within-subject variability of SVRI ranged from 2.3-10.7 % and 
the group mean C.V. was 7.0±2.4 %. The between-subject variability as indicated by 
the mean of the group coefficients of variation was 18.6±2.1 % with the range from 
15.5 to 21.3%. 
• Reproducibility in the sitting position on six different occasions 
The within-subject between-occasions mean of SVRI ranged from 1764.9-
5 2 
3929.2 dyne.sec/cmVm^ and the group mean was 2786.4 dyne.sec/cm /m • The mean 
of the individual coefficients of variation was 9.2 土 2.4 % ranging from 5.0-12.6 %. The 
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Figure 3. 9 Graph showing the percentage change of supine systemic vascular 
resistance index in the six TEB monitoring sessions in comparison to the mean 
value of the six visits of the twelve healthy subjects. 
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between-subject variability of SVRI as indicated by the mean of the group coefficients 
of variation was 23.8±2.3 % with the range 21.1-26.3 %. 
• Reproducibility during handgrip on six different occasions 
The within-subject mean of SVRI over the six occasions ranged from 2155.9-
4184.9 dyne.sec/cmVm^ with the group mean 3141.2 dyne.sec/cmVm^. The within-
subject variability varied from 2.7-15.8 % and the mean individual coefficients of 
variation was 9.7土3.9 %. The between-subject variability of systemic vascular 
resistance index ranged from 21.3-24.8 % and the group mean C.V. was 22.7±1.2 %. 
t 
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Table 3. 2 Variability of blood pressure parameters in healthy subjects. Mean 
values for twelve subjects on six occasions. 
Systolic blood pressure 
(mmHg) 
Supine 105.26 2.59 7.74 
Standing 108.57 3.12 7.52 
Sitting 107.90 4.30 7.39 
Handgrip 123.03 4.38 9.99 
DiiistoUc blood pressure 
(mmHg) 
Supine 64.67 4.04 11.75 
Standing 68.56 4.55 12.66 
Sitting 68.57 5.19 13.55 
Handgrip 78.07 775 17.49 
Mean arterial pressure 
(mmHg) 
Supine 80.00 4,23 9.63 
Standing 85.32 3.75 8.31 
Sitting 84.49 4.83 9.61 
； Handgrip 96.93 5.69 11.02 
« 
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Table 3. 3 Variability of TEB-derived haemodynamic parameters in healthy 
subjects. Mean values for twelve subjects on six occasions. 
Cardiac index (l/min/m^) 
Supine 3.42 6.24 20.97 
Standing 2.49 5.46 14.62 
Sitting 2.52 T53 17.79 
Handgrip 7.45 15.73 
Stroke volume (ml/m^) 
Supine 51.94 8,00 26.44 
Standing 33.27 6.01 23.53 
Sitting 36.09 S,66 25.24 
Handgrip ^ ^ 24.04 
Heart rate (beats/min) 
Supine 67.42 5.40 14.09 
Standing 76.81 5.69 13.24 
Sitting 71.47 5.53 13.66 
Handgrip 76.71 13.49 
Systemic vascular resistance 
index 
Supine 1993.89 8.10 32.48 
Standing 2803.63 7,01 18.64 
Sitting 2786.24 9.21 23.80 
； Handgrip 3141.20 22.66 
Thoracic fluid index 
Supine 26.6 5.35 9.14 
Standing 29.2 5.30 9.16 
Sitting 28.1 5.67 8.56 
Handgrii) 28.0 5,68 9.05 
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3.4 DISCUSSION 
The reproducibility of transthoracic electrical bioimpedance (TEB) between 
different occasions in twelve subjects under postural and physiological stress has been 
studied. Reproducibility is defined in laboratory medicine as follows: 
"the variation observed on repeated assay of a single test specimen in 
association with the complete re-calibration of the assay method with each test 
assay.” (Strike, 1991) 
Or simply, the variation observed on repeated tests using the same protocol and 
instruments. As a coefficient of variation < 10% is considered as good whereas < 20% 
is acceptable in biological science data (Scott, Randolph & Leier, 1989)，the results of 
our study showed reasonably good reproducibility of the haemodynamic data obtained 
by TEB. While systolic blood pressure, diastolic blood pressure and heart rate can be 
taken as internal physiologic standards, their mean C.V. at various conditions of the 
study (2.6-4.4 % for SBP, 4.6-7.8 % for DBP and 4.6-5.7 % for HR) were only 
slightly lower than that of cardiac output (5.5-7.5), stroke volume (6.0-8.7 %), and 
systemic vascular resistance index (7.0-9.7 %). However, the variation among 
individuals was wide as the mean between subjects C.V. of CI at supine rest was 
21.0士 1.0 %, whereas that of SI, 26.4土 1.9 % and SVRI, 32.5±2.9 % and it was 
comparable to the findings of other studies (Ng, Walley, Tsao & Breckenridge, 1991). 
According to the claim made by Sramek (1993) that the clinically acceptable 
margin of error for cardiac output and systemic vascular resistance index were both 
±20 o/o, the above results for CI and SVRI in different postures and during handgrip 
revealed that they were well below this limit as the mean within-subject between-
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occasion coefficients of variation were 5.5-7.5 % and 7.0-9.7 % respectively among 
the four different conditions in the study. Moreover, the coefficients of variation of the 
mean thoracic fluid index (TFI) in the different positions and during handgrip were 
below 10%. TFI is actually the base impedance (Z�) and reflects impedance of thoracic 
tissues. The small values for CV ofTFI indicated the capability of the TEB technique 
to measure impedance of the thoracic tissues with a high reproducibility. 
It has been shown that the results of TEB measurements were less reproducible 
between-occasions than within-occasions as shown (Thomas, 1992). Possible reasons 
accounting for this in addition to inaccuracies in the method, were changes in physical 
environment, for examples, temperature, noise level and variations in individual 
physiological responses in between visits as cardiac output like other haemodynamic 
parameters is hardly likely to remain constant from one visit to the next. Nevertheless, 
it appears that TEB produces a reasonable measure of the changes in different postures 
and under stress, for example, the handgrip exercise in this study. Furthermore, it has 
been stated that detection of changes in CO or other cardiovascular parameters is more 
meaningful than the absolute values (Thompson & Joekes，1981) (Ng et al, 1991). 
Overall, TEB is a clinically useful non-invasive technique for estimating CO 
and it has the additional advantage of giving on-line, continuous measurements of 
cardiovascular variables. It has been verified by the vast majority of studies on TEB. 
For those studies showing a poor relationship between TEB results compared with 
other reference methods, it should be considered that there is no one method that is 
absolutely correct in measuring CO. All have their own inaccuracies inherent in their 
own theoretical designs. Also, the statistical methods used for comparison of data 
between TEB and other methods could be criticised because in some reports only the 
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correlations between sets of data obtained by two different methods are presented 
(Appel, Kram, Mackabee, Fleming & Shoemaker, 1986) (Salandin, Zussa, Risica, 
Michielon, Paccagnella, Cipolotti & Simini, 1988) which does not reveal the agreement 
between the compared methods as advocated by Bland and Altman that the use of 
correlation alone in such circumstance is inappropriate and misleading (Bland & 
Altman, 1986). Moreover, there was one study showing unsatisfactory results of TEB 
when comparing it with thermodilution in critically ill patients (Donovan, Dobb, 
Woods & Hockings, 1986) which used Kubicek's equation for calculating CO. As 
discussed above, the Sramek-Bernstein equation overcomes some of the disadvantages 
present in the former equation developed by Kubicek. Most studies which show a poor 
relationship of TEB with other clinically acceptable methods for estimating CO were 
only small studies, a letter or comments in a journal. More data are required to make 
definitive comparisons before the evidence shown by other studies which verified the 
validity and reproducibility of TEB in clinical use can be refuted. 
To conclude, thoracic electrical bioimpedance cardiography detects changes in 
postural and physiological stress and demonstrates acceptable reproducibility on 
healthy subjects in this study. Its application in the clinical pharmacological setting is 
discussed in chapter 4: literature review, chapter 5: the integrated hypertension study 
and chapter 6: acute haemodynamic effects of atenolol and pindolol. 
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CHAPTER 4 LITERA TUBE REVIEW 
4.1 A TENOLOL： BETA'ADRENOCEPTOR ANTA GONISTS WITH 
PI-SELECTIVITY 
Atenolol is a cardioselective betai-adrenoceptor antagonist. The usual oral dose 
of atenolol for the treatment of hypertension and angina pectoris is 50-100mg given 
once daily. Full anti-hypertensive effect is usually achieved within two weeks. The 
plasma half-life of atenolol is 6-14 hours but adequate twenty-four blood pressure 
control has been demonstrated with single daily doses. Atenolol is partially absorbed 
from the gastro-intestinal tract and it is not significantly metabolised in the liver. Half 
of the drug is eliminated via the kidney and the rest is excreted in the faeces (Reynolds, 
1989). As with other beta-blockers, it has adverse metabolic effects including 
increases in total cholesterol, low density lipoprotein cholesterol and triglycerides and 
decreases in high density lipoprotein cholesterol. Glucose intolerance may also be 
aggravated. Exercise tolerance is reduced (except in angina) because the 
haemodynamic response to exercise is impaired (Houston, 1989). The most common 
side effects are fatigue, bradycardia, dizziness, hypotension, nausea and vomiting. It is 
used mainly for the treatment of hypertension, angina pectoris and following acute 
myocardial infarction to reduce subsequent cardiovascular morbidity and mortality 
(Reynolds, 1989). 
The probable anti-hypertensive mechanisms of beta-adrenoceptor antagonsists 
with Pi-selectivity and without intrinsic sympathomimetic activity (ISA), atenolol, 
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decrease CO and hence blood pressure. However, reduction in blood pressure is 
opposed by a tendency to elevate vascular resistance through a baroreflex-mediated 
increase in vasoconstrictor nerve activity. Since blockade of prejunctional P-receptors 
may counteract the effect of high sympathetic tone on postjunctional a-receptors, 
vascular resistance may increase above to baseline values with a decrease in CO. 
Furthermore, the fall in blood pressure is correlated with a reduction in vascular 
resistance and the change of vascular resistance is directly proportional to the 
magnitude of cardiodepression of the drug (Man iri't Veld & Schalekamp, 1982). 
There are apparent differences between the acute and chronic effects of beta-
adrenoceptor antagonists. The initial anti-hypertensive effects are counteracted by an 
increase in vascular resistance which is directly related to the fall in CO. Subsequently, 
reduction in blood pressure occurs in association with a fall in SVRI. It is believed that 
I 
beta-adrenoceptor antagonists reduce blood pressure through their interference on 
vasoconstrictor mechanism (Man in't Veld, 1991) which may be mediated through the 
central nervous system or by reduction of renin secretion. 
The use of non-invasive TEB to study the haemodynamic effects of three 
different classes of beta-adrenoceptor antagonists was examined in a group of eight 
healthy subjects (Thomas, Cooper, Ekwuru, Fletcher, Gilbody, Husseyin, Ishaque, 
Jagathesan, Reddy & Smith, 1992). They underwent a series of recordings at rest, 
during passive tilting and graded upright bicycle exercise two hours after taking 
placebo, propranolol 40mg and 80mg, atenolol 50mg and lOOmg and pindolol 5mg 
and lOmg. The authors found that without treatment there were increments in heart 
rate, diastolic blood pressure and systemic vascular resistance and decrements in stroke 
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index and cardiac index in head-up tilting; increases in HR, SBP, SI and greater 
increase in CI during graded exercise, and all measurements returned to resting values 
with SI increased in the early stages but decreased to below resting levels in the later 
stages during recovery. Moreover, the authors of this study found that the 
haemodynamic effects of atenolol lOOmg and propranolol 80mg were similar. There 
were decreases in HR, SBP and mean arterial pressure (MAP) during supine rest but 
more marked during postural stress and exercise. SI remained unchanged except for a 
decrease during high levels of exercise and an increase during recovery because if HR 
increases, SI decreases and vice versa. Whereas CO was reduced at all times, SVR 
increased. They reiterated that the beta-blocking efficacy of beta-adrenoceptor 
antagonists could be determined by their negative chronotropic effect on exercising 
heart rate.(Thomas et cd., 1992). They then discussed that the bradycardia produced by 
the beta-adrenoceptor antagonist permited a longer diastolic filling time and thus SV 
increased relative to pre-treatment values although beta-blockers are known to have 
cardiodepressant effects. Furthermore, they argued that the relative increase in SVR 
with both selective and non-selective antagonists in the study suggested that other 
mechanisms could be involved in mediating the hypotensive effects of the drugs. 
From a comprehensive review (Man in't Veld & Schalekamp, 1982), the acute 
haemodynamic effects of beta-adrenoceptor antagonists with Pi-selectiyity comprise a 
fall in HR, followed by a decrease in CO, blood pressure does not change implying that 
the calculated systemic vascular resistance index is elevated. On the other hand, the 
long-term effects are a fall in CO but SVRI remains unchanged or only slightly higher 
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than pre-treatment. This suggests that the fall in blood pressure is associated with 
restoration of vascular resistance towards baseline values. 
•• • 
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4.2 PINDOLOL: BETA-ADRENOCEPTOR ANTAGONISTS m m ISA 
Pindolol is a non-selective beta-adrenoceptor antagonist with intrinsic 
sympathomimetic activity (ISA) or partial agonist activity (PAA). The usual oral dose 
is 2.5 to 15 mg once or twice daily. It is well absorbed from the gastro-intestinal tract 
and peak plasma concentrations are attained within one to two hours. Pindolol is 
moderately protein bound (40-60%). Its half-life is about 3.5 hours in healthy subjects. 
It is partially metabolised in the liver and the metabolites together with the rest of the 
parent drugs are excreted via the kidneys (Reynolds, 1989). A neutral or slightly 
favorable effect on serum lipids has been reported (Houston, 1989). Adverse effects 
are similar to atenolol including fatigue, bradycardia, hypotension, headache, dizziness, 
depression, GI disturbances, and bronchospasm. It is less likely to cause cold hands 
and feet, but being more lipid soluble, it may cross the blood-brain barrier more readily 
and may cause sleep disturbance and vivid dreams. It is used for hypertension and 
angina, especially for patients with symptomatic bradycardia after taking beta-
blockade. Pindolol has the same efficacy as other beta blockers in hypertension but 
results in a higher CO and HR at rest (Reynolds, 1989). 
For beta-adrenoceptor antagonists with a high degree of ISA, such as pindolol, 
they replace basal sympathetic tone and this results in reduction in MAP with no 
change in HR, CO or vascular resistance initially. Also, it was observed that the 
reduction in MAP was directly correlated with that of the vascular resistance (van den 
Meiracker, Man in't Veld, Ritsema van Eck, Boomsma & Schalekamp，1988). 
Moreover, an inverse correlation between changes of CO and SVRI was found 
implying that a compensatory mechanism existed (van den Meiracker et al, 1988). On 
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decrement in blood pressure was associated with reduction in vascular resistance 
irrespective of the level of cardiac output after long-term therapeutic treatment (Man 
in't Veld & Schalekamp, 1982). 
The hypotensive mechanism of pindolol was described by Man in，t Veld (1982) 
as follows: with the high degree of ISA, pindolol does not reduce CO and hence there 
are no reflex changes in SVRI. After a period of time, blockade of prejunctional beta-
adrenoceptor results in decline of vascular resistance below the value of the 
pretreatment level As with atenolol, the fall in blood pressure is related to a reduction 
in vascular resistance. It appears that the reduction in blood pressure is related to 
vasodilation but not to decrease in CO (Man in't Veld & Schalekamp, 1982). 
In a study conducted by Thomas et. al. (1992), the partial agonist activity 
(PAA) or intrinsic sympathomimetic activity (ISA) of pindolol predominated and 
manifested as increased HR with higher doses at rest. The reduced HR during postural 
stress and exercise indicated that the antagonist effects of pindolol can be seen with 
higher levels of endogenous sympathetic activity. Moreover, SVR was reduced at all 
times except at high levels of exercise. SV was increased because of peripheral 
vasodilation and the positive inotropic effect of pindolol. Increments in both SV and 
HR caused an increase in CO during mild and moderate exercise similar to baseline 
values. It is of paramount importance to note that the haemodynamic. effects of pure 
antagonists and partial agonists as detected by TEB were similar to those in other 
studies using invasive methods of measurement. Thus, this study strongly supported 
the validity of TEB in measuring the cardiovascular effects of drugs (Thomas et al, 
1992). 
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Pindolol, as a beta-adrenoceptor antagonist with ISA, will not cause reflex 
tachycardia as other vasodilators might and it maintains cardiac output both at rest and 
during mild and moderate exercise because it lowers blood pressure through reduction 
in vascular resistance. All these beneficial effects render pindolol a useful agent in the 
treatment of hypertension (Weil & Waite, 1982). 
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4.3 ALPHA ^-ADRENOCEPTOR ANTA GONISTS 
Doxazosin is a rather new anti-hypertensive agent which antagonises post-
synaptic alphai-adrenoreceptors. It is recommended to start therapy at 1 mg daily and 
then titrate up to 16 mg once daily if required. Untoward effects are orthostatic 
hypotension, dizziness, vertigo, headaches and fatigue (Prasad, 1994). The drug is 
moderately well absorbed (63 %) after oral administration and its optimal therapeutic 
effect is attained 4-8 hours post-dose. It is highly protein bound to albumin. The 
elimination half-life of doxazosin is 9-22 hours. It is almost completely metabolized in 
man and excreted in the faeces with about 5 % of the drug excreted unchanged 
(Bainbridge & Elliott, 1992). It does not cause hyperglyceamia or hyperuriceamia, it 
maintains a normal cardiovascular response to exercise, it decreases left ventricular 
hypertrophy and inhibits platelet aggregation (Houston, 1989) (Sco伍eld & Reid， 
1992). In addition, the drug claims to depresses aortic collagen synthesis; it also 
reduces plasma triglycerides and causes higher high density lipoproteins / total 
cholesterol ratio and improves insulin responsiveness (Houston, 1989) (Bainbridge & 
Elliott, 1992). 
Doxazosin is an alphai-adrenoceptor antagonist acting on post-junctional a i-
adrenoceptors and it inhibits sympathetically mediated vasoconstriction in both 
arteriolar and venous vessels to counterbalance the increased systemic vascular 
resistance index in essential hypertension (see figure 4.2). It lowers BP as well as total 
peripheral vascular resistance, causes no change or a slight increase in HR, both at rest 
and during exercise (Bainbridge & Elliott, 1992). In one of the studies investigating the 
haemodynamic effects of doxazosin at rest and during exercise, patients with mild to 
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moderate essential hypertension were given oral doses of doxazosin at a starting dose 
of 2 mg once daily. The dosage of the drug was titrated up to 16 mg daily at two 
weeks intervals if necessary in order to achieve a blood pressure control of < 140/90 
mmHg. The mean dose of doxazosin taken was 6.5 mg after a period of eight to 
twelve months. The haemodynamic effects before and after long-term treatment of 
doxazosin indicated that falls in blood pressure resulted from reductions in SVRI 
without much change in cardiac output (Lund-Johansen, Omvik & Haugland，1986). 
In a comprehensive study investigating concentration-effect relationships in 
patients with essential hypertension during both acute and chronic treatment with 
doxazosin, significant correlations were found between responsiveness to doxazosin 
acutely and the level of blood pressure before treatment but there was a negative 
correlation between the former and the maximum reflex increase in HR. Furthermore, 
the same study also demonstrated a concentration-effect relationship in both systolic 
and diastolic blood pressure during acute and chronic treatment. There was also a 
statistically significant decrease in the responsiveness to doxazosin during long-term 
therapy in comparison with acute oral treatment. Interestingly, there were significant 
correlations between the responsiveness to the first dose of doxazosin and that after 
one and six weeks oral dose of the drug. It implies the possibility of using the response 
to first dose of doxazosin of an individual to estimate the response of the same patient 
during chronic treatment and thus the identification of potential responders or non-
responders (Donnelly, Elliott, Meredith & Reid，1989). 
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4.4 ANGIOTENSIN CONVERTING ENZYME INHIBITORS 
Enalapril is a non-sulphydryl angiotensin converting enzyme inhibitor pro-drug 
and its action is more long-acting than captopril. It inhibits the enzyme responsible for 
converting angiotensin I to angiotensin II (ACE). Furthermore, it hinders the 
conversion of bradykinin to inactive kinins. As a result, the level of bradykinin (a 
vasodilator hormone) remains high (Beevers & MacGregor, 1987). The initial oral 
dose is 5 mg once daily for treatment of hypertension, with doses titrated up to 10-40 
mg daily for adequate blood pressure control. The dosage is reduced in renal failure 
patients and initial dosage is reduced in heart failure. It is moderately well absorbed 
(55-75%) in the GI tract. It is a prodrug and undergoes biotransformation in the liver 
to the active form, enalaprilat. The elimination half-life of the parent drug enalapril is 
short and it is undetectable in the plasma four hours post dose. It is excreted mainly in 
the urine (Reynolds, 1989). Enalapril has no effect on glucose or uric acid, it maintains 
exercise haemodynamics and decreases left ventricular hypertrophy (Houston, 1989). 
It is used in the treatment of hypertension, chronic heart failure and diabetic patients 
with proteinuria. Adverse effects include hypotension, deterioration in renal function 
dizziness, headache, cough, angioedema, skin rash, fatique and lassitude (Reynolds, 
1989). 
Angiotensin converting enzyme (ACE) inhibitors are vasodilators which lower 
arterial blood pressure by reduction of the vasoconstricting action of angiotensin II. 
This results in an overall favorable haemodynamic profile in hypertension which 
involves reduction in vascular resistance with no significant change in cardiac output. 
Other evidence suggests that ACE inhibitors also mildly increase venous dilatation 
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despite the fact that there are no changes in right and left heart filling pressures 
(Fitzpatrick & Julius, 1985). However, they do not usually provoke orthostatic 
hypotension. Furthermore, they probably reduce renal vascular resistance to a greater 
magnitude than systemic resistance since better renal blood flow with increased 
glomerular filtration rate and natriuresis have been demonstrated after ACE inhibitor 
administration (Tarazi, Bravo, Fouad, Omvik & Cody, 1980). However, ACE 
inhibitors reduce glomerular capillary pressure and thus tend to lower GFR, but they 
generally do not give rise to blood volume expansion and fluid retention because of 
their effect in reducing aldosterone. Blood flow to vital organs such as the brain, heart 
and peripheral circulation also does not show much alteration. They do not usually 
produce reflex tachycardia after the fall in arterial pressure or cause neurohumoral 
counter-regulatory responses as other vasodilators do. This is because the drug inhibits 
the renin-angiotensin-aldosterone system and does not stimulate the sympathetic 
nervous system. Last but not the least, combination therapy with diuretics, beta 
blockers or sympatholytics which is common for other vasodilators is not usually 
required for ACE inhibitors to maintain blood pressure control or minimize side effects 
for mildly hypertensive patients (Fitzpatrick & Julius, 1985) although the combination 
with diuretics does increase the efficacy considerably in many patients. 
Musumeci V , Cardillo C., Guerrera G , Tutinelli F., Folli G. (1990) conducted 
a study to investigate the relationship between reduction of blood pressure and changes 
in systemic vascular resistance by drugs with known vasodilating effects, namely, 
nicardipine, enalapril or ketanserin in hypertensive patients. They argued that while 
vasodilators may lower blood pressure initially through a reduction of SVR, individual 
counter-regulatory mechanisms, for instance, sympathetic discharge, vagal withdrawal, 
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renal salt retention and activation of the renin-angiotensin system may be activated 
heterogenously and thus produce unexpected alterations in blood pressure and SVR 
during long-term treatment or during normal daily stress. They also suggested that a 
great inter-individual variability of SVR at rest and during exercise was probably the 
result of the complex anti-hypertensive effect of ACE inhibitors and the mediation of 
the hormonal and metabolic changes such as a reduction in angiotensin II and in 
aldosterone, and inhibition of bradykinin catabolism. They found that the hypotensive 
effect of ACE inhibitors was not associated with a reduction in SVR but a decrease in 
CO. It may be explained by a complex circulatory adjustment with a diminishing 
central sympathomimetic drive or a plasma volume redistribution during continuous 
treatment (Musumeci, Cardillo, Guerrera, Tutinelli & Folli, 1990). A similar report of a 
decrease in CO with treatment of ACE inhibitors has also been documented 
(Garavaglia, Messerli, Nunez, Schmieder & Frohlich, 1988). 
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4.5 CALCIUM CHANNEL BLOCKERS 
Nifedipine retard is a slow release formulation of the dihydropyridine calcium 
channel blocker, nifedipine. It acts on arteriolar smooth muscle by reducing the 
concentration of calcium ions (Ca++) within the cell. In long-term therapy, it has a mild 
diuretic effect and it is natriuretic and thus lowers blood pressure (Beevers & 
MacGregor, 1987). The usual dose for hypertension is 20-40mg twice daily. Nifedipine 
does not alter serum glucose, glucose tolerance tests or insulin requirements. Lipid 
changes are favorable or neutral (Houston, 1989). Vasodilating adverse effects such as 
facial flushing, headaches, ankle oedema and lethargy are not uncommon and gum 
hyperplasia and nocturia may occur. It is effective in angina pectoris and resistant 
hypertension. It is also indicated in severe hypertension not responding to other 
therapy. It reduces cardiac contractility and enhances peripheral vasodilatation. It has a 
steep dose-response curve with greater hypotensive effects with increasing doses of the 
drug (Beevers & MacGregor，1987). 
The calcium ion (Ca++) is an important activation messenger in the intracellular 
space. It undertakes an important role in contractions of the heart and vascular smooth 
muscle. The mechanism of action of calcium channel blockers is that they diminish the 
amount of the Ca++ entering into the intracellular space and thus prevent the Ca++ from 
initiating cellular processes or modifying cellular functions notably in the sinoatrial and 
atrioventricular nodes of the heart and in vascular smooth muscle. The rationale is that 
Ca++ carries depolarizing ionic currents across the plasma membrane into the cell and 
interferes with the normal resting electronegativity in the intracellular space. In the 
presence of higher concentrations of Ca++ in the heart, the myosin in the thick filament 
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and the actin in the thin filament interact and convert the chemical energy, adenosine 
triphosphate, into mechanical work. Conversely, in smooth muscle cells, Ca++ binds to 
calmodulin, a soluble protein and initiates a series of chemical reactions resulting in 
phosphorylation of the myosin light chain and contraction of smooth muscle (Katz, 
1986). 
There are three major groups of calcium channel blockers commonly use for 
treatment of hypertension. Two of these groups exemplified by verapamil and diltiazem 
act on both the heart and smooth muscle to weaken cardiac contraction, regulate heart 
rate in the sinoatrial node and slow atrioventricular conduction in the atrioventricular 
node of the heart as well as relaxing smooth muscle. The other group is the 
dihydropyridines which are vasodilators and act mainly on vascular smooth muscle. All 
three types are effective in blocking the Ca++ entry into muscle cells and hence, 
attenuate peripheral vascular resistance and reduce blood pressure (Katz, 1986). 
With respect to nifedipine, it dilates peripheral and coronary arteries and thus 
lowers blood pressure. Also, it has a negative inotropic action on the contractility of 
the heart (Braunwald, 1982); (Katz, 1986). The afterload reducing effect of nifedipine 
not only increases CO but also increases sympathetic tone and myocardial contractility 
(Lederballe Pedersen & Mikkelsen, 1978) which counteract its negative inotropic 
effect. 
In a study evaluating the haemodynamic effects of oral doses of nifedipine and 
nicardipine in healthy subjects (Thomas, Molyneux, Kelly & Smith, 1990)，the authors 
found that TEB could detect small changes in SV and CO with the drugs which 
resembled the haemodynamic effects of the drugs determined by more invasive 
methods. This further supported the role of TEB in assessing the cardiovascular effects 
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of drugs. Moreover, the TEB technique was comparatively less stressful than invasive 
methods and produces on-line display of haemodynamic parameters and also minimizes 
observer bias as compared to the ultrasound Doppler technique (Thomas & Smith, 
1990). 
In another study comparing the haemodynamic effects of nifedipine and 
nicardipine in the presence of atenolol using TEB (Thomas, 1991), total peripheral 
resistance was significantly reduced with no significant alterations in SV and CO. This 
showed that these two calcium channel blockers did not enhance ventricular 
performance in the presence of P-adrenoreceptor. He also repeated that as TEB gave 
reproducible results in their previous study (Thomas et al.，1990)，this technique was 
useful in detecting changes in blood flow and assessing the haemodynamic effects of 
drugs. 
Another study compared the anti-hypertensive effects of verapamil and 
nifedipine in essential hypertension and found that both of the calcium antagonists 
lowered blood pressure effectively (p < 0.001). However, only nifedipine increased HR 
significantly (p < 0.05, at least) especially in the standing position (Muiesan, Agabiti-
Rosei, Castellano, Alicandri, Corea, Fariello, Beschi & Romanelli，1982). Moreover, 
the clinical efficacy of calcium antagonists as arterial vasodilators in the treatment of 
hypertension is well documented in the literature. After chronic treatment, the initial 
sympathetic reflex activation and sodium and fluid retention subsidies (Kiowski, Bolli, 
Erne, Muller, Hulthen & Buhler, 1989) (Muiesan et al, 1982). It has also been 
observed that the response to calcium antagonist therapy relates not only to the level of 
pretreatment blood pressure as with most of the antihypertensive agents but also to the 
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percentage of reduction of blood pressure. Coincidentally, correlation of reduction in 
blood pressure with increasing age was also found in a study of a large unselected 
patient population (Kiowski et al., 1989). 
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4.6 CENTRAL ALPHA AGONIST 
Methyldopa is a central alpha agonist and it activates the alphaj-adrenergic 
receptors resulting in a decline in sympathetic tone and thus a reduction in blood 
pressure. The usual initial dose is 250mg twice or three times daily per oral, titrated up 
to 3g daily in divided doses. The maximum therapeutic effect occurs in 4-6 hours. The 
drug is incompletely absorbed and its elimination half-life is about 1.7 hours in the 
initial phase. It is partly metabolised in the liver to produce the active conjugate 
methyldopa 0-sulphate and excreted in the urine (Reynolds, 1989). Methyldopa 
adversely effects the lipid profile - decreasing high density lipoprotein • cholesterol by 
10% and increasing triglycerides by 10-20%. It does not induce hyperuricaemia or 
hyperglycaemia and it maintains normal haemodynamic responses to exercise and can 
reverse left ventricular hypertrophy (Houston, 1989). It may cause many side effects 
including drowsiness, depression, impaired mental acuity, nausea, dryness of the 
mouth, light-headedness, postural hypotension and sexual dysfunction, to name but a 
few. Also, thrombocytopenia, leucopenia, and haemolytic anaemia have been reported. 
As a result of frequent adverse effects, it is generally recommended only to be used for 
patients with moderate to severe hypertension (Reynolds, 1989). However, in Hong 
Kong, it is often still used as a first line treatment and appears to be well tolerated. 
There is a scarcity of studies on the haemodynamic effects of methyldopa in the 
last two decades. Methyldopa was introduced in the early sixties and represents a 
different class of anti-hypertensive agent which act on the central nervous system. The 
mechanism of action to lower arterial blood pressure may be by systemic vasodilation 
or reduction in cardiac output but is subject to some controversy (Mancia, Ferrari, 
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Gregorini, Leonetti, Terzoli, Bianchini & Zanchetti’ 1978). Moreover, it was 
suggested that methyldopa lowers blood pressure via its action on the blood pressure 
regulating centre in the medulla oblongata of the brain and its haemodynamic effects 
are not so apparent (Lund-Johansen, 1983). 
A study of haemodynamic responses to relatively large doses of methyldopa in 
a small group of hypertensive subjects (n = 7) revealed that methyldopa significantly (p 
< 0.005) lowered mean arterial pressure at supine rest without notable effects on either 
heart rate or cardiac output. The calculated total peripheral resistance index was also 
significantly reduced (p < 0.02) indicating that it was the reduction in total peripheral 
resistance that brought about the decrease in arterial blood pressure. On the other 
hand, there was no significant alteration of mean arterial pressure or other 
haemodynamic variables during the handgrip exercise (Mancia et al, 1978). However, 
a different hypotensive action of methyldopa through reduction of cardiac output has 
been reported from other study (Lund-Johansen, 1972). This could represent a 
disadvantage of methyldopa as an anti-hypertensive drug if it really were the case, as a 
reduction in cardiac output might imply a decrease in blood flow to the vital organs. 
Another study on haemodynamic effects of methyldopa in twenty patients with 
essential hypertension revealed findings rather similar to those observed by Mancia et. 
al. (1978). Whilst only systolic blood pressure was reduced with statistical significance, 
heart rate was not changed significantly at rest. Nonetheless, a different observation for 
heart rate during exertion was obtained in this study. Exercise heart rate was decreased 
significantly in this study in contrast to the lack of change during exercise as observed 
by Mancia et. al (Mallion, Debru, Mikler, Grubier, Laulhere, Cau & Muller, 1978). 
Furthermore, comparison of the haemodynamic effects of methyldopa and propranolol 
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by echocardiography in a group of hypertensive patients showed that the mean blood 
pressure was significantly reduced after methyldopa but not after propranolol 
(Richardson & von Bibra, 1978)，even though the latter demonstrated blockade of the 
beta-adrenoceptor receptors by decreasing the heart rate considerably. The same study 
detected a mild increase in cardiac output after methyldopa and a decrease after 
propranolol indicating the possible hypotensive action of methyldopa was via a 
reduction in peripheral resistance (Richardson & von Bibra, 1978). 
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4.7 THIAZIDE DIURETICS 
Navidrex K is a proprietary brand of the thiazide diuretic, cyclopenthiazide 
with a slow release potassium supplement. It acts on the renal tubules to impede 
sodium ion (Na+) and chloride ion (CI ) reabsorption. This stimulates compensatory 
mechanisms in the kidney to offset sodium ion and water loss. Renin levels will 
increase causing an increase in the level of angiotensin 11, inducing vasoconstriction 
and aldosterone causing renal potassium loss (Beevers & MacGregor, 1987). The 
usual dose of cyclopenthiazide for the treatment of hypertension is 0.25-0.5 mg daily. 
Diuresis occurs within one to two hours and potassium supplements may be required 
for prolonged treatment. Adverse effects are mainly hypokalaemia and effects on 
carbohydrate and lipid metabolism (Reynolds, 1989). Navidrex K increases total 
cholesterol, triglycerides and low density lipoprotein - cholesterol with no change or a 
decrease in high density lipoprotein - cholesterol and it tends to induce hyperuricaemia 
and hyperglycaemia. However, there is a normal haemodynamic response to exercise 
(Houston, 1989). 
The thiazide diuretics were introduced in 1958 mainly for treatment of sodium 
and water retention of other diseases and then their clinical efficacy in reducing blood 
pressure was discovered (Birkenhager, 1990). However, there have been few 
haemodynamic studies with the thiazide diuretics published in recent years. Moreover, 
their mechanism of action to lower blood pressure is also uncertain. Some hypotheses 
have been put forward to elucidate their hypotensive actions. Among them, the 
vasodilator theory and the volume depletion theory are the two most common 
assumptions advocated. Freis E D. (1983) observed that there was an average loss of 
Chapter 4 Literature Review 95 
after administration of chlorothiazide in a group of hospitalized hypertensive patients. 
This loss of sodium which was determined by the twenty-four hour urine collections, 
mainly happened in the first forty-eight hours after medication. Then it appeared that 
there was no further loss of sodium (Freis, 1983). As suggested by the author in his 
other studies (Wilson & Freis, 1959), the extracellular fluid which decreased by about 
two litres was the source of sodium loss. It is supported by the fact that the amount of 
sodium depleted after the initial forty-eight hours of chlorothiazide administration was 
similar to the volume of decrement of the extracellular fluid which would contain that 
approximate amount of sodium. Also, the weight loss of patients was directly 
proportional to the decrease in the extracellular fluid. However, Freis questioned that 
the accompanying loss in plasma volume which accounted for 15% would not have 
been sufficient to produce the reduction in blood pressure. 
Plasma volume and extracellular fluid were reduced by thiazides not only after 
short-term but also after long-term treatment (Wilson & Freis, 1959). It was confirmed 
by the fact that body weight increased after withdrawal of the medication which had 
been taken for six to twelve months. On the other hand, the haemodynamic picture 
after two weeks of thiazide administration was of no alteration in systemic vascualr 
resistance but with a fall in cardiac output. Later, cardiac output increased and blood 
pressure was reduced by a decrease in systemic vascular resistance (Freis, 1983). 
Although another hypothesis, that of autoregulation has been postulated to explain the 
long-term haemodynamic effects of thiazide diuretics, further investigations need to be 
performed to verify this. 
i 
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Table 4.1 The haemodynamic effects of the anti-hypertensive drugs studied 
(Houston, 1989). 
I 
1) Pindolol • decreases SVR and slightly decreases CO 
• HR is unchanged or increased at rest 
• RBF and GFR are unchanged and RVR is unchanged or slightly 
decreased 
• negative effects on the haemodynamic response to exercise with a 
reduced COandHR 
2) Doxazosin • lowers SVR and no change or a slight increase in both HR and CO 
• decreases arteriolar vasoconstriction and blood viscosity or SVR 
and thus maintains microcirculatory blood flow and tissue 
perfusion 
• renal blood flow is maintained and renal vascular resistance is 
reduced 
• BP control during exercise is expected to be good with normal 
haemodynamic response to exercise, i.e. an increase in CO and HR 
and a decrease in SVR of about 20% 
3) Enalapril • decreases SVR, RVR, does not change CO and HR 
• maintains or increases RBF and GFR 
• during short-term or long-term treatment, BP is reduced at rest and 
during exercise 
4) Nifedipine R e t a r d ~ • decreases SVR and RVR but CO is increased or unchanged, 
increases HR 
• maintains or increases RBF and GFR 
• there is a normal haemodynamic response during exercise 
5) Methyldopa • reduces sympathetic nervous system activity 
• maintains CO and RBF, decrease SVR and HR 
• maintains BP response both at rest and during exercise 
6) Thiazide diuretics • decreases intravascular volume, increases HR, decreases CO, GRF 
and RBF initially 
• after eight weeks of treatment, SVR decreases, CO returns to near 
normal and intravascular volume is reduced by 5% or less 
• CO is maintained and SVR decreases during exercise 
• BP is controlled long-term but adverse effects are volume depletion, 
electrolyte imbalance, muscular cramping and fatigue 
1) Atenolol • unfavorable haemodynamic changes in essential hypertension with 
long-term treatment: CO decreases 15% to 20%, SVR increases 
15% to 20% 
• abnormal resting haemodynamic changes 
• abnormal haemodynamic changes during exercise: increases DBP 
andHR 
• decreases blood flow to skeletal muscle, liver and kidney both at 
rest and during exercise 
• decreases GFR, RBF and natriuresis 
• decreases aerobic conditioning — 
I ‘ 
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CHAPTER 5 THE INTEGRA TED MYPEBTENSION STUDY 
5.1 OBJECTIVES 
The purpose of this study was to compare the haemodynamic changes induced 
by different antihypertensive drugs using the technique of thoracic electrical 
bioimpedance (TEB). 
5 . 2 METHODOLOGY 
5.11 Subjects 
Chinese patients with essential hypertension who were newly diagnosed or who 
had been untreated or withdrawn from treatment for at least two weeks were studied. 
All subjects were found to have a diastolic blood pressure (DBP) > 95 mmHg at the Li 
Ka Shing Specialist Clinic at the Prince of Wales Hospital, Shatin prior to recruitment. 
The study was approved by the Ethical Committee of the Chinese University of Hong 
Kong and all patients gave their informed consent. Criteria for inclusion were 
delineated as follows: 
• age between 25-75 years. 
• DBP was 95-120mmHg and SBP was >150 mmHg in L.K.S. specialist clinic. 
• patients with or without non-insulin dependent diabetes mellitus (NIDDM) 
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whereas criteria for exclusion were: 
• insulin dependent diabetes mellitus (IDDM) 
• significant renal failure (plasma creatinine > 150 nmol/1) 
• significant liver disease 
• secondary hypertension 
The baseline clinical characteristics of patients recruited for each of the 
different anti-hypertensive drugs studied are summarized in table 5.1. Other baseline 
characteristics of patients recruited for the study were shown in figures 5.1-5.6. They 
are described below for reference only. 
1. The frequency distribution of plasma aldosterone (pmol/1) in patients of the 
integrated hypertension study is presented in figure 5.1. The reference values of plasma 
aldosterone in supine and erect positions in normal subjects are 25 - 400 pmol/1 and 
100-900 pmol/1 respectively. Most of the them had a value below 400 pmol/1 and only 
about 9 % had a value over 400 or below 650 pmol/1. 
2. The frequency distribution of plasma renin (ng/ml/h) in patients of the 
integrated hypertension study is shown in figure 5.2. There were 87 % of them had the 
value below 1.25 ng/ml/h whereas others had the value ranging from 1.5 to below 3.75 
ng/ml/h. 
3. The frequency distribution of 24 hour urinary sodium excretion (mmol/d) in 
patients of the integrated hypertension study is presented in figure 5.3. Urinary sodium 
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excretion depends on intake and most of the patients studied had values from 100 to 
300 mmol/d. 
4. The frequency distribution of 24 hour urinary dopamine output (nmol/d) in 
patients of the integrated hypertension study is shown in figure 5.4. Age related range 
of 24 hours urinary dopamine output was 221 • 2410 nmol/d. Only about 12 % of the 
recruited hypertensive patients had a value outside the normal range. 
5. The frequency distribution of 24 hour adrenaline output (nmol/d) in patients of 
the integrated hypertension study is presented in figure 5.5. Age related range of 24 
hours adrenaline output was 19 -113 nmol/d. There were roughly 8 % of the recruited 
patients beyond the normal range. 
6. The frequency distribution of 24 hours noradrenaline output (nmol/d) in 
patients of the integrated hypertension study is presented in figure 5.6. Age related 
range of 24 hours noradrenaline output was 63-416 nmol/d. There were about 5 % of 
them outside the normal range. 
Moreover, the percentage changes of MAP, SI and HR relative to the supine 
position in different posture and under stress (handgrip in the present study) measured 
by TEB both in healthy subjects (n = 12) and in hypertensive patients without 
treatment (n = 89) were showed in figures 5.7 and 5.8. It could be seen that the 
patterns of changes of MAP, SI and HR in the two groups were comparable to each 
other. All the percentage changes of these parameters relative to the supine position in 
both groups were statistically significant except the percentage change of HR in 
healthy subjects in the sitting position. It showed that TEB could detect reliably the 
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Figure 5 .1 Frequency distribution of baseline plasma aldosterone (pmol/1) 
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Figure 5. 2 Frequency distribution of baseline plasma renin (ng/ml/h) in 
Chinese hypertensive patients (n = 66). 
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Figure 5. 3 Frequency distribution of baseline 24 hour urinary sodium 
excretion (mmol/d) in Chinese hypertensive patients (n = 57). 
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Figure 5. 4 Frequency distribution of baseline 24 hours urinary dopamine 
output (nmol/d) in Chinese hypertensive patients (n = 70). 
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Figure 5. 5 Frequency distribution of baseline 24 hour urinary adrenaline 
output (nmol/d) in Chinese hypertensive patients (n = 72). 
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Figure 5. 6 Frequency distribution of baseline 24 hours urinary 
noradrenaline output (nmol/d) in Chinese hypertensive patients (n = 73). 
k.： 
ii 
9 Chapter 5 The Integrated Hypertension Study 107 
r — 一 m • 
45 -] ： 
40 一 
35 一 
g 30 一 ； 
G - ^ i 
w) t i ^ h 
c 20 - I ^ H 
. H a a 1 
0 — ^ r ^ I 
Standing Sitting Handgirp 
WMA % changes relative to supine position in healthy volunteers (n = 12). 
I ^ W % changes relative to supine position in hypertensive patients (n = 89). 
Figure 5. 7 Percentage changes (±SEM) of mean arterial pressure relative 
to the supine position without treatment in healthy volunteers (n = 12) and in 
Chinese hypertensive patients (n = 89)，* denoted p < 0.05. 
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Figure 5. 8 Percentage changes (±SEM) of stroke index and heart rate 
relative to the supine position without treatment in healthy volunteers (n = 
12) and in Chinese hypertensive patients (n = 89)，奴 denoted p < 0.05. 
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5.12 Study design 
Patients were instructed to fast overnight and to attend the Clinical 
Pharmacology Studies Unit (CPSU) in the Department of Clinical Pharmacology, 
the Chinese University of Hong Kong, Prince of Wales Hospital, Shatin, Hong 
Kong as scheduled. Prior to the visit they were asked to complete two consecutive 
24-hour urine collections if possible. On the morning of their study visit, they 
handed in two 24-hour urine collections for analysis for urinary catecholamines 
(adrenaline and noradrenaline), dopamine, sodium, potassium and creatinine. In 
addition, they had a blood sample taken for liver and renal function tests, complete 
blood count, fasting plasma glucose and plasma lipids. These investigations were 
done to. exclude some causes of secondary hypertension as well as to provide 
baseline data. Supine blood pressure was measured after the patient had been 
resting supine for at least ten minutes. If blood pressure readings met the inclusion 
criteria, the patient would be recruited for the study and had the baseline 
impedance cardiography measurements done. Then they were randomly started on 
either atenolol (Tenormin 丁” 50 mg o.d.，pindolol (Visken 丁” 5 mg b.d., doxazosin 
(Cardura 丁从）1 mg o.d., enalapril (Renitec 丁” 5 mg o.d., nifedipine retard (Adalat 
retard tm) 20 mg b.d., methyldopa (Aldomet tm) 250 mg b.d. or cyclopenthiazide 
with potassium SR (Navidrex K tm) 0.25 mg o.d.. (We had a pilot study of 12 
patients on atenolol prior to the present study and we included these data in the 
statistical calculation.) The anti-hypertensive drug was supplied to the patient for at 
least four weeks and appointments were given for follow up visits after two and 
four weeks of drug treatment. In addition, they were reminded to fast overnight 
！ ‘ 
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before each appointment and not to take the prescribed medication on those 
mornings. 
At each clinical visits, the subjects were carefully interviewed about 
compliance to the drug regimen and the occurrence of any adverse effects related 
to the prescribed anti-hypertensive drug. Then they had the haemodynamic 
monitoring performed in exactly the same way as for the baseline session. 
5.2.3 Non-invasive haemodynamic monitoring 
After applying eight self-adhesive pregelled disposable ECG electrodes 
(CONMED Corporation, 310 Broad Street, Utica, NY 13501, USA) to the base of 
the neck and lower chest at the level of the xiphoid process (See figure 2.1), the 
subject was requested to rest in the supine position comfortably and quietly for ten 
minutes. The various haemodynamic parameters were then recorded and displayed 
on a personal computer connected to the thoracic electrical bioimpedance (TEB)-
BOMED N C C O M 3 - R 7 by an RS-232 connector as described in chapter 2 - section 
2.1 and 2.2. After input of the patient's particulars such as specific subject code, 
weight and height, the haemodynamic variables estimated by TEB were saved on 
the hard disk of the computer along with the real time of acquisition. All these 
measurements were collected over four minutes in the supine position after lying 
for ten minutes, three minutes in the erect position with recordings commencing 
after standing for two minutes, two minutes after sitting for five minutes and over 
the last minute of the two-minute handgrip exercise. The recorded data were then 
saved on floppy disks for analysis later by other spreadsheet and statistical software 
w^ -
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5.2.4 Blood Pressure Measurement 
Blood pressure was measured by an automated sphygmomanometer 
(Dinamap 8100, Critikon) before starting treatment and pre-dose after two and 
four weeks of drug treatment. The cuff was applied on the right upper arm of the 
patient and the blood pressure readings were taken at one-minute intervals during 
the TEB recordings. Mean arterial pressure (MAP) was calculated automatically by 
the Dinamap and systemic vascular resistance index was calculated as the quotient 
between mean arterial pressure (MAP) times 80 and cardiac index (refer to chapter 
3 - section 3.2.4). 
5.2.5 Isometric Exercise 
Detailed description of the development and application of isometric 
exercise in the form of handgrip is given in chapter 3 - section 3.2.5. 
5.2.6 Data analysis 
The stored data of different haemodynamic parameters in rows were 
imported into a spreadsheet software (QUATTRO PRO for Windows, version 5.0, 
Borland International, 1993) for further analysis. For details, please refer to chapter 
3 - section 3.2.6. A blank summary electronic spreadsheet entitled "clinical 
pharmacology hypertension assessment" with all the labels and formulas was 
created for each patient. In addition, baseline biochemistry and urine results were 
included on this hypertension assessment spreadsheet (see figure 5.9). Then, this 
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pharmacology hypertension assessment" with all the labels and formulas was 
created for each patient. In addition, baseline biochemistry and urine results were 
included on this hypertension assessment spreadsheet (see figure 5.9). Then, this 
spreadsheet was saved under a different filename according to the specific code of 
the patient assigned and it was designed for easy referencing of each patient's 
record. Moreover, a master spreadsheet including all the calculated mean values of 
the parameters from the different monitoring sessions for every subject having the 
same drug treatment was made (see figure 5.10). Means and standard errors 
(SEM) of these values were then calculated. After calculating the changes between 
the baseline visit and the visits after two and four weeks of treatment, t values in 
each position and during isometric exercise were computed by the quotient of the 
mean and standard error of the changes and they were used to assess primary 
statistical significance. Changes and percentage changes among the three separate 
visits were also calculated. For instance, the changes between visit 1 and visit 2， 
visit 1 and visit 3 as well as visit 2 and visit 3. Afterwards, they were transferred 
into a statistical package for further detailed statistical analysis (see section 5.2.6). 
5.2.7 Statistical analysis 
The effects of each drug measured at the different time intervals were 
determined by the one way repeated measures analysis of variance (ANOVA) using 
a statistical software package (SigmaStat for Windows version 1.0, Jandel 
Scientific). The one way ANOVA was used to test for a statistically significant 
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difference in response in each of the primary and derived haemodynamic 
parameters between the anti-hypertensive drugs. If the result was significant, the 
Student-Newman-Keuls all pairwise multiple comparison procedure was applied. 
Results are presented as mean 士 standard error (SEM). The level of statistical 
significance was accepted at p < 0.05. 
5.2.8 Limitations of the study 
We recognized that the number of subjects in each of the groups of anti-
hypertensive drug treatment was not great enough to detect small differences 
between drug effects. This was partly due to limited availability of laboratory time 
to perform the TEB monitoring procedures and limited availability of patient who 
were able to comply with the laboratory visits. Most of the patients were of 
working age, and some of those who were housewives had to look after their 
children at home. Since attending for the measurements involved taking time off 
work or making other domestic arrangements, we very much appreciated their 
participation in the study and compliance to the protocol. 
We used the recommended initial doses of the different anti-hypertensive 
drugs and adjusted the dosage after two weeks of drug treatment only if it was felt 
to be clinically necessary to attain the desired blood pressure control. However, 
this was required only in a few cases. It could be argued that the dosages of the 
different anti-hypertensive drugs which were of apparently different therapeutic 
efficacy were not comparable to each other. However, the main objective of this 
study focuses on the detection of pattern of the haemodynamic changes with the 
w m 
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anti-hypertensive drugs as detected by the thoracic electrical bioimpedance 
technique rather than the comparative efficacy for blood pressure reduction of the 
‘ 
different drugs studied. 
Lastly, we measured the trough effects but not the acute effects of the anti-
hypertensive drugs. Many trials of antihypertensive drug treatments compare the 
trough effects on blood pressure as their main measure of efficacy. Thus, we felt it 
was appropriate to examine the more detailed haemodynamic effects at this point 
after dosing rather than to study peak effects. Also the haemodynamic state is 
likely to be more stable at the trough effect whereas the haemodynamics may be 
likely to change around the time of the peak effect and the time of peak effect may 
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Figure 5. 9 An illustration of a summary electronic spreadsheet entitled 
"Clinical Pharmacology Hypertension Assessment" for each patient of the 
integrated hypertension study. 
肩 一 1 . 5 2 
^ ^ ^ m 2 7 . 9 2 國 _ _ _ 
STARTING DAT STOP DATE 
1 DOXAZOSIN Img QD 28/11/92 
2 DOXAZOSIN 2mg QD 12/12/92 
l/min/ni^ ml/m^ b/min mmHg mmHg vwiHg dyne.sec/cm /m 
SUPINE 4.49 65.83 68.42 140.00 80.50 105.25 1875.28 
STANDING 3.38 42.60 78.80 144.67 91.33 110.00 2603.55 
SITTING 3.47 46.67 74.67 146.00 87.00 109.00 2512.97 
EXERCISE 3.45 43.00 81.00 165.00 97.00 121.00 2805.80 
SUPINE 3.32 47.10 71.30 179.50 100.50 135.25 3259.04 
STANDING 3.24 42.57 76.57 178.33 97.67 118.67 2930.04 
SITTING 2,20 32.33 68.33 172.50 96.50 122.50 4454.55 
EXERCISE 2.05 32.00 64.50 173.00 100.00 128.00 4995.12 
_ T 3 • � . � � 
SUPINE 5.16 73.91 70.09 151.75 90.50 112.50 1744.19 
STANDING 3.46 40.20 85.70 143.00 87.67 107.67 2489.40 
SITTING 3.56 48.20 74.20 149.50 86.50 114.00 2561.80 
EXERCISE 3.23 41.33 77.67 146.00 96.00 116.00 2873.07 
28/11 /92 
Na: 138.00 K: 4.10 U: 6.30 Cr: 62.00 
Prot: 70.00 Alb: 36.00 Bili: 3.00 AlkP: 58.00 
Ut: 0.35 ALT: 16.00 Glucose: 5.10 
Chol(imnol/l): 4.80 TG(mmo 0.55 HDL(m 1.31 LDL(mm 3.20 
™ i 2 6 / 1 2 / 9 2 i l i l * ™ 
Vol(l): 1.30 Sod(mm 131.00 Cr(mmol 6.89 K(mmol) 31.00 
DA(nmol): 1063.40 NA(nmol 174.00 ADR(nm 70.00 
• • 2 7 / 1 2 / 9 2 
Vol(l): 1.20 Sod(mm 127.00 Cr(mmol 6.11 K(mmol) 30.00 
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5.3 RESULTS 
5.3.1 Atenolol 
The following results have been represented graphically in Figures 5.11-
5.15 and the mean values with standard error (SEM) were given. Blood pressure 
was lowered with statistical significance after two and four weeks of treatment in 
comparison to baseline values. Systolic blood pressure was decreased to a greater 
extent than diastolic blood pressure. The SBP was reduced in all positions and 
during isometric exercise (p < 0.001) at two and four weeks. The mean (S.D.) 
values of SBP before treatment and after two and four weeks of treatment were 
153.2 (17.5), 135.4 (21.6), 131.1 (16.6) mmHg respectively in the supine position; 
155.7 (19.5)，140.0 (24.2) and 134.1 (20.0) mmHg in the standing position; 156.6 
(21.1)，140.7 (23.1) and 136.1 (20.1) mmHg in the sitting position and 179.3 
(24.2), 162.9 (25.8) and 156.8 (23.5) mmHg during isometric exercise. In addition, 
there was significant reduction of SBP between two and four weeks of treatment in 
the standing position. 
Alterations of DBF after two and four weeks of treatment were all of 
statistical significance in comparison to baseline values (p < 0.001). The respective 
mean (S.D.) values of DBF before treatment and after two and four weeks of 
treatment were 93.1 (13.6)，79.6 (14.0) and 78.3 (12.6) mmHg in the supine 
position; 98.5 (16.4)，85.8 (14.5) and 83.7 (12.8) mmHg in the standing position; 
97.7 (16.4)，85.7 (15.6) and 82.3 (12.9) mmHg in the sitting position and 110.3 
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(18.7)，100.1 (16.4) and 97.8 (14.1) mmHg (p = 0.001) during handgrip. There 
was no significant change in DBP in any position between two and four weeks. 
Similarly, significant reductions in MAP were found in all the different 
conditions (p < 0.001). The mean (S.D.) values of MAP before treatment and after 
two and four weeks of treatment were 113.8 (13.8)，98.4 (17.6) and 98.7 (14.3) 
mmHg respectively in the supine position; 118.8 (14.5)，105.1 (18.1) and 102.5 
(12.6) mmHg in the standing position; 119.1 (17.0), 105.8 (20.3) and 103.2 (14.9) 
mmHg in the sitting position and 135.2 (16.4), 123.0 (21.6) and 120.5 (16.0) 
mmHg during handgrip. 
Atenolol 50 mg daily produced significant reductions in heart rate in all the 
different positions as well as during handgrip after two and four weeks of treatment 
(p < o.obl). The mean (S.D.) values of HR before treatment, and after two weeks 
and four weeks of treatment were 72.3 (11.9)，61.2 (12.1) and 61.3 (9.8) beats/min 
respectively in the supine position; 76.3 (11.8), 65.0 (13.1) and 64.2 (10.0) 
beats/min in the standing position; 72.5 (11.7)，61.2 (12.4) and 60.6 (9.8) 
beats/min in the sitting position and 80.1 (10.9), 65.7 (11.4) and 66.1 (10.5) 
beats/min during handgrip. The reductions after two and four weeks of treatment 
were all statistically significant when compared to baseline value. 
Estimated stroke index (SI) was increased significantly in the four 
conditions in the study especially during isometric exercise (p < 0.001). The mean 
(S.D.) values of SI before treatment and after two and four weeks of treatment 
were 43.7 (13.5), 51.3 (13.6) and 49.6 (13.3) mlW respectively in the supine 
position; 32.2 (5.4), 39.2 (8.8) and 36.7 (7.3) mlW in the standing position; 34.4 
(7.3), 40.8 (9.3) and 40.5 (9.7) ml/m^ in the sitting position and 32.7 (5.5), 39.8 
— ^ — 
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(10.2) and 36.8 (7.7) ml/m^ during handgrip. When compared to baseline value, the 
: changes after two and four weeks of treatment were all of statistical significance 
and the same was true when comparing the results of the two visits at two and four 
weeks after starting treatment during the isometric exercise. Thus, SI was reduced 
further between two and four weeks. 
In this study, the significant reduction in heart rate was offset by the 
increase in SI and so CI remained unchanged at all different conditions and in 
different visits. The only exception was during handgrip which produced 
statistically significant reductions in CI when the results after four weeks of 
atenolol treatment were compared to baseline and two weeks of treatment. The 
mean (S.D.) values of CI during handgrip before treatment and after two and four 
weeks oif treatment were 2.6 (0.5)，2.6 (0.5) and 2.4 (0.5) 1/min/m^ respectively (p 
<0.001). 
SVRI was reduced instead of increased in all the different conditions in the 
study. The reductions were all of statistical significance (p < 0.01) except during 
handgrip. The mean (S.D.) values of SVRI before treatment and after two and four 
weeks of treatment were 3171.5 (924.6), 2715.8 (833.9) and 2806.4 (821.2) 
dyne.sec.cm-5.m-2 respectively in the supine position; 4037.4 (837.4), 3517.7 
(940.4) and 3675.5 (906.3) d y n e . s e c . e m ' s . m ' z in the standing position and 4082.4 
(1127.4)，3623.3 (1007.3) and 3606.1 (1003.2) d y n e . s e c . c m . s . m - : in the sitting 
position. Reductions of SVRI in all the three different positions were all of 
statistically significant after taking the drug for two and four weeks. 
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Figure 5.11 Effect of atenolol on systolic and diastolic blood pressure (± 
SEM) after two and four weeks of treatment in Chinese hypertensives (n = 
22)，* denoted p < 0.05 compared to baseline and + denoted p < 0.05 
compared to that after two weeks of treatment. 
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Figure 5.12 Effect of atenolol on mean arterial pressure (土 SEM) after two 
and four weeks of treatment in Chinese hypertensives (n = 22)，*denoted p < 
0.05 compared to baseline. 
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Figure 5.13 Haemodynamic effects of atenolol on stroke index (土 SEM) and 
heart rate (士 SEM) after two and four weeks of treatment in Chinese 
hypertensives (n = 22)，* denoted p < 0.05 compared to baseline. 
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Figure 5.14 Haemodynamic effects of atenolol on cardiac index (士 SEM) 
and systemic vascular resistance index (士 SEM) after two and four weeks of 
treatment in Chinese hypertensives (n = 22), * denoted p < 0.05 compared to 
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Figure 5 .15 Mean (士 SEM) percentage changes from baseline in mean arterial 
pressure (MAP), heart rate (HR), stroke index (SI), cardiac index (CI) and systemic 
vascular resistance index (SVRI) after two (blank bar) and four (hatched bar) weeks 
of atenolol in the supine, standing and sitting positions and at peak handgrip, * 
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5.3.2 Pindolol 
The following results have been represented graphically in figures 5.16 -
5.20 and the mean values with SEM were given. Significant reductions in blood 
pressure were detected in different positions (p < 0.001) and during handgrip (p < 
0.01) after two and four weeks of drug treatment. The mean (S.D.) values of SBP 
before treatment, after two and four weeks of treatment were 148.8 (12.7)，137.6 
(7.9) and 134.0 (9.5) mmHg respectively in the supine position; 156.4 (11.4)， 
146.7 (10.6) and 142.2 (13.0) mmHg in the standing position; 160.5 (11.7)，148.3 
(11.7) and 144.7 (14.1) mmHg in the sitting position and 179.7 (8.1), 164.8 (17.8) 
and 166.1 (15.2) mmHg during handgrip. Falls in DBP at different positions and 
during isometric exercise were also of statistical significance (p< 0.05) although 
they were not as great as those in SBP. The mean (S.D.) values of DBP before 
treatment, after two and four weeks of treatment were 93.9 (10.4)，85.5 (9.6) and 
84.7 (8.5) mmHg respectively in the supine position; 103.1 (9.2)，97.0 (11.9) and 
94.9 (9.1) mmHg in the standing position; 102.3 (10.3)，95.1 (9.5) and 94.1 (9.9) 
mmHg in the sitting position and 116.3 (8.8)，109.7(12.7) and 110.9(11.8) mmHg 
during handgrip. The changes in both systolic and diastolic blood pressure in the 
second and third clinical visits were significant when they were compared to the 
values before treatment. 
Significant reductions of MAP were observed in all the different conditions 
(p < 0.01). The mean (S.D.) values of MAP before treatment, after two and four 
weeks of treatment were 112.9 (11.9), 105.0 (8.7) and 103.3 (8.8) mmHg 
respectively in the supine position; 123.6 (11.7), 117.4 (10.8) and 114.6 (10.4) 
k 
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mmHg in the standing position; 126.1 (10.3)，116.0 (8.7) and 113.1 (12.4) mmHg 
in the sitting position and 139.6 (8.6)，133.1 (13.1) and 129.3 (12.9) mmHg during 
handgrip. The alterations in MAP after two and four weeks of treatment were 
statistically significant in comparison to baseline value. 
Compared to the mean heart rate before treatment, heart rate was increased 
significantly (p < 0.05) after two and four weeks of treatment only at supine rest, 
the mean (S.D.) values of HR being 65.3 (9.6)，70.0 (9.5) and 70.1 (9.7) beats/min 
respectively. In contrast, HR tended to be reduced during isometric exercise 
though not of statistical significance and the changes of HR in the standing and 
sitting positions were not significant. 
Stroke index was similar to the baseline value in the supine, standing and 
sitting positions and during isometric exercise. On the other hand, the increase in 
CI at supine rest though not of statistical significance, however, was much greater 
than that in the standing and sitting positions and during handgrip after two and 
four weeks of pindolol. SVRI was significantly reduced in the supine position (p < 
0.05) when compared to the pretreatment value. The mean (S.D.) SVRI before 
treatment, after two and four weeks of treatment were 3528 (1163)，3022 (1211) 
and 2828 (796) dyne.sec.cm-^.m-� respectively in the supine position. Also, there 
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Figure 5.16 Effect of pindolol on systolic and diastolic blood pressure (土 
SEM) after two and four weeks of treatment in Chinese hypertensives (n = 
11)，^denoted p < 0.05 compared to baseline, 
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Figure 5.17 Effect of pindolol on mean arterial pressure (土 SEM) after two 
and four weeks of treatment in Chinese hypertensives (n = 11)，* denoted p < 
0.05 compared to baseline. 
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Figure 5.18 Haemodynamic effects of pindolol on stroke index (± SEM) and 
heart rate (士 SEM) after two and four weeks of treatment in Chinese 
hypertensives (n = 11)，* denoted p < 0.05 compared to baseline. 
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Figure 5.19 Haemodynamic effects of pindolol on cardiac index (士 SEM) 
and systemic vascular resistance index (士 SEM) after two and four weeks of 
treatment in Chinese hypertensives (n = 11), * denoted p < 0.05 compared to 
baseline. 
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Figure 5. 20 Mean (士 SEM) percentage changes in mean arterial pressure 
(MAP), heart rate (HR), stroke index (SI), cardiac index (CI) and systemic 
vascular resistance index (SVRI) after two (blank bar) and four (hatched bar) 
weeks of pindolol in the supine, standing and sitting positions and at peak 
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5.3 J Doxazosin 
The following results have been represented graphically in Figures 5.21 -
5.25 and the mean values with SEM were given. Blood pressure was not altered 
much by treatment with doxazosin 1 mg daily. Nonetheless, there was a statistically 
significant reduction (p < 0.01) in MAP during isometric exercise when baseline 
values and results after four weeks of oral treatment with the drug were compared 
and the MAP after four weeks of active treatment was also lower than after two 
weeks. The mean (S.D.) values of MAP before treatment, after two and four 
weeks of treatment were as follows: 139.0 (9.5), 136.3 (9.6) and 129.3 (8.1) 
mmHg respectively during handgrip. Generally there was no change in SBP or 
DBP but sitting DBP was increased significantly (p < 0.05) when the value after 
two weeks of treatment was compared to baseline. The mean (S.D.) sitting DBP 
values before treatment, and two and four weeks after treatment were 97.1 (9.9)， 
102.6 (9.4) and 100.6 (11.8) mmHg respectively. 
Alterations in HR, SI and CI at different time points of the study were 
insignificant and thus no statistically significant differences were detected in the 
three clinical visits. No significant reduction in SVRI was observed in this group at 
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Figure 5. 21 Effect of doxazosin on systolic and diastolic blood pressure 
(+SEM) after two and four weeks of treatment in Chinese hypertensives (n = 
9), * denoted p < 0.05 compared to baseline. 
L • 
Chapter 5 The Integrated Hypertension Study 118 
145 — 
w 1 幼 一 
1 135 一 
1 1 3 0 - 计 
J 1 2 5 -
u “ 
运 1 2 0 一 “ o 
§ 
§ 115 - 丄 
110 -‘ —1 1 1 
Baseline 2 weeks 4 weeks 
• supine position • standing position 
A sitting position • peak handgrip 
Figure 5. 22 Effect of doxazosin on mean arterial pressure (土 SEM) after 
two and four weeks of treatment in Chinese hypertensives (n = 9)，* denoted 
p < 0.05 compared to baseline and + denoted p < 0.05 compared to that after 
two weeks of treatment. 
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Figure 5. 23 Haemodynamic effects of doxazosin on stroke index (土 SEM) 
and heart rate (士 SEM) after two and four weeks of treatment in Chinese 
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Figure 5. 24 Haemodynamic effects of doxazosin on cardiac index (土 SEM) 
and systemic vascular resistance index (士 SEM) after two and four weeks of 
treatment in Chinese hypertensives (n = 9). 
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Figure 5. 25 Mean (士 SEM) percentage changes from baseline in mean 
arterial pressure (MAP), heart rate (HR), stroke index (SI), cardiac index 
(CI) and systemic vascular resistance index (SVRI) after two (blank bar) and 
four (hatched bar) weeks of doxazosin in the supine, standing and sitting 
positions and at peak handgrip, * denoted p < 0.05 compared to baseline. 
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5.3.4 Enalapril 
The following results have been represented graphically in Figures 5.26 -
5.30 and the mean values with SEM were given. Significant reductions in SBP 
were observed at two and four weeks compared with baseline with statistical 
significance at p < 0.001 in the supine and standing positions and during handgrip 
and at p < 0.01 in the sitting position. The mean (S.D.) values of SBP before 
treatment and after two and four weeks of treatment were 154.1 (9.1)，140.3 (9.8) 
and 135.5 (10.6) mmHg respectively in the supine position; 152.3 (12.8), 142.4 
(12.3) and 136.8 (8.5) mmHg in the standing position; 154.2 (11.7)，142.6 (15.5) 
and 140.1 (11.0) mmHg in the sitting position and 176.9 (13.1)，167.7 (15.0) and 
160.1 (14.5) mmHg during handgrip. Results of SBP during handgrip in the second 
and third visits were also significantly different indicating greater reduction of SBP 
after four weeks of treatment. 
In contrast, statistically significant DBP readings were only detected in the 
supine, standing and sitting positions (p < 0.01) but not during isometric exercise. 
The mean (S .D.) values of DBP before treatment and after two and four weeks of 
treatment were 94.8 (10.3)，88.7 (9.8), and 85.2 (9.3) mmHg respectively in the 
supine position; 98.8 (10.9)，92.6 (11.7) and 90.9 (8.3) mmHg in the standing 
position and 98.1 (12.7)，92.2 (12.8) and 90.0 (8.5) mmHg in the sitting position. 
Both DBP readings measured in the second and third clinical visits were 
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Moreover, statistically significant reductions in MAP were only observed in 
vt 
the supine and sitting positions (p< 0.05) when the results after four weeks of drug 
treatment were compared to baseline. The mean (S.D.) values of MAP before 
treatment, after two and four weeks of treatment were 115.4 (10.2)，108.8 (8.5)， 
104.0 (8.9) mmHg and 119.2 (12.1), 112.5 (11.7) and 110.1 (8.5) mmHg for the 
supine and sitting positions respectively. Consistent reductions in HR were noted in 
all the different conditions although this was only significant during isometric 
exercise at four weeks when compared to baseline (p< 0.05). The mean (S.D.) 
values of HR before treatment, after two and four weeks of treatment were 82.2 
(9.7), 78.7 (10.0) and 77.3 (11.5) beats/min respectively during isometric exercise. 
The changes in SI were not significant in any position as well as during 
handgrip. Furthermore, the changes of CI in different positions were not 
statistically different after short-term oral treatment with enalapril Nevertheless, a 
reduction of CI during handgrip was statistically significant when the mean CI after 
four weeks of treatment was compared to the corresponding value before 
treatment (p < 0.05). The mean (S.D.) values of CI before treatment and after two 
and four weeks of treatment were 2.83 (0.85), 2.62 (0.77) and 2.38 (0.49) l/min/m^ 
respectively during handgrip. Also, there were no statistically significant changes 
observed in SVRI after two and four weeks of treatment except in the supine 
position. The mean (S.D.) values of SVRI before treatment and after two and four 
weeks of treatment were 3234.4 (842.2)，2958.0 (676.4) and 2821.1 (685.2) 
dyn.sec.cm-5.m-2 respectively in the supine position. 
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Figure 5. 26 Effect of enalapril on systolic and diastolic blood pressure (土 
SEM) after two and four weeks of treatment in Chinese hypertensives (n = 
15)，*denoted p < 0.05 compared to baseline and + denoted p < 0.05 
compared to that after two weeks of treatment. 
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Figure 5. 27 Effect of enalapril on mean arterial pressure (士 SEM) after two 
and four weeks of treatment in Chinese hypertensives (n = 15), * denoted p < 
0.05 compared to baseline. 
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Figure 5. 28 Haemodynamic effects of enalapril on stroke index (土 SEM) 
and heart rate (土 SEM) after two and four weeks of treatment in Chinese 
hypertensives (n = 15), * denoted p < 0.05 compared to baseline. 
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Figure 5. 29 Haemodynamic effects of enalapril on cardiac index (土 SEM) 
and systemic vascular resistance index (土 SEM) after two and four weeks of 
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Figure 5.30 Mean (士 SEM) percentage changes from baseline in mean 
arterial pressure(MAP), heart rate (HR), stroke index (SI), cardiac index (CI) 
and systemic vascular resistance index (SVRI) after two (blank bar) and four 
(hatched bar) weeks of enalapril in the supine, standing and sitting positions 
and at peak handgrip, * denoted p < 0.05 compared to baseline, 
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5.3.5 Nifedipine Retard 
The following results have been represented graphically in Figures 5.31 -
5.35 and the mean values with SEM were given. Both systolic and diastolic blood 
pressure were lowered significantly by nifedipine retard in all the different positions 
and during handgrip after starting treatment. Systolic blood pressure was reduced 
to a greater degree than diastolic blood pressure. The mean (S.D.) values of SBP 
values before treatment and after two and four weeks of treatment were 143.8 
(9.1)，129.2 (15.8) and 131.4 (10.3) mmHg respectively in the supine position; 
142.2 (11.1)，133.1 (15.4) and 131.2 (14.5) mmHg in the standing position; 147 
(6.5), 136.9 (18.9) and 135.5 (13.1) mmHg in the sitting position and 168 (15.5)， 
152.4 (16.8) and 154.9 (16.0) mmHg during handgrip. Reductions of SBP after 
two and four weeks of treatment in the different positions and during handgrip 
were all of statistically significant difference (p < 0.05). 
Reductions ofDBP from baseline after two and four weeks of treatment in 
the supine position and during handgrip were of statistically significant difference 
(p < 0.01)，while there was only significant reduction of DBP at two weeks of 
treatment in the standing position (p < 0.05) and no significant decrease was 
detected in the sitting position. Mean (S.D.) values of DBP before treatment and 
after two and four weeks of treatment were 93.4 (9.7)，84.8 (14.3) and 87.1 (11.4) 
mmHg respectively in the supine position; 98.1 (8.2), 91.2 (13.4) and 92.6 (11.2) 
mmHg in the standing position and 114.3 (13.3)，102.5 (12.8) and 106.5 (14.3) 
mmHg during handgrip. 
i . 
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Reductions of MAP from baseline after two and four weeks of treatment in 
the different conditions were all of statistically significant difference (p < 0.05) 
except that in the sitting position. Mean (S.D.) values of MAP before treatment 
and after two and four weeks of treatment were 113.2 (8.3)，100.5 (14.1) and 
102.5 (10.0) mmHg respectively in the supine position; 116.0 (8.9), 108.1 (12.9) 
and 107.5 (12.3) mmHg in the standing position; and 136.4 (14.0), 125.9 (13.3) 
and 125.5 (15.4) mmHg during handgrip. 
Heart rate in the supine, standing and sitting positions as well as during 
handgrip exercise tended to be reduced after two and four weeks of treatments 
with nifedipine retard. However, these reductions in heart rate were small and not 
of statistical significance. 
Cardiac index tended to be reduced by nifedipine retard in the supine and 
sitting positions and during handgrip but not in the standing position when 
compared to baseline values after taking the drug for two and four weeks. 
However, the changes in CI were not statistically significant. In addition, the 
changes of stroke volume index in the different positions in the three clinical visits 
were small and statistical significance were not detected. 
Mild reductions in SVRI were observed in the supine and standing 
positions but they were not of statistical significance. The results on SVRI were 
not consistent in the sitting position and particularly during handgrip exercise 
which went down after two weeks of treatment and then went up again after four 
weeks of treatment. 
I . f 
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Figure 5.31 Effect of nifedipine retard on systolic and diastolic blood 
pressure (士 SEM) after two and four weeks of treatment in Chinese 
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Figure 5. 32 Effect of nifedipine retard on mean arterial pressure (士 SEM) 
after two and four weeks of treatment in Chinese hypertensives (n = 11)，* 
denoted p < 0.05 ocmpared to baseline. 
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Figure 5. 33 Haemodynamic effects of nifedipine retard on stroke index (士 
SEM) and heart rate (土 SEM) after two and four weeks of treatment in 
Chinese hypertensives (n = 11). 
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Figure 5. 34 Haemodynamic effects of nifedipine retard on cardiac index 
(±SEM) and systemic vascular resistance index (土 SEM) after two and four 
weeks of treatment in Chinese hypertensives (n = 11). 
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Figure 5. 35 Mean (土 SEM) percentage changes in mean arterial pressure 
(MAP), heart rate (HR), stroke index (SI), cardiac index (CI) and systemic 
vascular resistance index (SVRI) after two (blank bar) and four (hatched bar) 
weeks of nifedipine retard in the supine, standing and sitting positions and at 
peak handgrip, * denoted p < 0.05 compared to baseline. 
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5.3.6 Methyldopa 
The following results have been represented graphically in figures 5.36 -
5.40 and the mean values with SEM are given. The fall in blood pressure was 
consistent in the three positions and during isometric exercise and statistically 
significant for them all. Mean (S.D.) values of SBP before treatment, after two and 
four weeks of treatment were 159.4 (21.5), 148.1 (18.3) and 148.0 (18.6) mmHg 
respectively in the supine position; 158.2 (20.0), 145.8 (17.9) and 145.7 (18.5) 
mmHg in the standing position; 168.0 (24.7), 158.6 (23.8) and 154.5 (23.1) mmHg 
in the sitting position and 183.5 (23.1)，170.1 (24.2) and 169.2 (22.3) mmHg 
during isometric exercise. Reductions of SBP after two and four weeks of 
treatment were all significant when compared to baseline (p < 0.05). 
Significant reductions of DBP in the different positions were detected when 
the results of the two and four weeks of treatment were compared with the 
baseline values (p < 0.01). However, a significant fall in DBP during isometric 
exercise was only obsevered when the result of the four weeks of treatment was 
compared with the baseline values (p < 0.05). Mean (S.D.) values of DBP before 
treatment, after two and four weeks of active treatment were 90.8 (9.4), 83.5 (9.2) 
and 83.6 (9.5) mmHg respectively in the supine position; 94.1 (7.3)，84.9 (8.1) and 
86.4 (8.2) mmHg in the standing position; 98.9 (7.2)，88.3 (16.0) and «9.2 (10.5) 
mmHg in the sitting position and 107.9 (8.7) and 100.7 (18.1) and 98.0 (12.3) 
mmHg during handgrip. Again, the difference of alterations in DBP in the second 
and third visits among all the different conditions were alike confirming the 
competence of the drug to maintain blood pressure control. 
？ 
、：: 
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Significant reductions of MAP in the supine and standing positions and 
during handgrip were observed. When the mean value of MAP after two weeks of 
treatment was compared with the baseline in the supine position and the mean 
value of MAP after four weeks of treatment was compared to the baseline during 
handgrip, statistical significance a tp< 0.05 was detected. Whereas the results after 
two and four weeks of treatment were compared with the baseline in the standing 
position, statistical significance was detected at p < 0.001. Mean (S.D.) values of 
m a p before treatment, after two and four weeks of active treatment were 116.3 
(11.4)，104.1 (13.0) and 108.7 (11.2) mmHg respectively in the supine position; 
115.8 (6.6)，106.3 (7.2) and 105.1 (9.9) mmHg in the standing position and 134.5 
(8.5)，125.5 (19.5) and 122.9 (16.3) mmHg during handgrip. 
In our study, statistically significant reductions in HR were seen in all the 
different conditions when the results of the two and four weeks of active treatment 
were checked against the baseline values (p < 0.05). The mean (S .D.) values of HR 
before treatment, after two and four weeks of treatment of methyldopa were 71.1 
(12.7), 65.9 (13.2) and 67.1 (11.2) beats/min respectively in the supine position; 
77.4 (15.5), 71.6 (14.9) and 71.9 (12.0) beats/min in the standing position; 72.8 
(12.14), 66.1 (11.68) and 67.3 (9.49) beats/min in the sitting position and 84.0 
(20.1), 75.7 (19.0) and 76.5 (15.5) beats/min during handgrip. 
No significant change in SI was noted in any time point of the study. 
Nevertheless, we found significant reductions in CI in this group of patients both in 
the standing and sitting positions after two and four weeks of drug treatment (p < 
0.05). Mean with median and/or S.D. of CI before treatment, after two and four 
weeks of treatment were 2.39 (2.23-2.60), 2.21 (2.04-2.30)，2.24 (2.01-2.38) 
r 
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1.1. 
1/min/m^ and 2.45 (0.42)，2.18 (0.24), 2.21 (0.45) 1/min/m^ in the standing and 
sitting positions respectively. In contrast, the changes of SVRI were insignificant at 
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Figure 5. 36 Effect of methyldopa on systolic and diastolic blood pressure 
(±SEM) after two and four weeks of treatment in Chinese hypertensives (n = 
11)，* denoted p < 0.05 compared to baseline. 
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Figure 5. 37 Effect of methyldopa on mean arterial pressure (土 SEM) after 
two and four weeks of treatment in Chinese hypertensives (n = 11)，* denoted 
p < 0.05 compared to baseline. 
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Figure 5. 38 Haemodynamic effects of methyldopa on stroke index (土 SEM) 
and heart rate (士 SEM) after two and four weeks of treatment in Chinese 
hypertensives (n 11)，* denoted p < 0.05 compared to baseline. 
Chapter 5 The Integrated Hypertension Study 158 
3.2 - p 
1 “ 
Q I * 
2.0 -
, , 1 
Baseline 2 weeks 4 weeks 
5000 
r T 4500 - T J f I 
g 4000 — • _ 
i t T ^ ^ -
V 丄 
善 3500 - 丄 
g f - ^ ^ • 
^ 3000 — 丄 丄 
2500 -I 1 1 1 
Baseline 2 weeks 4 weeks 
• supine position • standing position 
A sitting position • peak handgrip 
Figure 5.39 Haemodynamic effects of methyldopa on cardiac index (士 
SEM) and systemic vascular resistance index (土 SEM) after two and four 
weeks of treatment in Chinese hypertensives (n == 11)，* denoted p < 0.05 
compared to baseline. 
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Figure 5. 40 Mean (士 SEM) percentage changes in mean arterial pressure 
(MAP), heart rate (HR), stroke index (SI), cardiac index (CI) and systemic 
vascular resistance index (SVRI) after two (blank bar) and four (hatched bar) 
weeks of methyldopa in the supine, standing and sitting positions and at peak 
handgrip, * denoted p < O.OS compared to baseline. 
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5.3J Cyclopenthiazide 
The following results have been represented graphically in figures 5.41 -
5.45 and the mean values with SEM were given. Consistent reductions in SBP 
were noticed in all conditions after two and four weeks of drug treatment with 
regard to the baseline values and they were of statistical significance (p < 0.05). 
The mean (S.D.) values of SBP values before treatment, after two and four weeks 
of drug treatment were 151.0 (22.4), 140.7 (24.3) and 134.7 (21.1) mmHg 
respectively in the supine position; 147.3 (23.9), 139.9 (21.1) and 134.3 (18.5) 
mmHg in the standing position; 148.8 (22.9)，140.8 (22.6) and 136.5 (18.1) mmHg 
in the sitting position and 169.9 (23.9)，156.3 (24.1) and 153.2 (15.3) mmHg 
during isometric exercise. 
Despite statistically significant falls in DBP only being detected in the 
standing position and during isometric exercise (p < 0.05), consistent reductions in 
DBP were seen in all the different conditions in the second and third visits of the 
study. Mean (S.D.) values of DBP before treatment, after two and four weeks of 
treatment were 90.9(11.9)，87.3(8.5) and 84.3(13.2) mmHg respectively in the 
standing position and 103.9 (14.9)，93.1 (13.0) and 91.3 (12.8) mmHg during 
handgrip. Comparable circumstances were observed in the reductions of MAP in 
the second and third visits of the study. Once again, statistically significant 
reductions in MAP were detected only in the standing position and during 
isometric exercise at two and four weeks after starting treatment (p < 0.05). The 
mean (S.D.) values of MAP before treatment, after two and four weeks of 
treatment were 114.9 (13.0)，107.8 (11.5) and 105.3 (14.7) mmHg respectively in 
r 
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Standing position and 132.3 (19.2)，119.7 (13.7) and 116.3 (11.7) mmHg during 
handgrip. 
A tendency for increases in HR was observed in the second and third 
haemodynamic monitoring sessions in the three different positions though not of 
statistical significance. As there was no statistically significant increase in HR and 
SI in the various conditions throughout the study were not statistically different, CI 
remained more or the less the same throughout the different time point of the • < ‘ 
study. 
Although constant falls in SVRI were observed at various time points of the 
study, statistically significance was only detected in the standing position after two 
and four weeks of treatment (p < 0.05). The mean (S.D.) values of SVRI before 
treatment, after two and four weeks of active treatment were 4007.2 (923.7)， 
3647.5 (752.2) and 3563.7 (932.2) dyne.sec.cm-5.m-2 respectively in the standing 
position. 
r 
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Figure 5.41 Effect of cyclopenthiazide on systolic and diastolic blood 
pressure (士 SEM) after two and four weeks of treatment in Chinese 
hypertensives (n = 10)，* denoted p < 0.05 compared to baseline. 
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Figure 5. 42 Effect of cyclopenthiazide on mean arterial pressure (士 SEM) 
after two and four weeks of treatment in Chinese hypertensives (n = 10)，* 
denoted p < 0.05 compared to baseline. 
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Figure 5.43 Haemodynamic effects of cyclopenthiazide on stroke index 
(+SEM) and heart rate (土 SEM) after two and four weeks of treatment in 
Chinese hypertensives (n = 10). 
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Figure 5. 44 Haemodynamic effects of cyclopenthiazide on cardiac index 
(+SEM) and systemic vascular resistance index (土 SEM) after two and four 
weeks of treatment in Chinese hypertensives (n = 10)，叙 denoted p < 0.05 
compared to baseline. 
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Figure 5. 45 Mean (土 SEM) percentage changes in mean arterial pressure 
(MAP), heart rate (HR), stroke index (SI), cardiac index (CI) and systemic 
vascular resistance index (SVRI) after two (blank bar) and four (hatched bar) 
weeks of cyclopenthiazide in the supine, standing and sitting positions and at 
peak handgrip, * denoted p < 0.05 compared to baseline. 
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5.4 COMPARISONS OF THE ANTI-HYPERTENSIVE DRUGS STUDIED 
5.4.1 Baseline values 
One way analysis of variance (ANOVA) was performed for the baseline 
values of the different haemodynamic parameters - CI, SI, HR, SVRI and blood 
pressure recordings - SBP, DBP, MAP to examine if there was any statistically 
significant difference among the different groups of patients selected for the 
different anti-hypertensive drugs studied. The statistical test was performed for all 
the above-mentioned parameters in all the different positions and during isometric 
exercise. The various statistical results revealed that the differences in the mean 
values of all the tested parameters among the treatment groups were not large 
enough to rule out the possibility of random sampling variability. Therefore, none 
of them showed any statistically significant difference. We conclude that the 
different groups of patients randomly assigned for the study were not significantly 
different from each other and came from the same population. Thus, we can safely 
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5.4.2 Percentage changes after active treatment 
Percentage changes at two and four weeks of active treatment compared to 
baseline for the various parameters in the different positions and during isometric 
exercise were computed to investigate the effects of the different drugs under 
different conditions of posture and stress. Then, one way ANOVA was performed 
for the percentage changes of all the haemodynamic parameters as well as blood 
pressure readings after two and four weeks of active treatment of each anti-
hypertensive drugs. It was done to detect whether the difference in the responses 
to the anti-hypertensive drugs studied were of statistical significance. 
5.4.2.1 Blood pressure 
As the small dose of doxazosin used in this study had no sigmficant effect 
on blood pressure or any of the other haemodynamic parameters at two and four 
weeks. The doxazosin-treated group of patients could be considered as equivalent 
to a placebo group. In the comparisons between the effects of different drugs, most 
of the differences occur between the doxazosin groups and some or all of the other 
groups and in the following results section where it is indicated that the groups are 
different this means in comparison to doxazosin unless otherwise stated. Mean 
percentage reduction of supine SBP after two weeks of treatment was significant 
with atenolol, nifedipine retard, enalapril, pindolol, cyclopenthiazide and 
methyldopa compared to doxazosin (p < 0,001). Likewise, mean percentage 
reduction of supine DBP after two weeks of treatment was significant for all the 
other drugs except cyclopenthiazide (p < 0.001). Similar differences in change of 
L • • 
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supine SBP were seen after four weeks of treatment and additionally the effect of 
methyldopa was less than that of atenolol (p < 0.001). For mean percentage change 
of supine DBP after four weeks of treatment only atenolol, enalapril and pindolol 
showed a significant effect (p < 0.001) (see figure 5.46). 
The overall effects on standing blood pressure of the different anti-
hypertensive drugs apart from doxazosin were comparable but statistically 
significant differences of mean percentage reduction of standing SBP (p < 0.05) 
were only observed with atenolol after two and four weeks of treatment and with 
enalapril after four weeks of treatment. Similarly, significant differences in mean 
percentage reduction of standing DBP (p < 0.01) were detected with atenolol after 
two and four weeks of treatment and additionally between nifedipine retard and 
atenolol after four weeks of treatment (see figure 5.47). 
The effects of the anti-hypertensive drugs on sitting blood pressure showed 
an identical pattern to the supine blood pressure except that after four weeks of 
treatment significant reductions in sitting SBP were only seen with atenolol, 
pindolol and enalapril (p < 0.01). and in sitting DBP only with atenolol and 
methyldopa. Also the effect of nifedipine retard was less than that of atenolol (p < 
0.001) (see figure 5.48). 
The mean percentage changes of exercise SBP and exercise DBP with the 
various drugs showed no significant difference except there was a significant 
reduction with nifedipine retard, atenolol and pindolol after two weeks of treatment 
(p < 0.05) (see figure 5.49). 
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Figure 5. 46 Mean (士 SEM) percentage changes of systolic and diastolic 
blood pressure (%) at supine rest after two and four weeks of treatment by 
the anti-hypertensive drugs studied, * denoted p < 0.05 compared to 
doxazosin at two and four weeks and + denoted p < 0.05 compared to atenolol 
at four weeks. 
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Figure 5. 47 Mean (士 SEM) percentage changes of systolic and diastolic 
blood pressure (%) in the standing position after two and four weeks of 
treatment by all the anti-hypertensive drugs studied, * denoted p < 0.05 
compared to doxazosin and + denoted p < 0.05 compared to atenolol at two 
and four weeks. 
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Figure 5. 48 Mean (土 SEM) percentage changes of systolic and diastolic 
blood pressure (%) in the sitting position after two and four weeks of 
treatment by all the anti-hypertensive drugs studied, * denoted p < 0.05 
compared to doxazosin and + denoted p < 0.05 compared to atenolol at two 
and four weeks. 
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Figure 5. 49 Mean (土 SEM) percentage changes of systolic and diastolic 
blood pressure (%) during isometric exercise after two and four weeks of 
treatment by all the anti-hypertensive drugs studied, * denoted p < 0.05 
compared to doxazosin at two weeks. 
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5.4.2.2 Mean arterial pressure 
There were statistically significant differences in supine MAP detected 
among some of the studied drugs. Mean percentage reduction of supine MAP was 
significant with atenolol, nifedipine retard and methyldopa after two weeks of drug 
treatment (p < 0.001) and with atenolol after four weeks of drug treatment (p < 
0.05) (see figure 5.50). 
Regarding standing MAP, statistical significance was found only with mean 
percentage reduction of standing MAP (p < 0.01) with atenolol after two and four 
weeks of treatment (see figure 5.51) and likewise with mean percentage reduction 
of sitting MAP after two and four weeks of treatment (p < 0.05) (see figure 5.52). 
Nevertheless, the mean percentage change of exercise MAP showed no statistically 
difference among the drugs studied (see figure 5.53). 
Chapter 5 The Integrated Hypertension Study 157 
la Supine MAP 
丁 
J - 1 : I T ^ V 
e -15 _ J- * « * 
^ -20 - ‘ 1 1 1 1 I I ‘ 
AT PIN DOX EN NR MD CT 
I I 2 weeks treatment ^ ^ ^ 4 weeks treatment 
Figure 5. 50 Mean (土 SEM) percentage change of mean arterial pressure 
(%) at supine rest after two and four weeks of treatment by the anti-
hypertensive drugs studied, * denoted p < 0.05 compared to doxazosin at two 
and four weeks. 
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Figure 5. 51 Mean (土 SEM) percentage changes of mean arterial pressure 
(o/o) in the standing position after two and four weeks of treatment by the 
anti-hypertensive drugs studied, * denoted p < 0.05 compared to doxazosin at 
two and four weeks. 
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Figure 5. 52 Mean (土 SEM) percentage changes of mean arterial pressure 
(o/o) in the sitting position after two and four weeks of treatment by all the 
anti-hypertensive drugs studied, * denoted p < 0.05 compared to doxazosin at 
two and four weeks. 
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Figure 5. 53 Mean (士 SEM) percentage changes of mean arterial pressure 
(%) during isometric exercise after two and four weeks of treatment by all the 
anti-hypertensive drugs studied. 
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5.4.2.3 Heart rate 
The mean percentage reduction of supine HR with atenolol after two and 
four weeks of active treatment was significantly greater than all the other drugs in 
the study (p < 0.001). Conversely, significant differences in the percentage changes 
of supine heart rate with pindolol after two and four weeks of treatment were 
detected when they were compared to methyldopa (p < 0.001). In addition, the 
percentage change of supine heart rate of pindolol after four weeks of treatment 
was also of significant difference in comparison to that of nifedipine retard (p < 
0.001) (see figure 5.54). 
As a result of the beta blocking effect of atenolol, the mean percentage 
reduction on standing HR with atenolol was significantly different from all the 
other drugs in the study after two and four weeks of treatment (p < 0.001) except 
in the case of atenolol and methyldopa after two weeks of treatment as methyldopa 
also tended to reduce standing HR (see figure 5.55). 
The difference between changes with all the anti-hypertensive drugs on 
sitting HR were all statistically significant due to the notable reductions in HR by 
atenolol. Statistical significance were detected when the mean percentage change 
of sitting HR with atenolol was compared to those with other drugs after two and 
four weeks of treatment (p < 0.001). The only exception was when the values with 
atenolol were compared with those with methyldopa after two weeks of treatment 
(see figure 5.56). On account of the beta-blocking effect of atenolol on HR, the 
mean percentage changes of exericse HR with atenolol were statistically different 
in comparison to all the other anti-hypertensive durgs studied after both two and 
four weeks of treatment (p < 0.001) (see figure 5.57). 
Chapter 5 The Integrated Hypertension Study 157 
5.4.2.4 Stroke index 
With respect to the effects of the anti-hypertensive drugs on supine SI, no 
significant difference were detected after two and four weeks of treatment, (see 
figure 5.54). Interestingly, significant differences in standing SI were found among 
the different anti-hypertensive drugs after two weeks of treatment but not after 
four weeks of treatment. The mean percentage increase in standing SI with 
atenolol after two weeks of treatment was so prominent that it was statistically 
different from the rest of the drugs studied (p < 0.01) (see figure 5.55). 
Regarding the percentage changes of sitting SI, significant increase was 
observed with atenolol compared with all of the other drugs after two weeks of 
treatment (p < 0.01), but only with enalapril after four weeks of treatment (p < 
0.01) (see figure 5.56). Concerning the effects of the anti-hypertensive durgs on 
exercise SI, significant differences were observed when the mean percentage 
changes with atenolol were compared to all the other drugs after two weeks of 
treatment (p < 0.001) and also when the former was compared to nifedipine retard 
and enalapril after four weeks of treatment (p < 0.05) (see figure 5.57). 
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Figure 5. 54 Mean (土 SEM) percentage changes of stroke index and heart 
rate (%) at supine rest after two and four weeks of treatment by the anti-
hypertensive drugs studied, * denoted p < 0.05 compared to atenolol and + 
denoted p < 0.05 compared to pindolol at two and four weeks. 
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Figure 5. 55 Mean (士 SEM) percentage changes of stroke index and heart 
rate (%) in the standing position after two and four weeks of treatment by all 
the anti-hypertensive drugs studied, * denoted p < 0.05 compared to atenolol 
at two and four weeks. 
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Figure 5. 56 Mean (土 SEM) percentage changes of stroke index and heart 
rate (%) in the sitting position after two and four weeks of treatment by all 
the anti-hypertensive drugs studied, * denoted p < 0.05 compared to atenolol 
and + denoted p < 0.05 compared to methyldopa at two and four weeks. 
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Figure 5. 57 Mean (土 SEM) percentage changes of stroke index and heart 
rate (%) during isometric exercise after two and four weeks of treatment by 
all the anti-hypertensive drugs studied, * denoted p < 0.05 compared to 
atenolol at two and four weeks. 
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5.4.2.5 Cardiac index 
Mean percentage changes of supine CI after two and four weeks of 
treatment were not significantly different among the seven anti-hypertensive drugs 
studied. As a matter of fact, the effects of the drugs on supine CI varied (see figure 
5.58). The overall effects of the anti-hypertensive drugs on CI in the standing and 
sitting positions and during isometric exercise were similar to that observed in the 
supine position, that is, no statistically significant difference was detected among 
the different drugs after two and four weeks of treatment (see figures 5.59, 5.60 
and 5.61). 
5.4.2.6 Systemic vascular resistance index 
In spite o f the fact that all the anti-hypertensive drugs except doxazosin 
were inclined to lower SVRI in the supine position after two and four weeks of 
drug treatment, the overall difference among the different drug groups were not 
great enough to produce a statistically significant difference (see figure 5.58). 
Similarly, there was no significant difference observed in the mean percentage 
changes of SVRI in the other positions and during handgrip after active treatment 
of the different anti-hypertensive drugs (see figures 5.59，5.60 and 5.61). Table 5.4 
_ 5.7 tabulated the mean (S.D.) percentage changes in blood pressure and 
haemodynamic parameters of the anti-hypertensive drugs studied after two and 
four weeks of treatment. 
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Figure 5.58 Mean (土 SEM) percentage changes of cardiac index and 
systemic vascular resistance index (%) at supine rest after two and four 
weeks of treatment by the anti-hypertensive drugs studied. 
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Figure 5.59 Mean (士 SEM) percentage changes of cardiac index and 
systemic vascular resistance index (%) in the standing position after two and 
four weeks of treatment by all the anti-hypertensive drugs studied. 
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Figure 5.60 Mean (土 SEM) percentage changes of cardiac index and 
systemic vascular resistance index (%) in the sitting position after two and 
four weeks of treatment by all the anit-hypertensive drugs studied. 
Chapter 5 The Integrated Hypertension Study 191 
Exercise CI 
30 
1 0 - -I •；丨 WTW*^ 
！ -IS - T T 
a -20 - 丄 
CQ 
-25 J 
ifi o bi) d 
5 Exercise SVRI 
0 40 -1 
a 丁 
2 30 -
1 厂n T T fe 20 - 门 
I ：" ^ J j j n _ 
L ^ T T -L T 
- 1 0 一 丄 
-20 -J 1 1 1 1 1 1 I 
AT PIN DOX EN NR MD CT 
I 2 weeks treatment 4 weeks treatment 
Figure 5.61 Mean (土 SEM) percentage changes of cardiac index and 
systemic vascular resistance index (%) during isometric exercise after two 
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5.5 DISCUSSION 
5.5.1 Atenolol 
Our results on the short-term (two and four weeks of treatment) 
haemodynamic effects of atenolol showed a reduction in SVRI which appears to be at 
variance with the expected elevation in SVRI reported in other studies of the acute 
effects or long-term treatment with atenolol (Weil & Waite，1982) (Thomas, Cooper, 
Ekwuru, Fletcher, Gilbody, Husseyin, Ishaque, Jagathesan, Reddy & Smith, 1992). 
However, a study comparing different beta-adrenoceptor antagonists using the invasive 
dye dilution technique to estimate cardiac output indicated that atenolol only resulted 
in minor haemodynamic changes compared to pretreatment levels after chronic 
treatment for one year (Lund-Johansen, 1983). They found that an increase in SV 
together with a decrease in HR made the fall in CO being less apparent during exercise 
whereas the value of SVRI during exercise remained at pre-treatment level. These 
findings during exercise were very similar to our results with atenolol. Lund-Johansen 
proposed that atenolol by virtue of its betai-selectivity, reduce beta2-receptor mediated 
vasodilatation of resistance vessels unlike the non-selective beta-adrenoceptor 
blockers, for instance, timolol. Under the circumstances of higher adrenergic activity 
such as during exercise, blockade of beta2-receptors would result in unopposed alpha-
receptor mediated vasoconstriction by tending to reduce any fall in systemic vascular 
resistance. 
Anti-hypertensive drugs such as ACEI and calcium antagonists reduce vascular 
resistance either by inhibiting vasoconstrictor mechanisms or direct vasodilation. 
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However, the mechanism of the anti-hypertensive effect of beta-adrenoceptor 
antagonists is thought by some to be through a reduction in cardiac output and 
elevation in vascular resistance. An anecdotal report by Tarasi R.C. and Dustan H P. 
(1972) showed that the reduction in blood pressure with propranolol paralleled a fall in 
vascular resistance in long-term treatment. This suggests that the haemodynamic 
effects of acute and chronic treatment with beta antagonists may be different (Tarasi & 
Dustan, 1972). Nevertheless, as mentioned by Man in't Veld A.J. (1991)，we should 
consider the great individual variation in blood pressure response to different anti-
hypertensive drugs. 
In a comprehensive review of the long-term haemodynamic effects of beta-
adrenoceptor antagonists in hypertension (Man in't Veld, 1991), blood pressure falls in 
parallel to a reduction in SVRI and CO does not change much after chronic treatment. 
Possibly vasoconstrictor mechanisms play a role in the reduction in blood pressure with 
beta antagonists. Man in't Veld (1991) also conducted a study to compare the 
haemodynamic effects of different beta-adrenoceptor antagonists including atenolol 
and pindolol. All patients were on strict bed rest for 36 hours to minimize cardiac 
sympathetic drive. The trough effects after 24 hours of active treatment indicated that 
the reduction in blood pressure was associated with a decline in SVRI below the 
baseline value. These haemodynamic findings which were again compatable with our 
data, further support the notion that beta-adrenoceptor antagonists reduce blood 
pressure via interference with vasoconstrictor mechanisms (Man in't Veld, 1991). 
Furthermore, a significant positive correlation was found between MAP and SVRI and 
a negative correlation was also established between MAP and CO in the same study 
mentioned above. Our results also showed significant negative correlation between CI 
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and SVRI both after two and four weeks of treatment with the correlation coefficients 
(r) equal to 0.88 and 0.92, respectively. They indicate that the fall in blood pressure is 
associated with a reduction in SVRI and an increase in CO. 
The results of another study of the acute and chronic effects of beta-
adrenoceptor antagonists in forty hypertensive patients in the Netherlands (van den 
Meiracker, Man in't Veld, Ritsema van Eck, Boomsma & Schalekamp，1988) were 
also compatable with our findings. They found that reductions in MAP which were 
associated with falls in SVRI with CO returned to pretreatment levels on long-term 
treatment. They also concluded that beta-adrenoceptor antagonists have the property 
of reducing sympathetic vasoconstrictor nerve activity resulting in vasodilation. 
The nature of the vasodilating mechanism of beta-adrenoceptor antagonists is 
not well explained and other postulated mechanisms are an effect on central beta 
receptors involved in the sympathetic nervous system or blockade of postsynaptic beta-
receptors on the juxtaglomerular cells of the kidney reducing renin release (van den 
Meiracker et al, 1988) (Man in't Veld, 1991). In addition, it has been suggested that 
beta-adrenoceptor antagonists may or may not elevate SVRI in hypertensive patients 
depending upon the duration of beta-adrenoceptor antagonist therapy, the extent of the 
anti-hypertensive response, the degree of partial agonist activity and the level of 
sympathetic drive (van den Meiracker et al., 1988) (Man in't Veld, 1991). 
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5.5.2 Pindolol 
One can postulate that the increase in supine heart rate was due to the partial 
agonist properties of pindolol. This was associated with a reduction in SVRI and 
increase in stroke volume and cardiac output. The isometric exercise of the handgrip 
test results in a pressor response without much tachycardia and pindolol had no 
significant effect. These findings were comparable to previous studies on the 
cardiovascular effects of pindolol (Thomas et al.，1992) (Weil & Waite, 1982) (Man 
in't Veld & Schalekamp, 1982). 
Man in't Veld A.J. (1991) found that with beta-adrenoreceptor antagonists a 
positive correlation between the percentage change in MAP and SVRI and a negative 
correlation between the percentage change in MAP and CO. Moreover, of the various 
beta-adrenoreceptor antagonists they tested, pindolol was associated with a higher 
cardiac output and lower vascular resistance for every blood pressure level. Our data 
demonstrated a significant negative correlation between SVRI and CI after two and 
four weeks of treatment with pindolol and the correlation coefficients (r) were 0.90 
and 0.89 respectively. This is compatable with their postulation that the fall in arterial 
pressure is related to a reduction in SVRI with a consequent increment in CI. Thus, 
beta-adrenoceptor antagonists with ISA also appear to exert their hypotenisve effect 
through vasodilation (Man in't Veld, 1991). 
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5.5.3 Doxazosin 
In our study, we could not confirm the clinical efficacy of doxazosin as 
demonstrated in other studies (Lund-Johansen, Omvik & Haugland, 1986) (Donnelly, 
Elliott, Meredith & Reid, 1989). Our results demonstrated that blood pressure was not 
reduced effectively over a twenty-four hours period by the recommended starting dose 
of 1 mg daily. In fact blood pressure had actually slightly increased after two and four 
weeks oral administration of this dose of the drug. This 1 mg daily starting dose is 
recommeded for routine clinical use to avoid the well documented untoward effects of 
larger doses of doxazosin such as first dose postural hypotension, syncope, dizziness 
and headache (Sco伍eld & Reid, 1992) (Prasad, 1994). An initial dose of 1 mg 
doxazosin is reported to produce an acute hypotensive effect which may well diminish 
with repeated dosing due to the development of tolerance. 
Several studies in the literature use 2 mg as a standard starting dose but in 
hospital-based research studies, the mean final daily dose of doxazosin after titration 
was 11.6 mg. However some general practice studies claims a final effective dosage 
after titration of 2 - 4 mg daily (Scoffield & Reid, 1992). In retrospect we used too 
low a starting dose of doxazosin but despite this we found it to be very ineffective in 
our patient group. After the completion of the four-week study period used for this 
thesis, we titrated up the doxazosin dose and added in other anti-hypertensive agents if 
necessary. About half of our patients (five) required additional anti-hypertensive drugs 
despite a final doxazosin dosage of either 4 or 8 mg to control their blood pressure. A 
further three of the nine patients discontinued doxazosin and were changed to other 
anti-hypertensive agents by six to twelve months. Only one patient was successfully 
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treated with doxazosin alone and at a dose of 4 mg daily. Thus our findings with 
doxazosin in nine Chinese hypertensive patients are very different from that reported 
elsewhere (Scoffield & Reid，1992) but our study group was small in number. We 
included our 1 mg daily doxazosin data in the analysis as it was virtually a "placebo 
control" for comparison with the other anti-hypertensive drugs. 
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5.5.4 Enalapril 
Our data revealed that the reductions in blood pressure with enalapril were 
associated with significant falls in systemic vascular resistance measured in the supine 
position after two and four weeks of treatment. However, there was no significant 
change of SVRI when measured in the standing and sitting positions or during 
isometric exercise. We found that the significant reduction in blood pressure with ACE 
inhibition was associated with a decrease in CO in these positions but no change in the 
derived value of SVRI. Musumeci et. al. (1990) made a similar observation and 
proposed that the haemodynamic effects of the ACEI on systemic vascular resistance 
are affected by both the decrease in angiotensin II and in aldosterone on the one hand 
and complex circulatory adjustment including a decline of central sympathomimetic 
drive or a plasma volume redistribution on the other. 
« 
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5.5.5 Nifedipine Retard 
In this group of patients treated with nifedipine retard, we found significant 
reductions in blood pressure in all the different positions and during isometric exercise. 
However, no significant changes were detected in the other haemodynamic parameters. 
These findings contrasted with those reported by Thomas et. al. (1990). They found 
that the hypotensive response to nifedipine retard was associated with increases in both 
stroke volume and cardiac output and a reduction in calculated systemic vascular 
resistance. They commented that when using the impedance technique to estimate 
stroke volume, alterations in base impedance, peak rate change of impedance and 
ventricular ejection time may affect the impedance cardiograph measurements of stroke 
volume and such alterations may account for the apparent increased variability and 
inter-subject variations in response with posture and exercise (Thomas, Molyneux, 
Kelly & Smith, 1990). 
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5.5.6 Methyldopa 
Methyldopa is a central alpha-adrenoceptor agonist which is thought to lower 
blood pressure via its action on the blood pressure regulating centre in the brain (Lund-
Johansen, 1983) and reduces the sympathetic control of arterial blood pressure 
(Mancia, Ferrari, Gregorini, Leonetti, Terzoli, Bianchini & Zanchetti, 1978). Both 
blood pressure and heart rate were reduced significantly in the supine position whereas 
cardiac output was maintained at pre-treatment levels as well as systemic vascular 
resistance. Our data on methyldopa does not support the view that the hypotensive 
action of methyldopa involves a reduction in cardiac output (Lund-Johansen, 1972) or 
in peripheral resistance (Richardson & von Bibra, 1978). However, significant falls in 
CI were observed in the standing and sitting positions after two and four weeks of 
treatment. 
Moreover, it is worthwhile to note that the difference in the reductions in 
systolic blood pressure compared to the pretreatment values after two and four weeks 
of treatment were similar both in the supine position and during isometric exercise. 
Reductions of SBP by 11 mmHg after both two and four weeks of active treatment 
were seen in the supine position and by 13.5 and 14.5 mmHg respectively after two 
and four weeks of active treatment were noted during the isometric exercise. 
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5.5.7 Cyclopenthiazide 
Cyclopenthiazide is a thiazide diuretic which decreases extravascular volume 
and one might expect an increase in heart rate and a decrease in cardiac output to 
compensate for this volume change. However, no significant alterations in HR and CO 
were detected at either two or four weeks of treatment and in any position or during 
isometric exercise. Moreover, the reductions in mean arterial pressure were only 
significant in the standing position and during isometric exercise after both two and 
four weeks of treatment. Consequently only significant reduction in SVRI was 
observed in the standing position after two and four weeks of treatment. Thus we did 
not achieve the same degree of hypotensive response as with some of the other anti-
hypertensive agents. Furthermore, our data was just based on ten subjects. 
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5.5.8 Comparison of the anti-hypertensive drugs studied 
In the supine position, all the different anti-hypertensive drugs used except for 
Doxazosin had by four weeks lowered SBP and DBP by roughly similar amounts. 
Thus comparisons of the other haemodynamic changes between the drugs are usefiil. 
Doxazosin in the 1 mg daily dosage used for the two to four weeks study was an 
ineffective anti-hypertensive agent in our findings and required a four- to eight-fold 
dosage increase and usually with the addition of other anti-hypertenisve agents to give 
effective blood pressure control Its inclusion in the subsequent analysis was for in 
virtual "placebo" value. With regard to the effects of the drugs on supine HR and SI, 
all except pindolol, which increased heart rate presumably because of its intrinsic 
sympathomimetic activity, had opposing effects on these two parameters with cardiac 
output remaining fairly constant. Atenolol, the betai-adrenoceptor antagonist lowered 
HR to a greater extent than all the other drugs but with each drug the falls all reached 
statistical significance. Percentage falls in SVRI amongst the different anti-hypertensive 
drugs (excluding doxazosin) at two and four weeks were similar and no statistical 
differences were detected. 
In the standing position, all drugs (except doxazosin) reduced MAP to a similar 
extent. All the drugs had statistically different effects on both stroke index and heart 
rate at two and four weeks of treatment when compared to atenolol. As in the supine 
position, all drugs (except Doxazosin) had similar effects on SVRI at two and four 
weeks of treatment. 
In the sitting position, the haemodynamic pictures produced by the anti-
hypertensive drugs were very similar to those observed in the standing position and 
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thus the different anti-hypertensive drugs had comparable therapeutic effects on HR, 
CI and SVRI in the three different positions used in the study. 
During the isometric exercise, the haemodynamic effects of the seven anti-
hypertensive drugs on blood pressure, cardiac output and systemic vascular resistance 
were comparable to each other. No statistical significance was detected among these 
variables apart from that when the mean percentage change of SBP on doxazosin was 
compared with that on the nifedipine retard, atenolol and pindolol after two weeks of 
treatment. Again, the beta-blocking effect of atenolol was apparent and the decrement 
in HR with atenolol was statistically different when compared to the changes with the 
other drugs studied after both two and four weeks of treatment. The compensatory 
increase in SI with atenolol also showed significant differences when compared with 
the other drugs after two weeks of treatment. 
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CHAPTER 6 A CUTE HAEMODYNAMIC EFFECTS OF 
A TENOLOL AND PINDOLOL 
6.1 OBJECTIVES 
This study was an extension of the integrated hypertension study (MS) with 
the aim of examining the acute responses to the two beta-adrenoceptor antagonists, 
atenolol and pindolol using the thoracic electrical bioimpedance (TEB). The acute 
responses were compared with each other and with the chronic responses to the same 




Patients who were willing to undergo additional measurement at two hours 
after the first dose of medication in the first study visit were recruited from the atenolol 
and pindolol groups of the integrated hypertension study. Six out of twenty-two 
patients in the atenolol group and eight out of eleven patients in the pindolol group 
agreed to have additional measurements to determine the acute effects of these beta-
adrenoceptor antagonists. They all gave their informed consent and the study was 
approved by the ethical committee of the Chinese University of Hong Kong. The 
baseline characteristics of the two sub-groups of patients selected for studying the 
acute effects of atenolol and pindolol are listed in table 6.1. 
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6.2.2 Study Design 
Haemodynamic monitoring using the same protocol as that for the main 
integrated hypertension study (IHS) was performed at two hours after the initial dose 
of either atenolol 50 mg or pindolol 5 mg for the patients in these two sub-groups. 
Patients were requested to continue fasting until the completion of the second 
monitoring session to avoid any haemodynamic effects of food intake. Other 
procedures for blood pressure measurement and isometric exercise were carried out 
exactly the same as that for the IHS. The CONMED electrodes used in the 
haemodynamic monitoring were kept insitu after the baseline recording for the second 
monitoring session to exclude the effect of different positioning of the electrodes. Data 
stored were then computed and analysed in the same way as the two and four weeks 
studies. 
6.2.3 Statistical analysis 
Paired t-tests were performed using a statistical software package (SigmaStat 
for Windows version 1.0, Jandel Scientific) to detect whether the change taking place 
with treatment with either atenolol or pindolol two hours post dose was greater than 
would be expected by chance. One way repeated measues ANOVA was performed to 
compare the acute responses to either atenolol or pindolol with the values obtained 
after two and four weeks of treatment with the respective drugs. Unpaired t-tests were 
also performed to examine if the baseline values of the two treatment groups were 
significantly different from each other and whether the acute responses to the two 
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drugs were different. Results are presented as mean (SEM) and statistical significance 
was set at the p < 0.05 level. 
Table 6.1 Clinical characteristics of the two groups of patients treated with 
atenolol (50 mg) and pindolol (5 mg) who had haemodynamic measurements 
performed two hours post dose. 
r Atenolol (SO rag) rmdoM{Sm%)"""""T 
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S … 
Number of patients (n) 6 8 
Age (year) 5 3 . 2 ( 4 4 - 6 5 ) 4 5 . 5 ( 3 5 - 6 2 ) 
Body weight (kg) 66.1 (7.3) 一 59.7 (6.1) 
Height (cm) 162.4 (12) 158.8 (8.4) 
Body surface area (m') 169 (0.2) 1.59 (0.1) 
Body mass index 25.4 (3.4) 23.7 (1.9) 
Systolic blood prcssuc (mmHg) 161.1 (9.5) 147.5 (4.5) 
Diastolic blood pressure (mmHg) 98.5 (5.9) 92.4 (3.5) 
Mean arterial pressure (mmHg) 122 (7.4) 111 (4.1) 
Heart rate (beats/min) 71.8 (5.1) 68.1 (3.2) 
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6.3 RESULTS 
6.3.1 Acute haemodynamic changes of atenolol 
Reductions in SBP and DBP after two hours of oral dose of atenolol were of 
statistical significance (p < 0.05) in both the supine and standing positions but not in 
the sitting position or during isometric exercise. Statistically significant changes were 
likewise seen in MAP in the supine and standing positions. The changes of blood 
pressure in the supine position for the individual subjects at two hours post treatment 
with atenolol are presented in figure 6.1. 
While there were significant decreases in HR in all the different positions and 
during the handgrip, the changes in SI were not statistically significant. The changes in 
heart rate and stroke index in the supine position of the individual subjects at two 
hours post treatment with atenolol are presented in figures 6.2 and 6.3. 
With respect to the acute effects of atenolol on CI, significant reductions were 
only detected in the sitting position and during handgrip. A significant rise in SVRI 
was calculated during isometric exercise at two hours after oral dose of atenolol. The 
changes in cardiac index and systemic vascular resistance index in the supine position 
for individual subjects at two hours post treatment with atenolol are presented in 
figures 6.4 and 6.5. The above results of the acute haemodynamic changes of atenolol 
are tabulated in table 6.2 and 6.3. 
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Figure 6.1 Supine systolic (continuous line) and diastolic (dotted line) blood 
pressures for atenolol 50 mg (black symbols, n = 6) and pindolol 5 mg (open 
symbols, n = 8) at predose and two hours post dose. Each symbol represents one 
subject, + represents mean value. 
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Figure 6. 2 Supine heart rate for atenolol 50 mg (black symbols, n = 6) and 
pindolol 5 mg (open symbols, n = 8) at predose and two hours post dose. Each 
symbol represents one subject, + represents mean value. 
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Figure 6. 3 Supine stroke index for atenolol 50 mg (black symbols, n = 6) and 
pindolol 5 mg (open symbols, n = 8) at predose and two hours post dose. Each 
symbol represents one subject, + represents mean value. 
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Figure 6. 4 Supine cardiac index for atenolol 50 mg (black symbols, n = 6) and 
pindolol 5 mg (open symbols, n = 8) at predose and two hours post dose. Each 
symbol represents one subject, + represents mean value. 
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Figure 6. 5 Supine systemic vascular resistance index for atenolol 50 mg (black 
symbols, n = 6) and pindolol 5 mg (open symbols, n = 8) at predose and two 
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6.3.2 Acute and short-term haemodynamic changes of atenolol 
Haemodynamic changes at two hours post dose and after two and four weeks 
of chronic treatment with atenolol compared to baseline in the same group of patients 
were calculated. Then they were examined using one way repeated measures ANOVA 
to detect whether the differences in the acute and short-term responses to atenolol 
were statistically significant. The acute and short-term changes (mean 土 SEM) in blood 
pressure and haemodynamic parameters before treatment, at two hours post dose and 
after two and four weeks of treatment with atenolol are tabulated in table 6.2 and 6.3. 
6.3.2.1 Blood pressure 
Reduction in systolic blood pressure was significant when the supine SBP after 
four weeks of treatment was compared with the baseline and so were the standing SBP 
and the sitting SBP. The effects of atenolol on diastolic blood pressure were more 
prominent. Significant reductions were found at two hours post dose and after two and 
four weeks of treatment in the supine and standing positions and when the sitting DBP 
after four weeks of treatment was compared with the baseline. Regarding exercise 
DBP, significant reductions were detected when the exercise DBP measurements after 
four weeks of treatment were compared with the baseline values and those obtained at 
two hours post dose and after two weeks of treatment. 
Moreover, reductions in the supine MAP were significant only after short-term 
treatment with atenolol but not acutely in the supine position. Whereas statistical 
significances were detected only when the standing MAP and the sitting MAP 
measurements after four weeks of treatment were compared with the baseline values. 
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6.3.2.2 Heart rate 
There were no statistically significant differences detected between the acute 
and short-term effects of atenolol on the supine HR although it was decreased slightly 
more at two hours than at two and four weeks of treatment. However, statistically 
significant reductions were found in the standing HR, the sitting HR, the exercise HR 
after both acute and short-term treatments of atenolol. 
6.3.2.3 Stroke index 
The changes in the supine SI at two hours post dose and after two and four 
weeks of treatment was not statistically different although it showed a tendency to 
increase. Similarly, the haemodynamic effects of atenolol on the standing SI, the sitting 
SI and the exercise SI both acutely and after short-term treatment were not of any 
statistical significance. 
6.3.2.4 Cardiac index 
While there were no change in the supine CI, the standing CI and the sitting CI 
both acutely and after short-term treatment, the change in the exercise CI at two hours 
post dose of atenolol was statistically significant when compared to the baseline. 
6.3.2.5 Systemic vascular resistance index 
Nonetheless, the haemodynamic effects of atenolol on SVRI in all the different 
positions both acutely and after short-term treatment were not of any statistical 
significance. However, the SVRI exercise at two hours post dose was significantly 
different from the baseline and short-term treatment values. 
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6.3.3 Acute haemodynamic changes of pindolol 
Blood pressure was decreased two hours after the oral dose of pindolol. The 
reductions in SBP were all significant regardless of posture and exercise. Similarly, the 
changes in DBP were statistically significant except during the isometric exercise. The 
changes in MAP were likewise significant in all the different positions and during 
isometric exercise. The changes in blood pressure in the supine position for the 
individual subjects at two hours post treatment with pindolol are presented in figure 
6 .1. 
The falls in HR at two hours post dose were also statistically significant in the 
supine, standing and sitting positions and during isometric exercise. Conversely, the 
changes of SI at two hours post dose were minimal and not significant in any position • • 
or during handgrip test. The changes of heart rate and stroke index in the supine 
position for individual subjects at two hours post treatment with pindolol are presented 
in figures 6.2 and 6.3. Regarding the effects of pindolol on CI, only the reduction 
produced in the standing position was significant. However, none of the changes 
produced in SVRI were statistically significant. The changes of cardiac index and 
systemic vascular resistance index in the supine position for individual subjects at two 
hours post treatment with pindolol are presented in figures 6.4 and 6.5. 
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6.3.4 Acute and short-term haemodynamic changes of pindolol 
Haemodynamic changes at two hours post dose and two and four weeks of 
treatment with pindolol relative to the baseline values were compared using one way 
repeated measures ANOVA. It was done to detect whether the differences in the acute 
and short-term responses to pindolol were statistically significant. The acute and short-
term changes (mean 土 SEM) in blood pressure and haemodynamic parameters before 
treatment, at two hours post dose and after two and four weeks of treatment with 
pindolol are tabulated in table 6.4 and 6.5. 
6.3.4.1 Blood pressure 
After acute and short-term treatment of pindolol, there were significant 
reductions in both SBP and DBP in the supine, standing and sitting positions and 
during isometric exercise. However, reduction of sitting DBP was significant only at 
two hours post dose and after four weeks of treatment of pindolol and the falls in 
exercise DBP did not reach statistical significance. 
On the whole, significant reductions in MAP were detected in all the different 
positions and during isometric exercise after acute and short-term treatment with 
pindolol. Nevertheless, significant reductions in supine MAP were only observed at 
two hours post dose and after four weeks of treatment with pindolol. 
6.3.4.2 Heart rate 
Significant changes in supine HR were detected when the mean values of the 
supine HR at two hours post dose was compared with that after two and four weeks of 
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treatment. Again, there were significant changes in the standing HR and the sitting HR 
when their respective mean values at two hours post dose of pindolol were compared 
with the baseline and values after short-term treatment. On the other hand, the changes 
of exercise HR after acute and short-term treatment of pindolol were marked. 
Significant reductions were observed when the values of exercise HR at two hours 
post dose and after two and four weeks of treatment were compared with the baseline, 
and also when the values of exercise HR after two and four weeks of treatment were 
compared with that after two hours. 
6.3.4.3 Stroke index 
Regarding the acute and short-term haemodynamic effects of pindolol on SI, 
no significant changes were detected in all the positions studied and during isometric 
exercise. 
6.3.4.4 Cardiac index 
Similarly, the acute and short-term haemodynamic responses of CI in all the 
positions studied and during isometric exercise were not statistically different. 
t 
6.3.4.5 Systemic vascular resistance 
Again, no significant changes were detected in the haemodynamic effects of 
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6.3.5 Comparison of the acute haemodynamic effects of atenolol and 
pindolol 
The baseline values of the various haemodynamic parameters including blood 
pressure prior to drug treatment were compared and there were no significant 
differences between the groups although the atenolol group tended to be older, heavier 
and had higher systolic and diastolic blood pressures (Table 6.1). Comparison of the 
percentage changes in the various parameters at two hours post dose of either atenolol 
or pindolol are presented in figure 6.6 and in tables 6.6 and 6.7. 
No significant differences in the percentage falls in SBP, DBP and MAP were 
detected between the atenolol and pindolol groups at two hours post dose except with 
SBP in the sitting position. However, changes with pindolol tended to be greater in all 
positions. Despite equivalent acute hypotensive actions, there were marked differences 
in the acute HR responses with statistically significant differences in all positions and 
during handgrip. Although pindolol tended to lower HR, the reduction in HR was 
always greater with atenolol. 
However, the changes in CI and SI at two hours post doses of atenolol and 
pindolol were not of statistical difference in any of the positions or during isometric 
exercise. The same was true for SVRI, apart from the changes produced during the 
handgrip exercise. 
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Figure 6. 6 Mean percentage changes in mean arterial pressure (MAP), heart rate 
(HR), stroke index (SI), cardiac index (CI) and systemic vascular resistance index (SVRI) 
after atenolol (blank bar) and pindolol (hatched bar), two hours post dose in the supine, 
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6.4 DISCUSSION 
From a review of studies of the acute haemodynamic effects of beta-
adrenoceptor antagonists in hypertension (Man in't Veld, 1991), it was noted that 
prominent effects have been observed on HR, CO and SVRI but not blood pressure. It 
was also suggested that the effects of beta antagonists on HR and SVRI are inversely 
correlated to their degree of ISA. That is, the higher the degree of ISA, the less the 
effects on HR and SVRI and vice versa. These seemed to be at variance with our 
findings as statistically significant falls in HR were detected in all the positions we 
studied and during isometric exercise in both the atenolol and pindolol groups. 
However, by further comparison of the percentage changes in HR of the atenolol and 
pindolol groups at two hours post dose, it was found that atenolol lowered HR 
significantly greater than pindolol in all positions and during handgrip test (see table 
6.7). 
Moreover, the haemodynamic effects of different beta-adrenoceptor 
antagonists including atenolol and pindolol were studied by Man in't Veld (1991), with 
all patients kept on strict bed rest for 36 hours allegedly to "minimize the cardiac 
sympathetic drive". Results of their study indicated a fall in CO with all drugs studied 
except pindolol which maintained CO possibly due to its ISA. Nevertheless, our 
findings regarding the acute haemodynamic effects of atenolol and pindolol showed 
that CI in the supine position did not change significantly in either group. 
In the same study conducted by Man in't Veld (1991), reduction in blood 
pressure occurred after two hours and corresponded with the changes with SVRI in 
the pindolol group. With the other beta-adrenoceptor antagonists, SVRI increased 
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which prevented a fall in blood pressure (Man in't Veld, 1991). The author concluded 
that the decrement in blood pressure was due to the reduction in SVRI. However, our 
data on the acute haemodynamic effects of atenolol and pindolol do not support such 
claim. We found that SBP, DBP and MAP were lowered significantly in all the 
positions and during the handgrip test when compared to the baseline values in the 
pindolol group, whereas SBP, DBP and MAP were only lowered significantly in the 
supine and standing positions in the atenolol group. Despite the apparent capacity of 
both atenolol and pindolol to lower blood pressure, SVRI was not reduced 
significantly in any of the positions studied or during isometric exercise with either 
atenolol or the pindolol. The only exception was that SVRI fell significantly during 
isometric exercise in the atenolol group. 
Furthermore, it has been stated that the acute and chronic effects of beta-
adrenoceptor antagonists with or without ISA on SVRI are fundamentally different. 
Beta-adrenoceptor antagonists without ISA cause vasoconstriction acutely and SVRI 
often remains higher than the pre-treatment value. Beta-adrenoceptor antagonists with 
ISA maintain CO and do not cause reflex vasoconstriction acutely and SVRI may even 
fall well below baseline values (Man in't Veld, 1991). Once again, our data did not 
correspond with these findings althought we observed a tendency for SVRI to be 
higher than the baseline values in the atenolol group while SVRI remained unchanged 
or reduced in the pindolol group. However, these differences in SVRI compared to 
baseline did not reach statistical significance. 
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CHAPTER 7 CONCLUSION 
In the studies described in this thesis, we used thoracic electrical bioimpedance 
(TEB) to determine the haemodynamic effects of the different classes of anti-
hypertensive drugs (the integrated hypertension study), including a betai- adrenoceptor 
antagonist, atenolol; an intrinsic sympathomimetic beta antagonist, pindolol; an 
alphai - adrenoceptor antagonist, doxazosin; an angiotensin converting enzyme 
inhibitor, enalapril; a calcium channel blocker, nifedipine retard; a central alpha 
agonist, aldomet and a thiazide diuretics, navidrex K. Although previous studies by 
other groups had examined haemodynamic responses to most of the anti-hypertensive 
agents chosen, it was the first time that a non-invasive technique giving an assessment 
of beat to beat changes in the various parameters had been applied to a wide range of 
anti-hypertensive agents. In the cases of methyldopa and cyclopenthiazide, there were 
scanty amount of haemodynamic data to compare. Furthermore, the doses of anti-
hypertensive agents chosen in our study gave similar falls in blood pressure, except in 
the case of doxazosin, enabling a useful comparison of the other haemodynamic 
actions of these drugs. 
We also determined the reproducibility of the haemodynamic parameters 
generated by the TEB over time in order to evaluate the validity of our methodology. 
From this study of the reproducibility of the haemodynamic parameters under postural 
and physiological stress using TEB in healthy volunteers of Chinese origin, reasonably 
good reproducibility of the haemodynamic data was demonstrated with the mean C.V. 
Chapter 7 Conclusion 233 
of CI in the supine, standing and sitting positions and during isometric exercise ranging 
from 5.5 - 7.5 %. The mean C.V. of SI were 6.0 - 8.7 % and that of SVRI were 7.0 -
9.7 %. According to the inventor of the TEB device, Dr B. Bo Sramek, the clinically 
acceptable margin of errors for CO and SVR are 士 20 % and our results for CI and 
SVRI in different positions and during isometric exercise were well below this figure. 
Moreover, the Sramek-Bemstein equation used for calculating the stroke volume (SV) 
in TEB has overcome some of the drawbacks in the earlier Kubicek's equation and 
thus the data we obtained were more reliable than those using the former equation 
developed by Kubicek. Although our data revealed that the variation in haemodynamic 
parameters was large between subjects, it should be emphasized that in 
pharmacological studies it is the reliable detection of changes in haemodynamic 
parameters which is of importance rather than the precision of the absolute values of 
individual parameters. This sentiment has been expressed by others (Thompson & 
Joekes, 1981)(Ng, Walley, Tsao & Breckenridge, 1991). 
In the integrated hypertension study, atenolol treatment was associated with 
significant reductions in SVRI in different postures and this finding was comparable 
with those from other studies, for instance, that conducted by Man in't Veld in 1991. 
Atenolol also lowered HR significantly while pindolol increased supine heart rate 
presumably due to its intrinsic sympathomimetic activity (ISA). However, pindolol also 
reduced SVRI with an increase in CI and our data demonstrated a significant negative 
correlation between these two parameters both after two and four weeks of treatment. 
Thus the lowering of blood pressure by beta-adrenoceptor antagonists both with ISA 
and without ISA is associated with vasodilatation. 
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Doxazosin at a dose of 1 mg daily did not lower blood pressure after two and 
four weeks of treatment in the present study. This 1 mg daily starting dose is 
recommended for clinical use to avoid the adverse effects of larger doses of doxazosin, 
particularly first dose postural hypotension. Enalapril reduced blood pressure and this 
was associated with a significant reduction in SVRI in the supine position. 
Nevertheless, there was no change in SVRI in other postures or during isometric 
exercise. It was suggested that the haemodynamic effects of ACEI on systemic 
vascular resistance are affected by the decline in angiotensin II and in aldosterone as 
well as complex circulatory adjustments. Interestingly, despite its direct vasodilator 
action, we did not detect any significant haemodynamic changes apart from the 
reduction in blood pressure in the nifedipine retard treated group of patients. 
Methyldopa reduced significantly both the blood pressure and the heart rate 
and our findings did not support the view that the hypotensive action of methyldopa 
involves a reduction in either cardiac output or peripheral resistance. Although 
cyclopenthiazide may lower blood pressure by decreasing extravascular volume, no 
significant changes were observed in heart rate or cardiac output after two and four 
weeks of treatment with this thiazide diuretic. Overall, we found that the effects of 
most of the anti-hypertensive drugs on reduction of blood pressure were consistent 
whereas the effects on other haemodynamic parameters varied. 
Regarding the study of the acute haemodynamic effects of atenolol and 
pindolol, our data did not correspond well with reported studies in the literature. 
Despite the small number of patients in our study, we found atenolol lowered heart 
rate significantly more than pindolol in all positions as well as during isometric 
exercise. Although blood pressure was lowered effectively by these two beta-
^ ― ^ ― — " 
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adrenoceptor antagonists, the systemic vascular resistance index did not significantly 
fall in any of the different postures or during the handgrip test. 
To conclude, from our studies of the reproducibility of the measurement of 
haemodynamic parameters and its capacity to detect the haemodynamic changes 
associated with anti-hypertensive drug therapy, we consider TEB to be an acceptable 
non-invasive tool in determination of haemodynamic responses to drug therapy. As the 
haemodynamic data generated by TEB are reproducible and easy to obtain, more 
studies should be done on individual responses to anti-hypertensive drugs. This will 
give valuable information on the factors which determine the responses to and 
influence the choice of anti-hypertensive agents including dosage and dose interval. 
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